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Summary 
 
 
 
Faecal immunochemical tests for haemoglobin (FIT) are replacing traditional guaiac-
based faecal occult blood (gFOBT) tests in bowel screening programmes due to their 
many advantages.  An evaluation of using quantitative FIT within the Scottish Bowel 
Screening Programme (SBSP) has taken place with faecal haemoglobin (Hb) 
concentration recorded for 38,720 participants.  Subsequently, it has been established 
that faecal Hb concentration is related to severity of colorectal neoplastic disease, with 
higher median faecal Hb concentration in participants with advanced neoplasia 
compared to those with less severe outcomes (200.0 v. 166.0 µg Hb/g faeces, p < 
0.0001).  Those with elevated faecal Hb concentration (60.0 - 79.9 µg Hb/g faeces) at 
the time of a negative test result (< 80.0 µg Hb/g faeces) were more likely to be later 
diagnosed with an interval cancer than those with undetectable Hb (adjusted odds ratio 
= 24.7, 95% CI: 4.9 - 124.6).  Follow-up of participants with a negative test result then 
testing positive in the subsequent screening round allowed calculation of an adjusted 
odds ratio of 38.0 (95% CI: 20.2 – 71.2) for advanced neoplasia in those with initial 
faecal Hb concentration 60.0 - 79.9 µg Hb/g faeces compared to those with faecal Hb 
concentration < 20.0 µg Hb/g faeces. These results give firm support to the role of 
faecal Hb concentration as a strong predictor of future risk of advanced neoplasia.  The 
use of FIT in symptomatic patients was also evaluated, with results showing that using 
a cut-off faecal Hb concentration of any detectable Hb would have ruled out colorectal 
cancer and could have reduced the referral rate by 40%.  With introduction of FIT now 
approved for the SBSP, it is hoped that a risk scoring system can be developed based 
on age, gender and faecal Hb concentration to better direct colonoscopy resource and 
reduce the proportion of interval cancers.  
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1. Introduction 
 
 
 
 
 
1.1 The problem and the basis for colorectal cancer screening 
 
 
 
Colorectal cancer presents a significant health problem in Scotland, where it is the third 
most commonly diagnosed cancer in both men and women and accounts for the 
second highest number of cancer deaths after lung cancer.  The most recent data 
available from the Scottish Cancer Registry (Information Services Division (ISD) 
Scotland, 2015a) report over 3,800 cases diagnosed in 2013, representing a higher 
rate of the disease than seen in most other Western countries and resulting in almost 
1,600 deaths per year.  The risk of developing colorectal cancer increases with age, 
with 95.0% of cases diagnosed in Scotland between 2009 and 2013 occurring in 
people over the age of 50 years.  Scottish data from the same time period show risk of 
developing colorectal cancer at 0.9%, or 1 in 113, up to the age of 64 years, rising to 
an overall lifetime risk of 5.9%, or 1 in 17.  The overall five-year survival rates, relative 
to the general population, are around 60% for both genders, with prognosis highly 
dependent on early detection and treatment.  The latest colorectal cancer statistics 
from Cancer Research UK (2015) report that only around 9% of patients in the UK are 
diagnosed at the earliest stage of the disease, classified as Dukes’ stage A, where the 
cancer has not yet penetrated through the bowel wall.  Five-year relative survival rate 
at this stage is reported at over 93%, dropping progressively through to the late stage 
Dukes’ D involving widespread metastases, when only 6.6% of patients survive five 
years or more.  
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Numerous epidemiological, clinical, histopathological and genetic studies provide 
indirect support for the widely accepted view that most, if not all colorectal cancers 
arise from premalignant lesions, as summarised in the review by Leslie et al. (2002)  
This process follows a stepwise sequence from normal epithelium to the formation of 
adenomas which, over time, exhibit varying degrees of dysplasia.  Adenomas are 
highly prevalent among the general population, occurring in around 40% of inhabitants 
of Western countries, although only around 3% go on to develop colorectal cancer.  
Furthermore, a long precancerous phase of around 10-15 years exists in most cases. 
(Muto et al., 1975)  Malignant transformation is associated with adenoma size, 
(Villavicencio & Rex, 2000) but it is impossible to predict which adenomas will 
eventually develop into cancer.  It is therefore recommended that adenomas are 
removed if possible, by polypectomy at colonoscopy, or else surgically for particularly 
large or flat lesions for which endoscopic removal may carry a high risk of excessive 
bleeding or perforation. 
 
 
The high prevalence of potential premalignant lesions in the general population, along 
with the fact that symptoms associated with colorectal cancer do not occur until the 
later stages of the disease, and the clear importance of early detection in terms in 
survival rates contribute to the status of colorectal cancer as an ideal candidate for 
population screening.  Criteria for the appraisal of the validity of a screening 
programme were described by Wilson & Jungner (1968) for the World Health 
Organisation.  Based on these classic principles, The United Kingdom National 
Screening Committee developed updated criteria (Public Health England, 2013), listed 
under five subheadings: 1) the condition; 2) the test; 3) the intervention; 4) the 
screening programme and 5) implementation criteria.  To summarise, the condition 
being screened for should be a significant health problem, an appropriate and valid 
screening tool should be available with an agreed cut-off and policy for follow-up of 
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those with positive test results.  An effective intervention that shows association with 
better outcomes than usual care and the screening programme should be supported by 
evidence from randomised controlled trials (RCT) of a reduction in mortality and 
morbidity.  The benefits of screening should outweigh any harms arising from 
overdiagnosis, false screening results and complications.  The screening process as a 
whole should be cost-effective.  Finally, several implementation criteria are listed 
including consideration of current interventions, providing informed choice to invitees 
and scientific justification of decisions on eligibility, screening interval length and test 
sensitivity.  Colorectal cancer screening programmes are now employed in many 
countries with the main principles being early detection of cancer and removal of its 
precursors to prevent progression into malignant lesions. 
 
1.2 Screening tests for the presence of haemoglobin in faeces 
 
 
 
Several methods of population colorectal cancer screening methods exist, each with 
associated advantages and drawbacks relating to various issues including sensitivity 
and specificity for screen-relevant neoplasia, uptake of screening, associated risks, 
costs and capacity of resources.  Colonoscopy is regarded as the gold standard 
method of detecting colorectal cancer and its precursors, with Winawer et al. (1993) 
demonstrating that colonoscopic removal of all detected polyps resulted in reduced 
incidence of colorectal cancer.  However, colonoscopy is expensive, invasive and 
associated with potential complications.  As such, it is generally used in population 
screening programmes as part of a two-stage system, where abnormalities detected by 
the primary test are followed up with referral for colonoscopy as the reference test.  
The most commonly used strategy involves the use of tests in the first instance to 
detect the presence of haemoglobin (Hb) in faeces, commonly called faecal occult 
blood tests.  The presence of Hb in faeces can be associated with various 
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gastrointestinal conditions, but particularly with colorectal cancer and larger precursor 
lesions. 
 
Traditional guaiac faecal occult blood tests (gFOBT) are used in various countries.  
This test involves the application of faecal samples on to a test card with an integral 
guaiac impregnated paper.  To develop the test, hydrogen peroxide is dropped onto the 
paper to detect traces of Hb indirectly, based on the oxidation of the guaiac by the 
peroxidase activity of the haem moiety of Hb to give blue or green colours.  As yet, 
gFOBT is the only faecal test proven to reduce mortality in large-scale, long-term RCT 
using Hemoccult, a commonly used traditional gFOBT.  Trials conducted between 
1975-2002 in Minnesota, USA, (Mandel et al., 1993) Nottingham, UK, (Hardcastle et 
al., 1996) Funen, Denmark (Kronborg et al., 1996) and Gothenberg, Sweden 
(Kewenter et al., 1994) were examined in a meta-analysis by Towler et al. (1998) 
These studies involved around 330,000 participants aged between 45-80 years and 
follow-up ranged from 7.8-13.0 years.  The meta-analysis demonstrated that gFOBT 
screening was associated with a 16% reduction in colorectal cancer mortality in those 
intended to be screened compared with those not invited for screening.  This effect 
rose to a 23% reduction when adjusting for those actually screened.  In addition, 
publication of outcomes of the Bowel Cancer Screening Programme in England 
following the first 1 million tests after its roll-out in 2006 reported that, if the early results 
are maintained, the programme will meet its aim of reducing colorectal cancer mortality 
by 16%. (Logan et al., 2012) Seventy percent of cancers were early stage, meaning 
that a key aim of colorectal cancer screening that is, to detect cancer whilst death from 
colorectal cancer is still preventable, is being met.  Updated work on the cohort 
involved in the Minnesota RCT has shown that colorectal cancer mortality decreased 
with both annual and biennial gFOBT screening over the 30 year follow-up period 
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(relative risk 0.68 [95% confidence interval [CI]: 0.56 – 0.82] and 0.78 [95% CI: 0.65 – 
0.93], respectively), but with no decrease in all-cause mortality. (Shaukat et al., 2013)   
 
Debate exists, not just in colorectal cancer screening but with all mass population 
screening programmes, around the fact that there is a lack of evidence of a reduction in 
all-cause mortality in the literature. (Penston, 2011; Steele & Brewster, 2011).  
Potential sources of bias can be introduced when measuring disease-specific mortality 
that are not an issue with all-cause mortality which, by nature, simply counts the 
number of deaths, regardless of cause.  It is argued that this bias leads to an 
overestimation of the benefits and an underestimation of the harms of screening.  One 
example of the potential for harm in colorectal cancer screening comes from the 
complications associated with colonoscopy.  Bowel perforation, although rare, will 
occur in some healthy individuals undergoing investigation following a positive 
screening test result and can, in some cases, lead to death.  Other harms arising from 
the screening process are more difficult to quantify.  Those with false negative 
screening test results may be subject to what is described as the “certificate of health 
effect”.  This occurs when an individual receiving a negative result becomes less likely 
to improve their lifestyle to reduce disease risk and may also ignore disease symptoms.  
In addition, those with false positive results may be vulnerable to psychological 
morbidity arising from the anxiety of receiving a positive test result letter and while 
waiting for colonoscopy appointment.  Another issue when screening screening for the 
early stages of disease is overdiagnosis.  Some early stage colorectal cancers may 
never have been destined to become symptomatic in the lifetime of the screening 
participant, and the harms associated with treatment, potentially including death, 
means that these participants are therefore disadvantaged by their participation in 
screening.  Although the use of all-cause mortality would eliminate these examples of  
bias towards the case for screening being effective, it has been argued that it is 
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unreasonable to insist that a screening programme must be supported by evidence of a 
reduction in this measure (Steele & Brewster, 2011).  Colorectal cancer accounts for 
3% of all deaths in the UK, meaning that the likely reason that no studies to date have 
demonstrated a reduction in all-cause mortality is that they have not been highly 
enough powered for this to be possible; an RCT of the required large sample size 
would be unfeasible.  It is, however, important to continue to monitor the effect of 
screening on all-cause mortality to ensure no increase in this measure is occurring.. 
 
 
A matched cohort study performed using data from the three pilot rounds of the 
Scottish Bowel Screening Programme revealed a 10% decrease in relative risk of 
colorectal cancer mortality in those invited to take part in gFOBT screening compared 
with controls matched by age, gender and deprivation; this rose to 27% in participants. 
(Libby et al., 2012) 
 
Despite being proven to play a role in the reduction of colorectal cancer mortality and 
being relatively cheap and easy to post to participants, gFOBT also have 
disadvantages.  Although limited literature exists on the subject, a major issue is that 
gFOBT are associated with a high interval cancer proportion, i.e., colorectal cancer 
arising between screening rounds following a negative result.  Results from the RCT on 
gFOBT screening in Nottingham revealed an interval cancer proportion of 51.3%, 
(Hardcastle et al., 1996), the Funen study 55.2% (Kronborg et al., 1996) and, in a non-
randomised trial of gFOBT effectiveness conducted in Burgundy, 59.3%. (Faivre et al., 
1991)  Steele et al. (2012) investigated the proportion of interval cancer detected within 
the demonstration pilot of the Scottish Bowel Screening Programme from 2000-2007.  
Here, it was shown that the interval cancer proportion was 31.2%, 47.7% and 58.9% in 
the first, second and third rounds respectively.  In France, Tazi et al. (1999) compared 
characteristics of interval cancers with gFOBT screen-detected cancers over five 
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rounds of screening.  Of 398 colorectal cancers detected, 57.8% were interval cancers.  
These studies show that interval cancers are consistently accounting for more than half 
of the colorectal cancers detected in biennially screened populations, indicating poor 
test sensitivity.  Methods to improve test sensitivity without an unacceptable associated 
fall in specificity may be aided by knowledge of factors showing association with 
interval cancers.  Some characteristics have been identified from published studies 
analysing colorectal cancer diagnosed both following negative gFOBT results and 
negative colonoscopy. 
 
In the investigations of Steele et al., (2012)  50.2% of interval cancers were found to 
arise in women, representing a significantly higher proportion than seen with screen-
detected cancers (35.5%) and in the non-screened population (40.6%).  In addition, 
significantly more interval cancers were situated in the right colon or rectum than in 
both the screen-detected group and the non-screened group. Assuming the cancers 
were present at the time of the negative gFOBT, these findings suggest that gFOBT 
may tend to preferentially detect cancers in men and in the left side of the colon.  
Similar findings were demonstrated by Gill et al. (2012) using colorectal cancer audit 
data from the North-East of England.  The proportion of cancers occurring in women 
was higher in those with an interval cancer (39.6%, compared with 27.0% among 
screen-detected cancers), again suggesting that women may be disadvantaged with 
gFOBT.  Also, a third of interval cancers were located proximally compared with just 
over a fifth in the screen-detected group, suggesting that gFOBT is also less effective 
for detecting right-sided lesions.  On the other hand, Tazi et al. (1999)  found that, 
amongst cancers of the rectum, 72.2% were interval cancers, a higher proportion than 
at any other site.  Also, less interval cancers were classified as earlier stage than 
screen-detected cancers (57.4% compared with 73.8%).  These results are consistent 
with those of Jensen et al., (1992) who found interval cancers in their study group to be 
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more advanced, larger, less often Dukes’ stage A, more invasive to neighbouring 
organs and less often able to be resected for cure.  Again, interval cancers were 
located more often in the rectum than cancer detected through screening and those in 
non-responders to screening.  The reasons for the apparent association of colorectal 
cancer in the right colon and rectum with interval cancers in screening with tests for the 
presence of Hb in faeces are not clear and this requires further attention.  Some 
potential explanations, however, include a greater degree of degradation of Hb arising 
from right-sided lesions due to a longer passage through the colon, non-haemolysed 
erythrocytes from rectal tumours not yielding a positive screening test result and rectal 
tumours being associated with faster growth rates. (Launoy et al. 1997) 
 
 
Further evidence of characteristics associated with cancers missed by a screening test 
comes from studies of cancer diagnosed following negative colonoscopy.  Brenner et 
al. (2012) conducted a case-control study to assess predictors of colorectal cancer 
occurring within 10 years of a colonoscopy where no lesion was detected.  They found 
that a significantly higher proportion of these so-called interval cancers were found in 
women than in the population with screen-detected cancers, (56.4% v. 33.7%); female 
gender showed an odds ratio for interval cancer of 2.28 (95% CI: 1.35 - 3.83).  
Proximal location in the colon was also independently associated with interval cancer, 
with an odds ratio of 1.98 (95% CI: 1.17 - 3.35).  A positive gFOBT result was the most 
common indication for the negative colonoscopy and colonoscopy was more often 
incomplete amongst interval cancer cases than controls.  Interestingly, the association 
of these colonoscopy-related factors with interval cancer was gender-specific; follow-up 
of a positive gFOBT result was strongly associated with negative colonoscopy 
preceding colorectal cancer in men, but not in women, whereas incompleteness of 
colonoscopy showed strong association with interval cancer in women, but with no 
association found in men.  The higher proportion of interval cancers located proximally 
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compared with screen-detected colorectal cancer was only statistically significant for 
the first three years following negative colonoscopy.  Furthermore, interval cancers 
were more commonly late stage than screen-detected cancers and this was particularly 
true for proximal cancers and cancers detected within three years of a negative 
colonoscopy.  This evidence points towards interval cancers being previously missed 
lesions rather than fast-growing, de novo tumours not present at the time of 
colonoscopy.  Conversely, interval cancers occurring with a positive gFOBT result as 
the indicator for negative colonoscopy were associated with distal location in the colon.  
The authors speculated that, with sensitivity for adenoma detection with gFOBT being 
higher for men than women, small adenomas detected with gFOBT were being missed 
by colonoscopy in men.  Interestingly, a study by Shaukat et al.(2010)  examining gene 
mutations associated with interval cancer looked only at cancers diagnosed within five 
years of a complete colonoscopy, meaning that failure to inspect the proximal region of 
the colon was less of an issue.  A multivariate logistic regression model showed 
proximal location in the colon and micro-satellite instability to be independently 
associated with interval cancer (odds ratio = 1.85, 95% CI: 1.01 – 3.8 and 2.7, 95% CI: 
1.08 – 6.8, respectively).  Several other studies have also identified an association 
between proximal location in the colon and interval cancer following negative 
colonoscopy. (Cooper et al., 2012; Farrar et al., 2006; Hosokawa et al., 2003; Singh et 
al., 2010; Singh et al., 2006) 
 
  
The high interval cancer proportion associated with gFOBT is of concern, with the poor 
test sensitivity suggested by these rates being a major disadvantage.  Further research 
is required to identify potential methods of reducing proportions of interval cancer and 
addressing the imbalances seen between men and women, and between tumour sites, 
such as replacing gFOBT with a test that has higher clinical sensitivity. 
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Further to the high interval cancer proportion, most likely caused by false negative test 
results, gFOBT is also associated with a high false positive test result rate.  Data from 
the Nottingham (Hardcastle et al., 1996) and Funen (Kronborg et al., 1996) RCT show 
that no neoplasia is detected in around half of colonoscopies performed following a 
positive gFOBT result.  One reason for this may be that gFOBT are not specific for 
human Hb and are therefore subject to possible dietary interference, for example from 
red meat.  In addition, gFOBT have also been thought to be susceptible to interference 
from dietary high-peroxidase vegetables contributing to a false positive test result, and 
conversely, citrus fruits and high-dose vitamin C can inhibit the peroxidase reaction, 
generating false negative test results.  In consequence, some screening programmes 
instruct participants to adhere to dietary restrictions ahead of collection of faeces, 
although these restrictions may act as a barrier to screening and result in lower 
participation rates. (Pignone et al., 2001)  However, a systematic review by Konrad 
(2010) concluded that data from four RCT did not support dietary restrictions with 
gFOBT, with only large quantities of red meat having an effect, and recommended that 
restrictions are abandoned to improve uptake. 
 
Several further disadvantages associated with gFOBT have been highlighted. (Duffy et 
al., 2011; Fraser, 2008)  Test interpretation is subjective, leaving the detection of subtle 
colour changes on the test card open to inter-observer variation.  This testing is 
impossible to automate for more rapid-sample turnaround and as such, gFOBT have 
been regarded as inappropriate for large-scale population screening.  Another 
weakness identified with gFOBT is that with guaiac being a tree bark extract, it is 
subject to batch-to-batch variation that can result in fluctuation in the test positivity rate.  
This is clearly a drawback in screening programmes looking to maintain a consistent 
rate of referrals to a limited colonoscopy resource. 
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Newer, faecal immunochemical tests for Hb (FIT) have become available and are 
increasingly being used in screening programmes due to the plethora of advantages 
they have over gFOBT.  Unlike gFOBT, FIT are specific for the detection of human Hb, 
eliminating any potential for false positive test result arising from dietary interference.  
They differ from gFOBT in that they utilise antibodies to detect the globin moiety of the 
Hb molecule.  The globin from Hb released in the upper gastrointestinal (GI) tract is 
broken down by digestive enzymes before reaching the large bowel, meaning that FIT 
are also more specific than gFOBT for lower GI bleeding.  In addition to the ease-of-
use advantage owing to the lack dietary restriction requirements, modern FIT generally 
provide a more convenient method of sample collection, using probes attached to the 
lid of the collection device rather than the less convenient card and spatula methods 
associated with gFOBT.  Due to its greater sensitivity for detecting blood in the faeces, 
FIT are often one sample kits, in contrast to gFOBT, which usually require two samples 
of faeces from each of three consecutive bowel movements.  These less-demanding 
features of sample collection are thought to account for the improvements in uptake 
seen when comparing FIT with gFOBT, widely reported across several RCTs (Federici 
et al., 2005; Hoffman et al., 2010; Hol et al., 2010; Hol et al., 2009) and other 
publications (Birkenfeld et al., 2011; Canadian Agency for Drugs and Technologies in 
Health (CADTH), 2010; Digby et al., 2013; Martínez et al., 2011; Shuhaibar et al., 
2011; Vart et al., 2012).  A particularly pleasing outcome from the evaluation of 
quantitative FIT within the Scottish Bowel Screening Programme was that the 
improvement in uptake seen when comparing those invited with a group invited via the 
usual gFOBT/qualitative FIT two-tier reflex algorithm was greatest in men, those in the 
youngest age quintiles, and those in the most deprived quintiles of socioeconomic 
status. (Digby et al., 2013)  A thorough recent review of tests and investigations for 
colorectal cancer screening makes the statement that “the ideal screening test is the 
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test that gets done” and points towards FIT as the non-invasive test of choice for 
implementation in organised screening worldwide. (Carroll et al., 2014) 
 
Another major advantage of FIT is that automated versions are available that not only 
have advantages over gFOBT in terms of improving analytical quality and potentially 
laboratory costs, but also the quantitative nature of these tests mean that a faecal Hb 
concentration result is generated.  This means that, rather than being limited to the cut-
off faecal Hb concentration set by the manufacturer, quantitative FIT allow screening 
programme organisers to set an appropriate cut-off concentration for a positive test 
result to give optimum sensitivity and specificity within current colonoscopy capacity.  
Indeed, Terhaar sive Droste et al. (2011) demonstrated the benefits of different cut-off 
concentrations by showing substantial reductions in test positivity rates with increasing 
cut-off ranging from 10 to 40 µg Hb/g faeces using OC-Sensor (Eiken Chemical Co. 
Ltd, Tokyo, Japan), with only modest effects on detection rates of screen relevant 
neoplasia, classed as advanced adenoma or early stage colorectal cancer. 
 
Further support for FIT as a screening tool comes from the recent interim report by 
Quintero et al. (2012) on a RCT being conducted in 57,404 subjects aged 50-69 years 
to compare biennial FIT at a cut-off of 15 µg Hb/g faeces using OC-Sensor with a 
strategy of offering one-time colonoscopy. The interim results show that one-time 
screening with FIT shows a similar detection rate for colorectal cancer as colonoscopy, 
with no significant difference in stage of tumours detected.  Although more adenomas 
were identified with colonoscopy, uptake with significantly lower in this arm compared 
to that of the FIT group.  The completion of the 10 year trial is awaited with much 
interest as to their full findings on the comparative effectiveness of the strategies for 
reducing colorectal cancer mortality. 
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1.3 Guaiac faecal occult blood tests v. Faecal Immunochemical Tests for 
haemoglobin 
 
 
 
When selecting the most appropriate screening test, programme organisers must 
carefully consider its clinical performance in a screening setting.  Four possible 
outcomes of a screening test result exist - true positive, false positive, false negative 
and true negative - and important indicators of the clinical performance of a screening 
test can be assessed from calculations involving the numbers of participants in each 
group, as outlined in Figure 1.1 in the context of colorectal cancer detection.  Positive 
Predictive Value (PPV) in colorectal cancer screening is the proportion of participants 
undergoing colonoscopy as follow-up to a positive test result who actually have disease 
detected.  Negative Predictive Value (NPV) is the proportion of participants with a 
negative test result who are, in fact, free from the disease in question e.g. correctly 
predicted as not having colorectal cancer.  Sensitivity is a measure of the test’s ability 
to identify the disease being screened for, e.g. the proportion of participants in the 
screened population who have colorectal cancer, who are identified via a positive 
screening test result.  Conversely, test specificity is how well the test rules out those 
without disease.  Other indicators of the clinical performance of a screening test include 
detection rate (number of true positives relative to the number of persons participating), 
and number needed to scope (NNS) to detect disease.  In colorectal cancer screening 
(as in other average-risk population screening programmes), the vast majority of 
participants will have true negative test results.  As a result, significant gains in 
sensitivity achieved by, e.g., lowering of the cut-off concentration, are associated with 
much smaller changes in specificity.  These small reductions in specificity can, 
however, result in a substantial increase in those with false positive test results, with an 
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associated impact on costs and colonoscopy workload and this must be taken into 
account. 
 
Figure 1.1 2x2 contingency table of possible colorectal screening outcomes with equations 
for calculation of indicators of test performance. 
 
  Detection of colorectal cancer (CRC) 
at colonoscopy 
 
  CRC present CRC absent  
Result of test 
for 
haemoglobin 
in the faeces 
Positive True positives 
(TP) 
False positives 
(FP) 
Positive Predictive Value: 
TP / (TP + FP) 
Negative False negatives 
(FN) 
True negatives 
(TN) 
Negative Predictive Value: 
TN / (FN + TN) 
   
Sensitivity: 
TP / (TP + FN) 
 
Specificity: 
TN / (FP + TN) 
 
 
 
Clinical performance of FIT in comparison to gFOBT has now been investigated in 
several studies, with RCT showing that FIT perform better in the detection of screen-
relevant neoplasia.  Van Rossum et al. (2008) compared the performance of a 
standard gFOBT to the OC-Sensor FIT by inviting 20,623 of the general population in 
The Netherlands, aged 50-75 years, randomly assigned to complete either three 
traditional two-sample gFOBT cards or a single quantitative FIT with a cut-off 
concentration of 20 µg Hb/g faeces.  From results of colonoscopies performed on 103 
gFOBT-positive participants and 270 FIT-positive participants, it was found that 2.5 
times more cancers and advanced adenomas were detected with FIT than with 
gFOBT.  However, the NNS to detect one cancer was comparable between the tests, 
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no significant difference was seen in the PPV for cancer and advanced adenomas, and 
specificities favoured gFOBT. 
 
In another RCT, Hol et al. (2009) evaluated the performance of traditional gFOBT in 
comparison to OC-Sensor FIT at various cut-off concentrations between 10 and 40 µg 
Hb/g faeces in subjects aged 50-74 years in a screening-naïve population in The 
Netherlands.  They concluded that FIT was a more effective screening tool than 
gFOBT at all seven cut-off concentrations examined owing to its superior performance 
with regard to both uptake and detection rate of colorectal cancer and higher-risk 
adenomas combined, termed advanced neoplasia.  In keeping with the trial by van 
Rossum et al., PPV for advanced neoplasia were not significantly different between the 
two tests and specificity was significantly lower with FIT. 
 
A later publication by Hol et al. (2010) incorporating the same dataset showed the 
results of the RCT when additionally evaluating flexible sigmoidoscopy as a screening 
modality.  A randomly selected study population of 15,011 individuals were invited 
using a 1:1:1 ratio to participate in screening completing either gFOBT, FIT or flexible 
sigmoidoscopy.  Colonoscopy was indicated in those with a positive faecal test, or, in 
the flexible sigmoidoscopy group, when advanced neoplasia was detected.  Uptake 
was higher in the FIT group (61.5%) than in both the gFOBT group (49.5%) and the 
flexible  sigmoidoscopy group (32.4%).  The difference in uptake between the two 
faecal tests was thought to be attributable to the more demanding sampling procedure 
associated with the gFOBT.  The detection rate for advanced neoplasia was 
significantly higher for FIT and flexible sigmoidoscopy than gFOBT.  Flexible 
sigmoidoscopy gave a superior diagnostic yield per 100 invitees (2.4 [95% CI: 2.0 – 
2.8]) than seen in both faecal test groups (1.5 [95% CI: 1.2 – 1.9] and 0.6 [95% CI: 0.4 
– 0.8] for FIT and gFOBT, respectively).  The authors, therefore, recommended 
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consideration of a dual-mode screening programme, involving both FIT and flexible 
sigmoidoscopy. 
 
A more recent trial by Levi et al. (2011) randomised participants aged 50-75 years from 
an average-risk population in Israel to a FIT or gFOBT screening arm.  From the 4,657 
offered FIT and 7,880 a high-sensitivity guaiac FOBT (sFOBT), FIT had higher 
sensitivity for cancer detection at 100% compared with 61.5% for sFOBT, although 
specificity was again lower, at 85.9% compared with 96.4% with the sFOBT.  The study 
also found FIT to provide increased detection rates for advanced adenoma with an 
odds ratio of 2.7 (95% CI: 1.6 – 4.5), rising to 3.2 (95% CI: 1.8 – 5.4) on an intention-to-
screen basis.  The authors stated that FIT seemed to meet the objectives of mass 
screening for colorectal cancer outlined by the World Health Organization of detecting 
50 prevalent cases of colorectal cancer per 10,000 persons completing the test. 
(Wilson & Jungner, 1968) 
 
In addition to the four RCT detailed above, three very recent comparison studies have 
been conducted of gFOBT and FIT performance in screening settings. 
 
Brenner & Tao (2013)  have published results of their head-to-head comparison of 
three quantitative FIT and a traditional gFOBT in 2,235 first-time participants aged 50-
79 years in the German colonoscopy-based screening programme.  Unlike other 
comparison studies, they adjusted FIT cut-off concentrations to generate an equal 
positivity rate across the tests.  At this universal test positivity rate of 5%, all three FIT 
outperformed the gFOBT for all performance indicators examined.  All sensitivities 
were around 2-3 times greater with the three FIT, with around twice as many 
neoplasms detected overall and three times as many advanced neoplasms than with 
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gFOBT.  Specificity was high with gFOBT at 95.4% for advanced neoplasia, but was 
higher with the three FIT at 96.8%, 97.1% and 97.4% for each.  PPV and Negative 
Predictive Values (NPV) were also significantly higher with FIT.  This study seems to 
offer strong backing to the argument for replacing gFOBT with FIT.  However, caution 
must be taken with interpretation of these results due to a flawed sampling technique 
with poorly preserved faecal samples, and cut-off concentrations that maximise 
comparability of the tests but may not be the most cost-effective or feasible to apply in 
full roll-out into population screening. 
 
Another similar population-based comparison of FIT and gFOBT was carried out in 
France by Raginel et al. (2013), who invited 19,797 individuals aged 50-74 years to 
complete two different quantitative FIT and one traditional gFOBT.  Results from 1,075 
participants referred for colonoscopy showed that when the tests were compared at the 
same positivity rates (1.6%) to give a similar number of colonoscopies, the number 
needed to screen to detect one case of advanced neoplasia was 30% lower with the 
first FIT than with gFOBT, and the NNS were 3.3, 2.3 and 1.8, for the gFOBT and the 
two different FIT, respectively.  Impressively, for the same number of positive test 
results, the second FIT detected almost double the number of cases of advanced 
neoplasia than did the gFOBT.  An important observation is that variation exists 
between different FIT, with receiver operating characteristic (ROC) curve analysis 
showing the second FIT to display superior accuracy in the detection of advanced 
neoplasia compared with the first FIT.  The second FIT is, however, more expensive at 
present, so again programme organisers have to give careful consideration to cost-
effectiveness analysis. 
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Another recent French-based study by Hamza et al. (2013) demonstrated improved 
clinical performance with FIT compared with gFOBT in 23,231 average-risk screening 
invitees aged 50-74 years.  At a cut-off of 17 µg Hb/g faeces using FOBGold (Sentinel 
Diagnostics, Milan, Italy), the detection rate of FIT for non-invasive cancer was six 
times that of gFOBT and four-times higher for advanced adenoma.  At all cut-off 
concentrations examined (ranging from 17 up to 60 µg Hb/g faeces), PPV for advanced 
adenoma with were far higher than with gFOBT (ranging from 34.3 - 41.5% with FIT, 
18.2% with gFOBT).  These three recently published studies provide additional support 
to the case for replacing gFOBT with FIT in colorectal cancer screening. 
 
Further studies have also compared the clinical characteristics of gFOBT with FIT in 
screening settings, with several of these using a sFOBT.  Allison et al. (2007) 
compared a sFOBT with FIT in 5,841 average-risk participants aged over 50 years.  
FIT had significantly superior performance characteristics than the sFOBT with higher 
specificity and PPV both for colorectal cancer (96.9% v. 90.1% and 5.2 v. 1.5%, 
respectively) and advanced adenoma (97.3% v. 90.6% and 19.1 v. 8.9%, respectively), 
and a lower test positivity rate (2.1% v. 3.2%), although sensitivity for colorectal cancer 
and advanced adenomas was not statistically significant between the two tests.  An 
evaluation by Levi et al. (2006) comparing a group of 162 subjects aged 50-75 years 
with a positive sFOBT result undergoing colonoscopy with 151 subjects due for 
colonoscopy additionally completing a FIT, found identical sensitivity for the detection 
of advanced neoplasia between FIT and sFOBT (both 75%), but with a statistically 
significant increase in specificity with FIT (94% v. 34%).  Similarly, Rozen et al. (2009b) 
evaluated the performance of the qualitative FIT with a stated cut-off concentration of 
50 ng/ml against a sFOBT in a population scheduled for colonoscopy either due to a 
positive test result from the sFOBT, increased colorectal cancer risk, or mild symptoms.  
From 330 participants completing both tests, similar sensitivity was found between the 
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two tests but with vastly improved specificity for FIT at 94.0% compared to 59.4% for 
sFOBT and 2.1 colonoscopies conducted to detect one neoplasm compared to 8.1 
colonoscopies required with the sFOBT.  In contrast, Smith et al. (2006) found that FIT 
had higher sensitivity for cancer and significant adenomas (36.6% v. 19.5%), but their 
indirect measurement of specificity slightly favoured sFOBT (97.5% v. 96.6%). 
 
Several other studies comparing FIT with a traditional gFOBT rather than a sFOBT 
have been conducted, with a common finding being that sensitivity is better with FIT, 
but associated with lower specificity (Graser et al., 2009; Guittet et al., 2007; Park et 
al., 2010; Parra-Blanco et al., 2010; Wong et al., 2012).  However, in a 2007 review, 
Young & Cole (2007) did not deem the diminished specificity commonly seen with FIT 
to be unacceptable when balanced with the gain in sensitivity.  Moreover, the nature of 
modern quantitative FIT allows modification of the cut-off concentration to potentially 
counteract this effect to some extent. 
 
Further reviews of the available literature comparing the gFOBT and FIT exist.  The 
2010 meta-analysis conducted by Zhu et al. (2010) comparing gFOBT and FIT in 
screening and surveillance of advanced neoplasia concluded that FIT performed 
significantly better than gFOBT, with higher sensitivity and specificity in the diagnostic 
cohort studies reviewed.  However, a systematic review by Burch et al. (2007) 
focussing on the diagnostic accuracy of faecal tests in colorectal cancer screening 
concluded that there was no clear indication of either FIT or gFOBT showing 
superiority.  Although there was some evidence of FIT having higher sensitivity and 
specificity, this did not occur consistently and there were few direct comparisons 
available.  Similarly, American guidelines (Levin et al., 2008) state that there are no 
clear patterns of superiority in test performance between sFOBT and a variety of FIT, 
and that other factors such as cost-effectiveness and screening uptake should 
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therefore be considered by policy makers when selecting a test kit.  Indeed, an 
evaluation of using quantitative FIT in two Scottish NHS Boards concluded that, despite 
clinical outcomes being similar to those observed with the two-tier reflex gFOBT 
followed by qualitative FIT algorithm in place, introduction of qualitative FIT was 
supported by various other advantages.  These included improved uptake, good 
analytical reproducibility, removal of the possibility inter-observer variation and 
elimination of a fluctuating test positivity rate owing to batch-to-batch variation in 
reagents, a problem previously experienced in the programme. (Steele et al., 2013) 
 
Growing evidence demonstrates that FIT displays superiority over gFOBT specifically 
for adenoma detection, documented well in the review by Rabeneck et al. (2012) 
comparing the two types of faecal test.  This observation is highlighted in the study 
conducted in France by Guittet et al. (2007)  during the first year of a screening 
programme offered to 50-74 year olds using a standard gFOBT, with participants also 
asked to complete a Magstream FIT (Fujirebio Inc., Tokyo, Japan) with a relatively low 
cut-off concentration of 20 ng/ml (conversion factor for µg Hb/g faeces unavailable).  
644 participants who had a positive test result from one of the two faecal tests had 
colonoscopy results available.  It was observed that raising the cut-off concentration to 
75 ng/ml would give the same test positivity rate with both tests (2.4%), with FIT having 
superior PPV for neoplasia than gFOBT, particularly for high-risk adenoma where the 
PPV was 49.2% compared with 27.7% with gFOBT. 
 
Hundt et al. (2009) compared six different qualitative FIT kits and one gFOBT for 
detection of colorectal cancer precursor lesions in average risk participants in Germany 
undergoing colonoscopy.  They found that the different tests had widely varying 
performance characteristics but FIT performed better for advanced adenoma detection 
with sensitivity and specificity ranging from 25% to 72% and 70% to 97%, respectively, 
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for the FIT, but just 9% and 96%, respectively, for gFOBT.  The results from these 
studies suggest that, although overall comparison of performance characteristics 
between FIT and gFOBT is inconclusive, the real benefit of FIT in terms of clinical 
performance may lie in superior detection of precursor lesions – a key aim for an 
effective screening programme. 
 
Further support for the replacement of gFOBT with FIT in screening may come from 
the 2011 report by Scholefield et al. (2012), detailing follow-up the participants of the 
RCT of biennial gFOBT conducted in Nottingham after 20 years.  In the 152,850 
individuals tracked, they found a reduction in colorectal cancer mortality in the 
intervention arm of 13% compared with the control arm.  With an uptake of 57%, this 
figure rose to 18% when adjusted for actual screening participants.  However, no 
significant reduction in colorectal cancer incidence was apparent despite 615 large 
precursor lesions being removed.  It was suggested that a higher detection and 
removal rate would be required before an effect on incidence would be observed.  With 
FIT having been shown to exhibit superior detection of adenomas, perhaps its 
incorporation into colorectal cancer screening programmes could have a greater impact 
on reducing colorectal cancer incidence.  Indeed, a commentary on the study by 
Scholefield et al. went as far as to suggest that gFOBT is now obsolete in colorectal 
cancer screening and its replacement with FIT would not only enhance the observed 
reduction in colorectal cancer mortality but also contribute towards an impact on 
colorectal cancer incidence reduction through greater sensitivity for adenoma. (Young 
et al., 2012) 
 
It is important when selecting which screening test to implement that the constraints of 
the available resources are taken into account.  An informative review by Young et 
al.(2015)  considered the most appropriate test within four different scenarios: 1) limited 
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colonoscopy capacity; 2) expectation of maximum detection of neoplasia; 3) “adequate” 
colonoscopy capacity; and 4) aim of maximising screening uptake.  The authors 
concluded that quantitative FIT is the test of choice for all four scenarios with the 
adjustable cut-off making it convenient for 1), 2) and 3), and superior for scenario 4).  
gFOBT was deemed only to be suitable for scenario 1), where there is a real need to 
constrain the test positivity rate. 
 
 
1.4 Effects of adjusting the cut-off concentration with a Faecal 
Immunochemical Test for haemoglobin. 
 
 
Any gain in sensitivity obtained by replacing gFOBT with FIT in a colorectal cancer 
screening programme can potentially be augmented by a range of further adjustments 
to screening strategy.  However, improvement in sensitivity is only worthwhile if 
associated with an acceptable change in specificity to minimise false positive test 
results and maintain a referral rate that can be supported by the available colonoscopy 
resource.  Scotland, like many other countries, has had to develop its colorectal cancer 
screening programme to operate within a relatively limited capacity for colonoscopy.  A 
number of strategies can potentially be employed to minimise the burden placed on this 
resource by faecal testing.  These include narrowing the age range, lengthening the 
screening interval, increasing the number of samples with referral only triggered by 
more than one positive test result, and limiting follow-up referrals in those with 
pathology detected.  A further option afforded by quantitative FIT is setting the cut-off 
concentration to deliver a test positivity rate appropriate to the number of referrals that 
can be handled by the available colonoscopy resource. 
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Several studies have assessed the impact of modification of the cut-off faecal Hb 
concentration on various performance indicators associated with colorectal cancer 
screening.  As would be expected, a general trend has been identified from the 
published data showing that as the cut-off concentration is raised, sensitivity for 
colorectal neoplasia detection decreases and specificity increases. (Grazzini et al., 
2009; Guittet et al., 2009; Launoy et al., 2005; Levi et al., 2007; Nakama et al., 2001; 
Rozen et al., 2010; Wilschut et al., 2011a)  Similarly predictable effects when 
increasing the cut-off faecal Hb concentration, such as diminished detection rates, 
increasing PPV and decreasing NPV for cancer and adenomas, were additionally 
reported in further studies (Brenner et al., 2010; Castiglione et al., 2002; Kovarova et 
al., 2012; Terhaar sive Droste et al., 2011).  To identify the cut-off concentration at 
which optimal clinical performance is achieved, the concentration at which there is an 
acceptable trade-off between these characteristics must be established.  Numerous 
publications now exist documenting identification of this optimal concentration in 
various FIT screening settings. 
 
Van Rossum et al. (2009) studied 428 average risk participants aged 50-70 years old 
undergoing colonoscopy following a faecal Hb concentration over 10 µg Hb/g faeces.  
Performance characteristics were also calculated at 15 and 20 µg Hb/g faeces and, as 
expected, detection rates and NNS to detect one colorectal cancer or advanced 
adenoma both fell as the cut-off concentration rose.  From these results, the authors 
advocated the use of a cut-off faecal Hb concentration of 15 µg Hb/g faeces, given 
sufficient colonoscopy capacity, and recommend increasing up to 40 µg Hb/g faeces 
where this is not the case.  A rise in the cut-off concentration from 10 to 40 µg Hb/g 
faeces saw a 50% reduction in the number of colonoscopies, while the detection rate 
for advanced neoplasia fell from 3.1% to 1.8% and the NNS to detect one case of 
advanced neoplasia also fell from 2.3 to 1.8.  The reduced detection rate for advanced 
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neoplasia when the cut-off concentration was raised from 20 to 40 µg Hb/g faeces was 
found to almost entirely relate to missed adenomas, with the detection rate for 
colorectal cancer unaffected.  With progression of the adenoma-to-cancer pathway in 
the colon being a gradual process, this fall in adenoma detection rate may be 
acceptable in view of the potential for eventual detection of such lesions in subsequent 
screening rounds while they are still at an early stage of malignancy. 
 
The randomised comparison of FIT and gFOBT performance carried out by Hol et al. 
(2009) also examined the effect of varying the cut-off faecal Hb concentration in 
screening.  Although stating that a full cost-benefit analysis is essential for accurate 
determination of the ideal cut-off concentration at which the benefits associated with 
screening, i.e., early detection of colorectal cancer, outweigh the harms, such as costs, 
anxiety and complications associated with undergoing colonoscopy, Hol et al. 
considered that the ratio between detection rate and NNS acts as a good indicator of 
this. Their assessment of this balance gave findings in agreement those of van 
Rossum et al. in that a cut-off faecal Hb concentration of 15 µg Hb/g faeces was 
deemed to give an acceptable trade-off.  Interestingly, they found that a considerably 
larger decrease in test positivity occurred when raising the cut-off faecal Hb 
concentration from 10 to 15 µg Hb/g faeces than that occurring with any further similar 
increase, with the trade-off between detection rate and NNS being less favourable 
when further raising the cut-off faecal Hb concentration to 20 µg Hb/g faeces. 
 
Detailed cost-effectiveness analysis, such as that conducted by Chen et al. (2007), is 
of paramount importance in selecting a cut-off faecal Hb concentration that can be 
deemed optimal for all relevant parties.  The study, conducted in Taiwan, invited 
22,672 participants aged over 50 years to complete a FIT with a cut-off faecal Hb 
concentration of 20 µg Hb/g faeces; interval cancer data were collected on those with a 
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faecal Hb concentration below this concentration.  An optimum cut-off concentration in 
terms of test performance was identified at 20 µg Hb/g faeces using ROC curve 
analysis with an area under the curve of 0.87 (95% CI: 0.81 - 0.93), at which sensitivity 
was 81.5% and the false positive rate 5.7%.  Further to this, economic appraisal 
determined that the optimum number of life-years gained (LYG) and money saved 
occurred using a concentration equivalent to 22 µg Hb/g faeces.  It was demonstrated 
that, as the cut-off faecal Hb concentration rose above 20 µg Hb/g faeces, the average 
number of LYG fell and average discounted costs started to rise.  Although also related 
to the costs associated with referrals from false positive test results, this effect was 
found to be more attributable to the consequences of false negative test results, with 
cancers missed at screening associated with more expensive treatments when they 
later presented in a more aggressive form.  Therefore, although using a high cut-off 
faecal Hb concentration will lower the costs associated with demand on the 
colonoscopy resource, particularly from false positive test results, greater adverse 
consequences may arise with the indirect costs associated with failure to detect 
colorectal cancer at an early stage. 
 
Methods for adapting the screening programme to limit constraints on colonoscopy 
resource were further investigated by Wilschut et al. (2011a) using a series of 
simulated models.  They assessed the effects of various screening strategies on the 
number of colonoscopies required, costs incurred and health outcomes.  The 
adaptations simulated included narrowing the age range of invitees, reducing the 
number of screening interventions, employing a more specific test, and adjusting the 
cut-off faecal Hb concentration for a positive test result from 10 up to 40 µg Hb/g 
faeces.  The best strategy at all cost levels, assuming unlimited colonoscopy capacity, 
was annual FIT at a cut-off faecal Hb concentration of 10 µg Hb/g faeces offered to 45-
80 year olds.  However, when operating within limited capacity for colonoscopy, the 
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authors state that the first step is to raise the cut-off faecal Hb concentration used to 40 
µg Hb/g faeces.  To further reduce the burden on colonoscopy resource, limiting the 
age range to 50-75 year olds, then finally lengthening the screening interval is 
recommended, according to the results of the simulated models.  The impact of 
colonoscopy capacity on screening effectiveness was demonstrated by the finding that 
doubling this resource can increase LYG by up to 100%.  It was pointed out that using 
an elevated cut-off faecal Hb concentration would generate a higher-risk group of 
participants with a positive test result, for whom the potential for the intended health 
benefit of colorectal cancer screening was greater.  Indeed, it has become increasingly 
well documented that faecal Hb concentration relates to disease severity (Ciatto et al., 
2007; Hol et al., 2009; Launoy et al., 2005; Levi et al., 2007; Rozen et al., 2009a). 
 
Further analysis of the effects of raising the cut-off faecal Hb concentration to control 
the number of screening colonoscopies performed has been conducted by Terhaar 
sive Droste et al. (2011)  With participants aged over 40 years completing a single FIT, 
they assessed the impact of raising the cut-off faecal Hb concentration at increments 
between 10 and 40 µg Hb/g faeces on sensitivity and specificity for detection of screen-
relevant neoplasia, namely advanced adenoma and early-stage colorectal cancer.  
Test positivity rates ranged from 16.5% to 10.2% as the cut-off faecal Hb concentration 
was raised from 10 to 40 µg Hb/g faeces, representing a 42% reduction in the number 
of colonoscopies required.  The associated 6% drop in detection rates of early stage 
colorectal cancer was deemed acceptable.  Detection of advanced adenoma was 
diminished to a greater extent when raising the cut-off faecal Hb concentration, 
although, consistent with van Rossum et al., (2009) this was not viewed as too great a 
concern due to the potential for missed adenoma to be detected at subsequent  
screening rounds, with the long phase of adenoma to colorectal cancer disease 
progression meaning that the missed lesions would likely either still be presenting in a 
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subsequent round as an adenoma, or as a treatable early-stage cancer where 
colorectal cancer death remains preventable. 
 
It is evident that optimal cut-off faecal Hb concentration identified from the numerous 
analyses conducted will not be directly applicable across different geographic 
populations.  Each country looking to incorporate quantitative FIT into their colorectal 
cancer screening programme will need to carry out their own evaluations relevant to 
the specific screening population to be invited prior to selection of their cut-off faecal 
Hb concentration.  This should take into account numerous factors including disease 
prevalence, resource availability and cost-effectiveness.  Raising the cut-off faecal Hb 
concentration should be considered when colonoscopy capacity is limited, at the 
expense of detection rates which will suffer a gradual decline as the cut-off faecal Hb 
concentration is increased. 
 
 
1.5 Length of the screening interval 
 
 
Colorectal cancer prevention through screening is optimised by repeated invitations.  
Intermittent bleeding is associated with adenomas, particularly at an advanced stage 
(Chen et al., 2007), meaning that many participants with a negative faecal test result 
may harbour advanced adenomas not bleeding consistently enough to give a positive 
test result, but that are susceptible to malignant transformation over time.  Repeated 
testing allows further opportunity for relatively early detection and removal of such 
lesions.  The length of time between each screening round must be decided by 
programme organisers based on resource availability and recommendations for optimal 
use of the screening modality made in the available literature. 
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Van Roon et al. (2013) randomly invited 7,501 screening-naïve Dutch participants aged 
50-74 years to complete two rounds of single-sample FIT screening with an interval 
length of either one, two, or three years.  As would be expected in a previously 
unscreened population, the test positivity rate and advanced neoplasia detection rate 
was lower in the second round with all three interval lengths.  In addition, detection rate 
at the second round was not dependent on the interval length.  The authors suggested 
that this may mean that the screening interval can be tailored to local resources.  For 
example, when resources are limited, a longer interval can be used without significantly 
affecting test positivity and advanced neoplasia detection rates.  Interval cancers 
arising in the study population were also analysed.  Although only three interval cancer 
cases were identified, two were in the group invited triennially, accounting for 20.0% of 
colorectal cancer in that group.  The remaining interval cancer case arose in the 
biennially invited group, representing 9.1% of cancers in that group.  
 
Two studies have been published using microsimulation models to determine the 
optimal interval between rounds in colorectal cancer screening.  Modelling by Zauber et 
al. (2008) to measure LYG compared with no screening demonstrated that successive 
annual rounds of sFOBT or FIT screening has preventative effects similar to those 
seen with colonoscopy offered once every 10 years, and to 5-yearly sigmoidoscopy.  In 
general, a longer screening interval was associated with fewer LYG.  Wilschut et al. 
(2011b) examined cost-effectiveness of quantitative FIT using various cut-off faecal Hb 
concentration and screening intervals of 1, 1.5, 2 and 3 years in their models.  They 
found that biennial FIT was cost-effective in terms of LYG.  An interesting point made 
was that shorter intervals compensate for suboptimal uptake of screening, where those 
not participating in one round soon have another opportunity.  However, shorter 
intervals were not necessarily found to be optimal for regular participants.  Indeed, van 
Roon et al. (2013) observed enhanced test uptake in the second round in those invited 
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biennially and triennially compared with those participating annually, with statistical 
significance reached with triennial compared with annual invitation.  Considerable 
evidence showing quantitative FIT to be associated with improved uptake compared 
with gFOBT may mean that a shift towards longer screening intervals could become 
the more cost-effective route. 
 
Further advantage gained from introduction of quantitative FIT may be that there is 
scope for participants with a negative test result to be identified as being at high-risk 
due to a faecal Hb concentration close to the cut-off faecal Hb concentration perhaps 
being invited for their subsequent screening round at a shorter interval than those who 
are deemed low-risk.  This hypothesis was made by Chen et al. (2011) in conclusion to 
their important investigations into faecal Hb concentration as a predictor of colorectal 
neoplasia that will be discussed in more detail later in this Chapter, and is an idea that 
represents an interesting new area for research into more efficient use of quantitative 
FIT. 
 
 
1.6 Number of samples 
 
 
An additional measure to improve detection rates whilst reducing false positive test 
results could be to increase the number of faecal tests to be completed per round of 
colorectal cancer screening.  The reasoning behind the use of multiple samples again 
comes from the knowledge that some lesions are associated with intermittent bleeding, 
affecting the sensitivity and specificity of screening with FIT.  Numerous studies have 
been conducted investigating how many samples are required to optimise measures of 
diagnostic accuracy, whilst maintaining cost-effectiveness and not adversely 
influencing participation rates. 
30 
 
 
 
A study by Goede et al. (2013) using a microsimulation model based on data from an 
RCT compared cost-effectiveness of one- v. two-sample FIT testing in colorectal 
cancer screening.  Two-sample testing provided an additional 7.3 - 12.4 LYG 
compared with one-sample testing, with the accompanying extra costs deemed 
acceptable.  However, it was also found that a similar or greater number of LYG with 
lower associated costs can be achieved by using one FIT and intensifying screening by 
means of widening the age range or shortening the screening interval and therefore 
recommended such strategies ahead of increasing the number of samples to achieve 
cost-effectiveness. 
 
Oort et al. (2011) conducted a prospective cohort study with 1,096 subjects scheduled 
for colonoscopy completing two FIT.  Clinical sensitivities and specificities were 
compared for when participants with an overall positive screening test result were 
identified by one of three different pathways: either one of the two test results positive, 
both test results positive, or the mean faecal Hb concentration of the two being above 
the cut-off used.  At any of the cut-off faecal Hb concentration examined, the lowest 
sensitivity for screen-relevant neoplasia (early stage colorectal cancer or advanced 
adenoma) was in the group with both test results positive (range of 35 - 44%).  
Sensitivity was best when test positivity was considered with one out of two tests being 
above the concentration (range of 42 - 54%).  ROC curves of double FIT sampling 
were similar to those calculated from single-sampling data and neither of the double-
sampling strategies displayed a superior combination of sensitivity and specificity over 
single-sample FIT. 
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Van Roon et al. (2011) conducted a population-based trial in which 5,007 participants 
were invited to complete one FIT and 3,197 to collect faecal samples on two 
consecutive days.  No difference in participation rate was seen between the two 
groups, at 61.5% and 61.3% respectively.  Participants were referred for colonoscopy 
when at least one positive test result was obtained and test positivity and detection 
rates for advanced neoplasia in the single-sample group were compared with those 
calculated for three positivity strategies in the two-sample group, analogously to Oort et 
al. (one of two test results positive; both test results positive; mean of two test results 
above cut-off faecal Hb concentration).  Using a cut-off faecal Hb concentration of 10 
µg Hb/g faeces, two-sample FIT screening using a least one positive test result as the 
referral criteria provided a higher detection rate for advanced neoplasia than single-
sample FIT screening (4.1% v. 3.1%).  However, this was at the expense of higher test 
positivity rates (12.8% v. 8.1%), and therefore greater demand on colonoscopy 
resource.  It was recommended that development of efficient screening strategies that 
can be adapted according to colonoscopy capacity rather than varying the cut-off 
faecal Hb concentration with single-sampling, pointing to their results showing that with 
test positivity rates up to 3.2%, two-sample FIT at a cut-off concentration of 20 µg Hb/g 
faeces, when demanding both test results to be positive for referral, provided the most-
efficient strategy. 
 
Similarly, Guittet et al. (2009) investigated the performance of FIT according to the 
number of samples whilst varying the cut-off faecal Hb concentration used.  Single-
sample screening displayed sensitivities and specificities comparable to those of the 
strategy requiring one positive test result from two samples to warrant colonoscopy.  
Taking the mean of the faecal Hb concentration of the two samples to determine a 
positive test result brought about improved performance at any test positivity rate 
generated.  In contrast to the later study by van Roon et al, (2011) it was suggested 
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that the use of one positive test result from two tests should be replaced by single-
sampling, or for even better clinical outcomes, a strategy using the mean faecal Hb 
concentration of two samples providing uptake remained at similar level to that seen 
with single-sampling. 
 
The study by Wong et al. (2012) comparing performance of gFOBT and FIT also 
included analysis of single- against two-day FIT sampling.  A trend towards superior 
sensitivity for colorectal cancer and adenoma was seen when one out of two samples 
having positive test results warranted referral compared with single-sampling and when 
two positive test results were demanded; however, the difference was not significant.  
False positive test result rates, however, were significantly higher when using one 
positive test result in two samples compared with the other two strategies.  Single-
sampling was deemed to be an acceptable option for screening with the aim of raising 
participation rates. 
 
Further work examining the effect of the number of FIT samples completed on clinical 
performance comes from the analysis of Rozen et al. (2009a) of adenoma detection 
using FIT.  1121 participants scheduled for colonoscopy completed three consecutive 
daily FIT.  Diagnostic power was calculated by comparing colonoscopy findings with 
the test result when using the first, the higher of the first two and the highest of the 
three faecal Hb concentration measurements.   Sensitivity and specificity were 
assessed at various cut-off faecal Hb concentration between 10 and 30 µg Hb/g 
faeces, and at the higher end of this range, sensitivity increased and specificity 
decreased as the number of samples collected increased.  These findings again 
demonstrate how, as well as by adjusting the cut-off faecal Hb concentration with 
quantitative FIT to suit colonoscopy capacity, programme organisers can modify the 
number of samples tested to give the best performing strategy.  Detailed analysis of 
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cost-effectiveness will be required prior to any such decision to determine whether the 
extra costs associated with processing additional samples are justified by the benefits 
gained from the potentially more sensitive screening strategy. 
 
Levi et al. (2007) investigated the performance of quantitative FIT in a population at 
increased risk of colorectal cancer.  1,000 participants collected three samples and 
faecal Hb concentration were compared with colonoscopy results.  They found that at a 
cut-off faecal Hb concentration of 15 µg Hb/g faeces, detection of colorectal cancer 
when taking the highest faecal Hb concentration of three was the same as when using 
the higher of the first two faecal Hb concentration (area under the curve 0.96, [95% CI: 
0.94 - 0.98] and 0.96, [95% CI: 0.93 - 0.98], respectively), but taking the first faecal Hb 
concentration only diminished diagnostic performance (area under the curve 0.87 [95% 
CI: 0.78 - 0.97]).  Similar findings, but to a lesser extent, were seen when also 
performing a ROC curve analysis for advanced neoplasia.  As such, it was stated that 
use of the highest of the faecal Hb concentration found in two or three samples is 
superior to single-sampling in terms of diagnostic performance. 
 
The European Guidelines for Quality Assurance in Colorectal Cancer Screening and 
Diagnosis (Halloran et al., 2012) included a review of existing studies examining the 
effect the number of faecal samples used in colorectal cancer screening.  In summary, 
it was recommended that adoption of screening strategies involving collection of more 
than one sample with specific test positivity criteria should be considered to give an 
appropriate referral rate in terms of cost-effectiveness, clinical performance and 
logistical feasibility. 
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From the studies including analysis in this facet of the use of FIT, it is evident that 
modifying the number of samples collected per participant is a potential adaptation to 
programme strategy that warrants consideration when seeking to improve screening 
effectiveness with faecal tests.  It is, however, a complicated matter, to be guided by 
various associated factors including participation rates, available resources and cost-
effectiveness. 
 
1.7 Age and gender differences in colorectal cancer screening 
 
 
 
Another important area identified for potential improvement in the efficiency of 
colorectal cancer screening is to take into account age and gender differences in 
screening detection rates.  The imbalance between different age groups and genders, 
in colorectal cancer screening in terms of test positivity rates and disease prevalence is 
well established, having been identified in several studies. 
 
Steele et al. (2010) investigated the effect of age and gender on key performance 
indicators generated in the Scottish Bowel Screening Programme using biennial 
gFOBT and reported significant increases in test positivity rates, colorectal cancer 
detection rates, and PPV for colorectal cancer with age, and also in men compared 
with women for all ages.  
 
 Furthermore, prevalence of colorectal neoplasia among individuals with a negative 
gFOBT result was studied by Rex et al., (1993) who showed, using multivariate 
analysis, that increasing age and male sex were both strong indicators of colorectal 
neoplasia.  Their data showed a particularly substantial prevalence among elderly men.   
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Regula et al. (2006) used multivariate logistic regression to identify associations 
between advanced neoplasia detection and participant characteristics in a 
colonoscopy-based screening programme, and confirmed the findings on a validation 
data set.  When adjusted for age and family history, male sex was found to be 
associated with advanced neoplasia, with an adjusted odds ratio of 1.73 (95% CI: 1.52 
- 1.98).  An odds ratio of 2.91 (95% CI: 2.21 - 3.83) was calculated for those aged 60-
66 years compared with those aged 40-49 years.  At all ages, the NNS to find one case 
of advanced neoplasia was significantly lower in men than in women.  To address this 
discrepancy, the authors suggest the strategy of only offering screening to population 
groups with a NNS below a pre-determined threshold, but stress that this needs to be 
backed up by cost-effectiveness analysis. 
 
In a study conducted to assess how neoplasia detected in the distal colon predicts the 
risk of neoplasia found proximally, Imperiale et al. (2000) found older age and male sex 
to be associated with higher rates of advanced neoplasia in the proximal colon, with 
relative risk reported as 1.3 for every five years of age and 3.3 for male gender. 
 
A review of the literature detailing gender as a risk factor conducted by Nguyen et al. 
(2009) calculated a pooled risk ratio for advanced neoplasia of 1.83 (95% CI: 1.69 - 
1.97) for men compared with women, rising to 2.02 (95% CI: 1.53 - 2.66) for colorectal 
cancer.  Again, the NNS to detect advanced neoplasia was lower in men than in 
women, in all age groups studied.  Possible reasons listed for the gender imbalance 
included smoking prevalence and alcohol intake, use of hormone replacement therapy 
(HRT), Body Mass Index (BMI) and genetic factors.  Diet and use of medications such 
36 
 
 
as aspirin and non-steroidal anti-inflammatory drugs are also potential contributors to 
the observed gender imbalances. 
 
Kolligs et al. (2011) investigated the risk of advanced neoplasia according to age and 
gender, by analysing results of 625,918 colonoscopies.  To determine whether 
screening should start at an earlier age according to gender, the analysis included 
colonoscopies performed in those within the age range 18-79 years.  Advanced 
neoplasia was detected in 8.6% of men, compared with 4.6% of women.  Logistic 
regression modelling was used to determine age- and gender-specific risk of advanced 
neoplasia.  Men were found to be at higher risk of advanced neoplasia than women at 
any age, with an overall odds ratio of 1.93 (95% CI: 1.89 - 1.97).  Comparable numbers 
of colonoscopies needed to detect advanced adenoma were reached up to 20 years 
earlier in men than in women.  The authors suggest starting screening earlier in men to 
increase detection rates relevant to their increased risk.  However, with Kolligs et al. 
(2011) also stating that lifetime risk of colorectal cancer appears fairly similar for both 
men and women, the findings lead to speculation that some mechanism exists whereby 
development of advanced neoplasia is delayed in women.  Possible driving factors 
include protective hormonal effects in pre-menopausal women, and then continuation 
of this through HRT use during the menopause, as well as preferential lifestyle choices 
adopted by women such as lower smoking rates and alcohol intake. 
 
Evidence of a potentially delayed process along the pathway to malignancy comes 
from a study by Brenner et al. (2007b) investigating the progression of advanced 
adenoma to colorectal cancer by age and gender.  They found similar rates of 
transition to colorectal cancer between men and women, with a strong gradient existing 
for age in both genders.  However, they identified a greater increase in advanced 
adenoma prevalence when comparing the 50-59 years to the 80 years and over age 
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groups in women, (3.4% to 7.3%), than in men (6.2% to 9.5%). In addition, an even 
stronger relationship existed between increasing age and colorectal cancer incidence, 
with an increase greater than five-fold observed in women between the two age 
categories, whereas men had a more than four-fold increase.  Similarly, projected 
annual and ten-year percentages of advanced adenoma progression to colorectal 
cancer were estimated to be higher in women than men at later ages, particularly at 70-
80 years.  This may add strength to the hypothesis that the development of neoplastic 
lesions in women is delayed by hormonal factors and lifestyle choices.   
 
Further backing to this idea comes from work conducted by Schoenfeld et al. (2005)  It 
was demonstrated that for those aged 60-69 years, a significantly higher prevalence of 
advanced neoplasia existed in men than in women, and a trend towards this was 
observed in those aged 50-59 years, but not in those aged over 70 years.  As with the 
findings of Brenner et al. (2007b), this has importance in helping to explain the age and 
gender differences in disease prevalence.  The narrowing of the gender gap in 
prevalence of advanced neoplasia with increasing age supports the theory of women 
experiencing protective hormonal effects, which disappear with age, perhaps along 
with the benefits of women making more favourable lifestyle choices than those 
adopted by men.  Another interesting discovery from the data of Schoenfeld et al. was 
that a lower diagnostic yield of flexible sigmoidoscopy was evident among women than 
in men, pointing to a shift to right-sided neoplasia in women.  A particular concern 
pointed out was that 70% of advanced neoplasia in women aged 50-59 years would be 
missed using flexible sigmoidoscopy alone as a screening tool.  This ties in with 
findings from studies on interval cancer using gFOBT in colorectal cancer screening 
showing a disproportionate number of cases occurring in women with proximal lesions 
(Gill et al., 2012; Steele et al., 2012).  In the case of gFOBT screening, a commonly 
stated possible reason for this finding is a slower colonic transit rate in women 
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compared with men, allowing a longer time scale for faecal Hb degradation and 
therefore a negative test result.  With right-sided lesions, this effect would be 
accentuated by the further distance that blood will have to travel through the colon in 
these cases before defaecation. 
 
Rozen et al. (2012) further highlight the influence of age and gender on screening 
results in their follow-up analysis of 1,630 who had undergone colonoscopy and had 
completed three FIT with a cut-off faecal Hb concentration set at 10 µg Hb/g faeces.  
Linkage of data from the Israel National Cancer Registry with mean follow-up of 
patients over 51.5 months showed colorectal cancer and advanced adenoma to be 
significantly more common in men than women.  Using a reference category of patients 
aged under 50 years, it was calculated that men had an increased relative risk (4.639) 
of developing advanced neoplasia between the ages of 51-73 years, but this was not 
observed among women.  However, at 74 years or older, the relative risk of colorectal 
cancer or advanced adenoma increased significantly in both genders.  Although it 
would be useful to see changes in relative risk in narrower age groups than reported in 
this study, the finding that risk of advanced neoplasia increased at a younger age in 
men than it did in women once more indicates that some delay in disease progression 
may exist in women. 
 
A further study by Brenner et al. (2007a) investigated gender differences in colorectal 
cancer incidence in respect of the implications they may have for recommendations 
concerning age for initiation of screening.  Following their analysis of data from the 
United States, they state that as the potential benefits of screening are heavily 
influenced by colorectal cancer incidence and mortality rates at various ages, the 
optimal screening start age would be around five years earlier for men than for women 
when aiming to improve cost-effectiveness.  However, this would be based on the 
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assumption that screening is equally effective in both genders.  The disproportionately 
high number of interval cancers in women shown with gFOBT, and the potentially high 
false negative rate of flexible sigmoidoscopy in younger women suggest this may not 
be the case. 
 
In a more recent paper, Brenner et al. (2010) documented the prevalence of advanced 
neoplasia in 1,157 men and 1,167 women in the German screening programme at 
range of cut-off faecal Hb concentration for quantitative FIT, as well as six qualitative 
FIT and a gFOBT.  They found a substantially higher prevalence in men than in women 
(13.5% v. 7.5%) and observed that at any cut-off faecal Hb concentration, and with all 
other tests examined, sensitivity and PPV were significantly higher and specificity and 
NPV were significantly lower among men than women.  These findings were 
particularly striking for the gFOBT, perhaps suggesting that the advantages offered by 
FIT may go some way to reducing the gap in test performance between men and 
women.  Indeed, it was established that gFOBT performed no better in women than 
would random selection for referral for colonoscopy and was therefore deemed unable 
to differentiate between those who do and do not have disease.  A possible reason for 
gender differences in test performance could be that men have higher average faecal 
Hb concentration than women, and therefore more positive screening test results arise 
in men.   
 
Evidence for this comes from McDonald et al., (2012) who studied the distribution of 
faecal Hb concentration by age and gender in 38,720 screening participants completing 
one quantitative FIT.  At any single faecal Hb concentration, test positivity was higher in 
men than women as well as in older participants than in those younger.  An 
observational study documented variation in distributions of faecal Hb concentration 
across geography when comparing data from Scotland, Taiwan and Italy but, in all 
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three datasets, faecal Hb concentration was higher in men than women and in older 
than younger subjects. (Fraser et al., 2014)  This work was supplemented by the same 
trends being found in the prevalence screening round of the Barcelona Colorectal 
Cancer Screening Program (Fraser & Auge, 2014) where it was stated that test 
positivity rate should be viewed as a surrogate marker for faecal Hb concentration.  
Further confirmation of this idea has come from recent data presented in an important 
study from Australia. (Symonds et al., 2015b)  Correspondence generated in light of 
these findings recommended that when selecting an appropriate cut-off faecal Hb 
concentration for colorectal cancer screening using quantitative FIT, programme 
organisers should perform pilot studies to examine faecal Hb concentration by age and 
gender, with characteristics of the invited population assessed regularly with evolution 
of the programme to avoid the problems that have been seen in some countries where 
colonoscopy services have been overwhelmed by the demands of significantly higher 
than expected test positivity rates. (Fraser, 2015)  A letter submitted as an addendum 
to the published results of Symonds et al. (2015a) then stated that men were found to 
have statistically significantly higher median faecal Hb concentration than women 
among those who had no colorectal disease at colonoscopy, indicating that the fact 
that there is a greater prevalence of colorectal neoplasia in men than women is not the 
sole reason for the disparity in baseline faecal Hb concentration between the genders.  
Test sensitivity for advanced neoplasia at a faecal Hb concentration cut-off of 10 µg 
Hb/g faeces was 50.4% in men compared with 42.7% in women, and a faecal Hb 
concentration cut-off of 5.4 µg Hb/g faeces would have been required to detect the 
same proportion of advanced neoplasia in women as in men.  The authors stated that 
these findings supported the argument that gender differences in test sensitivity may 
lead to women having a greater proportion of interval cancers and missed adenomas 
than men in population screening and that further work is needed to devise an optimal 
strategy providing equity of screening within the constraints of the colonoscopy 
resource.  
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Additionally, faecal Hb concentration has been shown to increase according to lesion 
size in those with colorectal neoplasia detected (Ciatto et al., 2007).  This is relevant to 
the findings of Brenner et al., (2010) who reported a higher proportion of colorectal 
cancer and large adenoma among men with neoplasia than women with neoplasia, 
meaning that the neoplasia in men was more likely to be associated with higher faecal 
Hb concentration and therefore higher test sensitivity.  However, when advanced 
neoplasia was stratified by size, sensitivity, albeit somewhat reduced, was still 
substantially higher in men than women, suggesting that differences in neoplastic 
pathology was only partly the reason for the disparity in sensitivity between genders. 
 
A review of gender-specific and site-specific differences in colorectal cancer screening 
by Massat et al. (2013) stated that biennial gFOBT screening was equally effective for 
men and women, but gender differences in test performance between gFOBT and FIT 
had not been investigated with enough power to draw conclusions.   Thus, a strong 
recommendation was made that researchers publish results by gender whenever 
possible. 
 
From the evidence published thus far on age and gender differences in colorectal 
cancer prevalence and detection, it is apparent that this is a facet for programme 
organisers to address when seeking to improve screening effectiveness.  Although 
there is clearly a greater prevalence of advanced neoplasia amongst men than women, 
some screening modalities are associated with a higher number of false negative test 
results in women.  It has been shown that gFOBT may disadvantage women, 
particularly those with right-sided lesions.  Therefore, careful consideration must be 
made with regard to adjustment of screening programmes such as use of a gender-
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specific age of screening commencement.  A very recent study has emerged from The 
Netherlands documenting gender differences observed in FIT screening using a faecal 
Hb concentration cut-off of 10 µg Hb/g faeces. (Kapidzic et al., 2015)  Men were found 
to have a significantly higher test positivity rate, advanced neoplasia detection rate and 
false positive rate than seen in women.  The authors recommend use of the same 
faecal Hb concentration cut-off in men and women based on no significant differences 
in PPV for advanced neoplasia by gender.  However, further research is crucial to 
understanding the mechanisms driving differing average faecal Hb concentration 
between genders, a possible shift to right-sided lesions in women and the apparent 
delay in dysplastic progression in women which may be alluded to from a number of 
studies discussed previously.  With Brenner et al. (2010) showing that replacing 
gFOBT with FIT may go some way to reducing the gender gap in test performance, 
using quantitative FIT with age- and gender-specific cut-off faecal Hb concentration for 
a positive test result also seems worth investigating with the aim of optimising 
screening efficiency and reducing interval cancer.  Before such tailoring of screening 
programmes using quantitative FIT, it is crucial firstly to understand the importance of 
faecal Hb concentration as a predictor of colorectal disease.  Some studies have been 
conducted to investigate what correlation exists between faecal Hb concentration and 
colonoscopy findings. 
 
1.8 Significance of faecal haemoglobin concentration in colorectal disease, 
and risk scoring 
 
 
Levi et al. (2007) investigated faecal Hb concentration in 1,000 consecutive subjects 
scheduled for colonoscopy.  They found that those with advanced neoplasia had 
significantly higher faecal Hb concentration that those with other diseases or no 
pathology detected.  Although no faecal Hb concentration perfectly distinguished those 
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with advanced neoplasia from others, most non-advanced adenomas were associated 
with low faecal Hb concentration (< 15 µg Hb/g faeces) meaning false positive test 
results arising from low-risk adenoma in screening using FIT should be limited.  In 
addition, differences in faecal Hb concentration were observed between adenomas 
with differing histological characteristics.  Patients with adenomas displaying villous or 
serrated components, or high-grade dysplasia - all features associated with greater 
malignant potential (Lieberman et al., 2012) - had higher faecal Hb concentration than 
those with lower risk adenomas, or no neoplasia.  No variation in faecal Hb 
concentration was observed between advanced adenoma found in the proximal region 
of the colon and those found more distally.  The overriding finding was that lesion size 
was highly related to faecal Hb concentration, with small proximal cancer and small 
advanced adenoma both being associated with low faecal Hb concentration.  This 
seems to suggest the detailed histology of the lesion is not so much responsible for 
causing bleeding as is the more simple explanation that the larger the lesion, the more 
susceptible its associated vasculature is to interference from the mechanical effects of 
faeces passing through the colon. 
 
Rozen et al. (2009a) also correlated faecal Hb concentration with adenoma 
characteristics, collecting three daily samples for FIT from 1221 individuals scheduled 
for colonoscopy.  Those with adenoma had elevated faecal Hb concentration, which 
increased with advanced histology, size, pedunculated shape and multiplicity.  As with 
the findings of Levi et al., (2007) adenomas with villous or serrated features, or those 
displaying high-grade dysplasia had higher faecal Hb concentration than those without 
these features.  Again, size was cited as an important factor in the degree of bleeding 
associated with a lesion, with no difference in faecal Hb concentration between those 
with small adenomas and those with no neoplasia.  Pedunculated adenomas were 
larger than sessile adenomas, and it can be deduced that this, in combination with their 
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more protruding shape, is the reason for their elevated faecal Hb concentration.  
Advanced adenoma had a larger mean size than non-advanced adenoma.  No 
significant difference was found in faecal Hb concentration or size of adenomas 
between proximal and distal sites.  Again, most non-advanced adenoma were 
undetected by FIT at the cut-off concentration used of 15 µg Hb/g faeces; 
advantageous in avoiding unnecessary follow-up. 
 
Ciatto et al. (2007) discovered similar results from their multivariate analysis showing 
age, lesion size and left-sidedness to show independent association with increasing 
faecal Hb concentration in adenomas.  A trend of increasing faecal Hb concentration 
according to colonoscopy findings was evident, from benign outcomes through a 
spectrum of disease severity up to colorectal cancer.  Advanced adenomas (classified 
as those > 9 mm in diameter, > 20% villous or tubulovillous histological pattern, or 
displaying high-grade dysplasia) had significantly greater faecal Hb concentration than 
non-advanced adenoma.  High-grade dysplasia was associated with larger adenoma, 
with increasing size also associated with villous histology in adenoma.  Adenoma found 
in the left colon were larger than right-sided adenoma.  The authors suggest that the 
association between elevated faecal Hb concentration and left-sided adenoma may be 
attributable to a greater effect of the mechanical action of faeces in this section of the 
colon since the faeces is more formed.  Multivariate analysis further consolidated size 
as key to a lesion’s propensity to bleed with this being the factor to show the strongest 
association with faecal Hb concentration. 
 
Further work demonstrating a continuum of increasing faecal Hb concentration with 
increasing severity of colorectal disease comes from Kovarova et al., (2012) who 
showed that, in 682 participants completing two FIT prior to complete colonoscopy, 
median faecal Hb concentration increased from normal, through adenoma, to 
45 
 
 
advanced adenoma, to colorectal cancer.  However, as with the other studies 
discussed, much overlap was apparent. 
 
The findings of these studies confirm the importance of faecal Hb concentration as an 
indicator of colorectal neoplasia.  In addition, an important recent study provides a 
significant message that not only is elevated faecal Hb concentration related to 
increased risk of colorectal cancer mortality, but also a similar, although less marked, 
increased risk of all-cause mortality. (Chen et al., 2013)  Those with faecal Hb 
concentration above 90 µg Hb/g faeces had an adjusted hazard ratio for all-cause 
mortality of 1.67 (95% CI: 1.54 – 2.07) as compared to the baseline group with faecal 
Hb concentration 1.0 - 3.9 µg Hb/g faeces.  This work emphasises the importance of 
faecal Hb concentration as a predictor of disease and the contribution it can make to 
detection of colorectal cancer through screening.  The technological advancement in 
faecal testing facilitated by quantitative FIT allows potential for better use to be made of 
faecal Hb concentration measurements obtained from screening participants.  Risk 
scoring systems that include faecal Hb concentration as a variable may be a step 
towards such use of FIT to improve screening efficiency. 
 
An increasing number of studies focussing on the use of risk scoring models in 
colorectal cancer screening programmes are emerging. (Chen et al., 2014; Driver et 
al., 2007; Kaminski et al., 2014; Wang et al., 2014; Wong et al., 2014; Yeoh et al., 
2011) Common risk factors included in such models include gender, age, BMI, smoking 
status etc., but only very few have incorporated faecal Hb concentration. (Aniwan et al., 
2015; Stegeman et al., 2014)  A very recent publication from Thailand (Aniwan et al., 
2015) combined the Asia-Pacific Colorectal Screening score  (Yeoh et al., 2011) 
incorporating age, gender, family history of colorectal cancer and smoking status, with 
the result of a qualitative FIT set at 50 ng Hb/ml buffer (equivalent to 10 µg Hb/g 
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faeces), in 948 asymptomatic participants aged 50-75 years.  They found that those 
who were both at high risk according to their Asia-Pacific Colorectal Screening score, 
and had a positive test result, had a 6.15-fold higher detection rate for advanced 
neoplasia compared with those in the other three groups (high risk + negative test 
result, moderate risk + positive test result, moderate risk + negative test result).  Of 
significant interest here is a measure of the improvement that FIT brings to the 
performance of the scoring system.  The prevalence of advanced neoplasia in 
participants calculated as being at high risk using the score alone was 19.8%.  This 
rose to 36.9% in those with a high risk score and a positive test result, compared to just 
6.4% in the group at moderate risk with a negative test result, into which no colorectal 
cancer cases fell.  This was a small study with only seven cases of colorectal cancer, 
the Asia-Pacific Colorectal Screening score may not necessarily be transferable across 
geography, and qualitative rather than quantitative FIT was employed, but these results 
show promise of a sizeable added benefit when supplementing risk scoring models 
with FIT.  A Dutch group have performed similar analysis, this time using questionnaire 
data from 1,112 participants aged 50-75 years, with logistic regression modelling being 
used to identify significant risk factors in age, family history of colorectal cancer, alcohol 
intake, smoking status and history, calcium intake and physical activity, along with the 
quantitative measure of faecal Hb concentration. (Stegeman et al., 2014)  Faecal Hb 
concentration was found to be the most influential of all the variables in the model, but 
the multivariate risk model including faecal Hb concentration had better sensitivity than 
screening with faecal Hb concentration alone.  Offering colonoscopy to the 102 
individuals at highest risk according to the model rather than to the 102 who had a 
positive FIT result with a cut-off faecal Hb concentration of 10 µg Hb/g faeces would 
have detected five more cases of advanced neoplasia.  However, again, only seven 
cases of colorectal cancer were detected overall in the cohort.  Programme organisers 
may be discouraged from implementation of a screening strategy based on the results 
of this paper due to the use of a questionnaire, which may have a negative effect on 
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screening participation.  A simpler model, with easily acquired variables such as age, 
gender and faecal Hb concentration, would be more desirable for implementation into a 
national screening programme. 
 
An example of study using only these three variables for risk stratification has emerged 
from Catalonia, Spain, with retrospective analysis of 3,109 screening participants aged 
60-69 years old. (Auge et al., 2014)  Multivariate logistic regression analysis revealed 
age, gender and faecal Hb concentration to be independently associated with 
advanced neoplasia and 16 risk categories were formed by combining these factors.  
The highest category - men aged over 60 - 69 years old with faecal Hb concentration 
above the third quartile (> 177 µg Hb/g faeces) - had an 11.46-fold (95% CI: 7.25 - 
18.10) increased probability of advanced neoplasia compared to the lowest risk 
category of women aged 50-59 years with faecal Hb concentration in the first quartile 
(20 - 32 µg Hb/g faeces).  It would be of interest to consider how these findings 
translate into an overall score to prioritise colonoscopy towards those at highest risk.  
Omata et al. (2011) collated data from 1,085 asymptomatic Japanese individuals 
completing both quantitative FIT and colonoscopy as part of a general health check-up.   
A very low cut-off faecal Hb concentration of 5 µg Hb/g faeces was deemed by the 
authors to be optimal for screening for significant neoplasia, but it was stated that the 
sensitivity at this concentration was less than would be desired at just 51% (95% CI: 39 
- 62).  However, screening accuracy for was improved through use of a scoring system 
incorporating faecal Hb concentration, age, gender and BMI, aided by a nomogram to 
facilitate clinical utility.  Once more, the authors conceded that further study with a 
larger sample size was required.  It is clear from the results of these studies, however, 
that there is a strong argument for the use of risk scoring systems incorporating faecal 
Hb concentration in colorectal cancer screening programmes, although more large 
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scale studies, in the screening setting, detailing simple methods of implementation, are 
required. 
 
Further argument in favour of the adoption into colorectal cancer screening 
programmes of risk-stratification methods using FIT comes from an important study by 
Chen et al., (2011) showing that faecal Hb concentration at first screening can be a 
predictor of subsequent colorectal neoplasia.  A prospective cohort study following up 
45,992 screening attendees using a cut-off faecal Hb concentration of 20 µg Hb/g 
faeces was conducted over a median of 4.39 years and it was found that the incidence 
of colorectal neoplasia rose from 1.74 per 1,000 person-years for those whose initial 
screening faecal Hb concentration was equivalent to 0.0 - 3.9 µg Hb/g faeces, up to 
7.08 per 1000 person-years in those with a faecal Hb concentration of 16.0 - 19.9 µg 
Hb/g faeces.  They concluded that risk-stratification methods could be applied to 
screening participants with faecal Hb concentration just below the cut-off faecal Hb 
concentration used for follow-up investigation, perhaps with a shorter screening interval 
so as to sooner detect advanced neoplasia presenting as false negative at initial 
screening.  Likewise, those with very low, or undetectable faecal Hb concentration 
could perhaps be invited for screening at less frequent intervals, owing to the long-
preclinical phase associated with disease progression in colorectal cancer.   
 
These studies demonstrate the value of assessing faecal Hb concentration using 
quantitative FIT and the potential this holds for improvement of clinical outcomes 
through future adaptations to colorectal cancer screening programmes.  This adds to 
the rapidly growing evidence base supporting the adoption of FIT in colorectal cancer 
screening programmes to replace the traditionally used gFOBT.  FIT exhibit many 
advantages over gFOBT as a primary test showing superior performance 
characteristics, particularly for precursor lesions which may, in the long-term, lead to a 
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reduction in colorectal cancer incidence.  FIT may also go some way to reducing the 
high number of interval cancers associated with gFOBT.  The disproportionate number 
of interval cancers detected in women suggests that the gFOBT may discriminate 
against women, who have been shown to have lower faecal Hb concentration than 
men (Fraser & Auge, 2014; Fraser et al., 2014; Kapidzic et al., 2015; McDonald et al., 
2012; Symonds et al., 2015b).  A solution to address this issue could be sought 
through adopting individually tailored screening strategies that are possible with the 
adjustable cut-off faecal Hb concentration afforded by automated FIT.  Although FIT 
have been, until recently, significantly more expensive than gFOBT, this may be offset 
by their advantages in terms of superior performance characteristics and improvements 
in test uptake.  Indeed, a cost-effectiveness analysis of FIT compared with gFOBT was 
conducted in France by Berchi et al. (2010) shows that comparing direct costs of one 
round of FIT screening at different cut-off faecal Hb concentration with gFOBT in 
20,322 participants completing both tests showed that using a cut-off faecal Hb 
concentration of 15 µg Hb/g faeces guaranteed more efficient screening than gFOBT, 
displaying better health outcomes and lower costs. 
 
 
1.9 Other screening modalities 
 
 
Although the focus of this thesis is solely on the use of tests for the presence of Hb in 
faeces, it is important to mention key studies investigating the effectiveness of other 
screening modalities. 
 
An alternative primary screening test to be considered for identification of participants 
relevant for referral for colonoscopy is flexible sigmoidoscopy.  Flexible sigmoidoscopy 
allows visual inspection of the distal 40 - 60 cm of the colon with an enema, usually 
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self-administered, used prior to the examination to cleanse the bowel.  Screening 
programmes can use flexible sigmoidoscopy in the first stage of screening, with referral 
for colonoscopy made following detection of adenomas.  The basis for this strategy 
comes from evidence showing that adenomas in the distal colon are predictive of the 
presence of advanced adenomas in the proximal region. Imperiale et al. examined 
colonoscopy results from 1,994 asymptomatic individuals aged over 50 years and 
found that compared with those with no adenomas or hyperplastic polyps found 
distally, those who had distal tubular adenomas had a relative risk of advanced 
proximal neoplasia of 4.0, and 6.7 in those with an advanced distal adenoma. 
(Imperiale et al., 2000)  However, they also observed that about half of the cases of 
proximal neoplasia would go undetected if colonoscopy was offered only to those with 
distal lesions.  Despite this, flexible sigmoidoscopy is the only screening test other than 
FOBT proven to reduce mortality in RCT and, unlike gFOBT, has also demonstrated a 
reduction in colorectal cancer incidence.  Three RCT have been conducted to assess 
the efficacy of flexible sigmoidoscopy screening in reducing colorectal cancer incidence 
and mortality.  The largest of these took place in the UK, where 170,432 participants 
aged between 55 and 64 years were assigned randomly on a 2:1 basis to a control 
group and an intervention arm, respectively. (Atkin et al., 2010)  Those in the 
intervention arm were offered a single round of flexible sigmoidoscopy screening.  The 
criterion for colonoscopy after flexible sigmoidoscopy was detection of high-risk 
adenoma, giving a 5% referral rate.  Results after a median follow-up of 11.2 years 
showed a 23% reduction in colorectal cancer incidence in the group invited, with the 
effect rising to 33% in those actually attending screening.  Likewise, in intention-to-treat 
analyses, a 31% reduction in colorectal cancer mortality was observed in the 
intervention arm, rising to 43% in those actually undergoing flexible sigmoidoscopy.  
The uptake was 71%; however, trial participants had previously indicated via 
questionnaire that they would participate in colorectal cancer screening, and lower 
adherence would be expected in the general population.  This is perhaps confirmed by 
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a very recent publication by McGregor et al. (2015) reporting uptake to be 43.1% over 
the first 14 months of the English Bowel Scope Screening programme pilot, which 
invites adults aged 55 years for a one off flexible sigmoidoscopy.  It was concluded 
from the UK RCT, (Atkin et al., 2010) however, that once-only flexible sigmoidoscopy 
was a safe and practical screening test offering substantial, lasting protection from 
colorectal cancer.  A pilot study similar to that running in England is now taking place 
as an adjunct to the Scottish Bowel Screening Programme, offering flexible 
sigmoidoscopy as a one-off screening modality in those aged 60 years who are due 
their gFOBT screening round; preliminary results are awaited to assess uptake and 
clinical outcomes in comparison to the gFOBT/FIT two-tier reflex algorithm.  Hoff et al. 
(2009) reported interim results of the Norwegian Colorectal Cancer Prevention 
(NORCCAP) trial where 55,736 participants aged 55-64 years were randomised to a 
screening arm offering once only flexible sigmoidoscopy, or a control group.  Half of the 
6,908 people in the screening arm were also asked to complete a single round of 
gFOBT testing, with either neoplasia detected with flexible sigmoidoscopy or a positive 
gFOBT result qualifying participants for full colonoscopy.  In contrast to the UK trial, no 
reduction in colorectal cancer incidence was observed and the trend towards reduced 
colorectal cancer mortality was non-significant between the screening and control 
groups.  However, a significant reduction in colorectal cancer mortality of 59% was 
shown when adjusting for attendees.  The smaller effect of once only flexible 
sigmoidoscopy screening compared with the UK trial is likely to be related, at least in 
part, to the shorter follow-up time of seven years for colorectal cancer incidence and six 
for colorectal cancer mortality, with the suggestion that the lag period of colorectal 
cancer development from precursor lesions is longer than this.  Another Norwegian 
RCT by Thiis-Evensen et al. (1999) examined the effect of polypectomy on colorectal 
cancer incidence in 400 participants offered a flexible sigmoidoscopy-based screening 
programme in 1983 compared with 399 in a control group.  After 13 years, both groups 
were invited for colonoscopy and cancer registrations in the interim period were 
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examined.  An 80% reduction in colorectal cancer incidence was reported in the 
screening group compared with the control group in the intention-to-screen analysis.  
This large effect may be attributed to the high uptake (81%) and to the criteria for 
referral for colonoscopy set as any kind of polyp detected with flexible sigmoidoscopy, 
with further colonoscopy offered after periods of 2 and 6 years. 
 
As yet, no randomised trial directly comparing the effect on colorectal cancer mortality 
of flexible sigmoidoscopy with gFOBT or FIT has been conducted.  Although the 
flexible sigmoidoscopy trials appear to show a greater reduction in mortality than that 
calculated from gFOBT RCT, despite poorer participation rates, overlap exists meaning 
that no clear superiority is indicated.  Some studies are now suggesting that strategies 
combining FIT and flexible sigmoidoscopy may represent a route to improved 
screening effectiveness. (Hol et al., 2010) 
 
 
1.10 Summary 
 
 
 
A diverse range of literature covering many aspects of colorectal cancer screening 
exists, with much knowledge to be gained from this regarding the best use of colorectal 
cancer screening tests.  Most importantly, the use of gFOBT as a primary test has 
been proven to reduce colorectal cancer mortality.  This screening modality carries 
disadvantages including a high proportion of false negative test results, gender 
differences in the clinical performance and a lack of specificity for human Hb.  The 
evidence base supporting the adoption of FIT in colorectal cancer screening 
programmes due to the many advantages they hold over gFOBT is growing rapidly.  
Although no RCT has been carried out demonstrating FIT to play a role in the reduction 
of colorectal cancer mortality, evidence supports the thesis that FIT show a particular 
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superiority over gFOBT for the detection of precursor lesions.  This may mean that FIT 
can enhance the reduction on colorectal cancer mortality seen with gFOBT and, in the 
longer term, additionally lead to a reduction in colorectal cancer incidence.  Up-to-date 
reviews of the evidence around the adoption of FIT into colorectal cancer screening 
programmes concluded that FIT offers opportunities for further enhancement to 
colorectal cancer screening programmes and its use as the test of choice can no 
longer be denied. (Allison et al., 2014; Young et al., 2015)  Further potential for more 
effective screening programmes comes from the highly favourable option to adjust the 
cut-off faecal Hb concentration used for referral for colonoscopy afforded to programme 
organisers with quantitative FIT.  A number of studies have demonstrated the 
advantages of this feature with identification of the cut-off faecal Hb concentration 
which provides optimal clinical performance, suitable to colonoscopy capacity.  A 
further potential use of this characteristic of quantitative FIT is the incorporation of cut-
off faecal Hb concentration that are tailored according to age and gender.  Evidence 
indicates that tests for the presence of Hb in faeces perform less well in women than in 
men, although FIT may go some way to reducing the gap compared with gFOBT.  Also, 
colorectal cancer risk increases with age.  With many other biomarker tests commonly 
using reference values stratified according to age and gender, surely a similar 
approach can be incorporated in to screening with quantitative FIT.  Such adaptations 
of the screening programme could improve overall test sensitivity and specificity.  This 
area has not yet been investigated in colorectal cancer screening, representing a gap 
in the current published research.  A further option afforded by quantitative FIT is 
incorporation of faecal Hb concentration into risk scoring systems.  With the screening 
interval being an important consideration in terms of balancing costs, participation and 
detection rates, perhaps monitoring changes in faecal Hb concentration across multiple 
screening rounds could allow participants to be assigned a risk category, where high-
risk participants can be invited more frequently, and vice-versa.  This imaginative 
approach has potential to boost cost-effectiveness by diverting resources away from 
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those consistently showing very low or undetectable faecal Hb concentration and 
focussing more on those showing fluctuations towards higher faecal Hb concentration, 
and hence greater colorectal cancer risk.  It is clear that more frequent screening 
invitations to those with faecal Hb concentration closer to the cut-off has the potential to 
reduce the interval cancer proportion, assuming that a proportion of cases of sub-
threshold bleeding are associated with lesions on their way to malignancy before the 
next screening round.  This, again, is an area into which research is scarce and the 
hypothesis that interval cancer proportion can be reduced using this cost-effective 
strategy deserves further attention. With missed cancers perhaps the most pressing 
concern associated with gFOBT screening, the potential for FIT to go some way to 
addressing the high interval cancer proportion is a crucial area of research interest. 
 
 
1.11 Thesis aims and objectives 
 
 
The next five Chapters of this thesis will aim to answer a series of research questions 
around the relationship between faecal Hb concentration and the risk of significant 
colorectal neoplasia in the setting of colorectal cancer screening. The main questions 
being asked in each of these Chapters will be: 
 What is the relationship between screening test results with a gFOBT/FIT two-
tier reflex algorithm and severity of colorectal neoplasia? 
 What is the relationship faecal Hb concentration and severity of colorectal 
neoplasia? 
 What was the faecal Hb concentration of participants who had a negative 
screening test result and were later diagnosed with interval cancer? 
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 What was the faecal Hb concentration of participants who had a negative 
screening test result, then had a positive screening test result at the subsequent 
screening round? 
 Is there an independent trend of increasing faecal Hb concentration with 
increasing degree of deprivation? 
 
If, in answering these questions, it is shown that faecal Hb concentration can act as an 
important predictor of colorectal neoplasia,  then perhaps the results will call for the 
properties afforded by quantitative FIT to be used to their maximal potential. This could 
allow for better detection rates of advanced neoplasia within the boundaries of the 
resources available to the programme. 
 
The final Chapter will shift focus from screening to the symptomatic population, 
assessing the potential benefits to be gained from the use of FIT in primary care to aid 
GP when making decisions with regard to which patients with lower abdominal 
symptoms should be referred for invasive investigation.  With investigative services in 
the UK being placed under an increasing burden from primary care referrals, a means 
to reduce the number of referrals without missing clinically important disease is 
urgently required.  With this in mind, the following research questions will be asked in 
the final results Chapter: 
 What is the diagnostic accuracy of quantitative FIT in patients presenting to 
primary care with colorectal symptoms? 
 What is the appropriate cut-off faecal Hb concentration to rule out significant 
colorectal disease? 
56 
 
 
If faecal Hb concentration can act as a good rule-in test for colorectal cancer and, more 
importantly, a good rule-out test for significant colorectal disease in primary care, 
potential exists for colonoscopy resource to be redirected into screening.  This would 
allow for lowering of the relatively high faecal Hb concentration cut-off used in 
Scotland, and for more sophisticated adjustment of screening strategy
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2. The relationship between results with the guaiac faecal 
occult blood test/Faecal Immunochemical Test two-tier 
reflex screening algorithm and severity of colorectal 
neoplasia 
 
 
 
 
2.1 Introduction 
 
 
Before investigating possible adaptations to colorectal cancer screening protocols 
which may be facilitated by the emergence of quantitative Faecal Immunochemical 
Tests for haemoglobin (FIT), it is first important to improve understanding of the 
relationship between faecal haemoglobin (Hb) concentration and disease severity.  Hb 
in faeces is strongly associated with colorectal cancer and larger precursor lesions.  
However, the presence of blood, often termed occult blood, can often also present in 
individuals with various other gastrointestinal conditions, or indeed in those with no 
evident pathology detected at colonoscopy, leading to individuals with false positive 
test results in colorectal cancer screening.  The possible mechanisms driving blood 
loss from the seemingly normal colon represent a poorly understood area.  It is vital for 
the success of any efficient screening programme that the primary test selects a group 
of participants with positive test results that harbour more cases of the disease of 
interest than would be found from simply a random selection of the screening 
population sent forward for invasive bowel visualisation.  Measures of test sensitivity 
and specificity for the detection of advanced neoplasia determine whether or not this 
crucial objective is being met, but calculation of these characteristics requires the 
disease status of participants with negative as well as positive screening test results.  
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This is not readily available when conducting an audit of screening data.  Detailed 
analysis of clinical outcomes of those with positive screening test results alone can, 
however, offer some valuable insight into the relevance of faecal Hb concentration in 
the detection of serious colonic lesions. 
 
Correlation of faecal Hb concentration with severity of colorectal neoplasia is now more 
easily afforded by the emergence of quantitative FIT.  However, some countries still 
use traditional guaiac faecal occult blood test (gFOBT); at the time of preparation of 
this work, this is still the case in Scotland.  Although it became clear during the pilot 
rounds of the Scottish Bowel Screening Programme that FIT had significant 
advantages over gFOBT, (Duffy et al., 2011; Fraser, 2011a) qualitative FIT were 
considerably more costly than gFOBT and their lower analytical detection limit meant 
that the test positivity rate would be much higher than the ca. 2% that could be 
sustained by the available colonoscopy resource in Scotland; their use as a first-line 
test was therefore precluded.  However, in order to take advantage of the superior 
analytical specificity of FIT and to cut down the number of false positive test results 
obtained with gFOBT, a suggested strategy is the use of gFOBT as a first-line test 
followed by use of FIT for individuals with positive gFOBT results. (Young et al., 2002) 
This strategy was investigated (Fraser et al., 2006; Fraser et al., 2007) and the 
theoretical benefits were attained, at least in the research setting.  The approach was 
described as the two-tier reflex gFOBT/FIT screening algorithm (Fraser et al., 2006) 
and, because of the positive experience, this was adopted for the Scottish Bowel 
Screening Programme, in which all individuals aged 50-74 years are invited to 
participate every two years. 
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Although no absolute faecal Hb concentration is quantitated, some scope for 
investigation of the relationship between the concentration of Hb detected in the 
sample and disease severity is, however, still possible within programmes using 
gFOBT due to the collection card featuring six ‘windows’ for the application of faeces, 
with two samples taken from each of three consecutive bowel movements required.  
The current protocol within the two-tier gFOBT/FIT screening algorithm sees 
participants being classified depending on how many of the six windows produce a 
colour change when hydrogen peroxide is applied to the test card in the laboratory, 
indicating the presence of Hb with the result determined as either negative (no 
windows positive), strong positive (five or six windows positive) or weak positive (one to 
four windows positive).  In those deemed weak positive, re-testing using a qualitative 
FIT, based upon lateral flow immunochromatography, is required to establish a final 
screening result.  It can be sensibly speculated that those with a strong positive gFOBT 
result have more severe colonic blood loss than those with fewer windows positive in 
the initial test.  It then follows that the prevalence of clinical outcomes detected 
between groups from the two routes to test positivity can be compared to establish 
whether or not strong positive test results show higher association with cases of 
colorectal neoplasia. 
 
With age and gender having been shown to relate to faecal Hb concentration 
(McDonald et al., 2012), variation in the demographic characteristics of participants 
following the different routes to test positivity can also be assessed to provide evidence 
of how this translates to the clinical outcomes detected following a positive gFOBT 
result.  This work may yield findings that offer important insight into the unravelling of 
some of the unanswered questions related to colorectal cancer screening, such as why 
women have a higher proportion of interval cancer than men. (Brenner et al., 2012; Gill 
et al., 2012; Steele et al., 2012)   Location of colonic lesions detected in relation to the 
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route to test positivity can also be analysed; right-sided, and rectal tumours have both 
been shown to be more prevalent in interval cancer cases than in screen-detected 
cases. (Gill et al., 2012; Hosokawa et al., 2003; Jensen et al., 1992; Steele et al., 2012; 
Tazi et al., 1999) 
 
The aims of this Chapter were to determine if more severe disease is detected in those 
with a strong positive gFOBT result compared with those with an initially weak positive 
gFOBT result and if there are any trends in positivity and clinical outcomes by gender.  
With gFOBT still utilised as the primary colorectal cancer screening test in Scotland 
and elsewhere in the UK, findings of this analysis are important in terms of 
understanding some of the strengths and weaknesses of the current screening 
algorithm. 
 
 
2.2 Materials and methods 
 
All invited were sent a gFOBT kit, which required two samples from each of three 
faeces collected by cardboard applicator and applied to the six windows of the test card 
(hema-screen, Immunostics Inc, Ocean, NJ, USA).  If no windows were positive, the 
participant was sent an informative letter.  If five or six windows were positive, this was 
described as a strong positive test result and the participant referred for colonoscopy in 
the NHS Board of residence.  If one to four windows were positive, the result was 
deemed a weak positive and the participant was sent a qualitative FIT kit that required 
one sample from each of two faeces collected by cardboard applicator and applied to 
the two windows of the card collection device: in the laboratory, the dried faeces on the 
tab of the card was placed in a tube containing buffer and qualitative analysis done on 
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an immunochemical test cassette (hema-screen SPECIFIC, Immunostics Inc, Ocean, 
NJ, USA).  The details of this FIT methodology have been described (Allison et al., 
2014; Fraser et al., 2007); positive test results are detected at a concentration of 50 ng 
Hb/ml buffer, equivalent to 50 µg Hb/g faeces.  If the test result was positive, the 
participant was referred for colonoscopy and.  Participants with an initial weak positive 
gFOBT who then had a negative qualitative FIT result were declared negative, not 
invited for colonoscopy,sent an informative letter and reinvited in two years if still 
eligible for screening.  Some participants did not provide a testable gFOBT due to the 
kit being expired, incomplete, spoiled by the participant or unused, or having a 
technical problem or an irresolvable participant identity difficulty; in order to expedite 
the screening pathway, these were sent a FIT rather than a repeat gFOBT.    
 
All analyses were carried out in the Scottish Bowel Screening Centre Laboratory by 
trained staff whose major function is to perform faecal test analyses; the Laboratory 
had a comprehensive total quality management system and was accredited to 
International Organization for Standardization (ISO) 15189 based standards by Clinical 
Pathology Accreditation (UK) Ltd. 
 
All results from 01 July 2007 to 30 June 2009 inclusive were examined: this represents 
the entire fourth round of screening in NHS Tayside. Positive results arose because 
test results were (1) strong positive gFOBT, (2) weak positive gFOBT followed by a FIT 
positive test result or (3) an untestable kit being submitted followed by a FIT positive 
test result.  For all positive test results, data for colonoscopy outcomes and pathology 
were downloaded from the appropriate NHS Tayside clinical IT systems.  Data on 
colonoscopy were collected on the quality of the investigation (quality of preparation, 
completeness of colonoscopy) and on the results including number, size and 
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localization of colorectal cancer and adenomas, and whether biopsy was performed.  
Full pathological data were collected on all excised/biopsy specimens including polyp 
type, presence or absence of malignancy and, in all adenomas, the severity of 
dysplasia.  Assignment as higher-risk adenoma was  ≥3 adenomas, or any adenoma 
with a maximum diameter ≥10 mm, derived from the recommendation from the British 
Society of Gastroenterology (Atkin & Saunders, 2002) as used in Scotland. Where 
participants had more than one diagnosis made, the most serious diagnosis was 
recorded. 
 
MedCalc (MedCalc Software, Mariakerke, Belgium) statistical software was used for all 
calculations. Logistic regression analysis was performed to calculate odds ratio for 
disease outcomes between the different routes to test positivity. 
 
This evaluation was approved by the Scottish Bowel Screening Programme Board and 
the Caldicott Guardian of NHS Tayside. 
 
 
2.3 Results 
 
Over the screening round observed, 131,885 people were invited and 73,315 
responded, giving an uptake of 55.6%.  As seen previously in the Scottish Bowel 
Screening Programme, uptake was higher in women (60.3%) than in men (53.2%).  Of 
the initial responses 66,957 (91.3%) results were negative.  There were 241 (0.3%) 
strong positive test results, of which 143 (59.3%) were men, 5,230 (7.1%) weak 
positive test results of which 2,999 (57.3%) were men, and 887 (1.2%) untestable 
results of which 471 (53.1%) were men.  Of the 5,230 with a weak positive test result, 
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983 (18.8%) went on to have a positive qualitative FIT result.  The overall test positivity 
rate was 1.77%, with a total of 1,301 participants with positive test results.  Table 2.1 
shows the proportions of participants in each route to test positivity. 
 
The majority of positive test results came about from an individual having a weak 
positive gFOBT result, followed by a positive qualitative FIT result (75.6%).  By all 
routes, 785 (60.3%) positive test results were found in men.  Of the strong positive 
gFOBT, weak positive gFOBT plus positive FIT and untestable followed by positive FIT 
result routes, 59.3%, 61.0% and 54.5% respectively were males.  There were no 
significant differences (p > 0.05) between the route to test positivity by gender, nor in 
median age in each route. 
 
Table 2.1. Numbers and proportions of participants in each route to test positivity. 
          Total         Men      Women 
  n % n % n % 
Total positive test results 1,301  785  516  
 Strong positive gFOBT results 241 18.5 143 18.2 98 19.0 
 Weak positive --> positive FIT results 983 75.6 600 76.4 383 74.2 
 Untestable gFOBT --> positive FIT results 77 5.9 42 5.4 35 6.8 
 
 
The clinical outcomes of colonoscopy and pathology in the 1,301 participants with 
positive test results overall, and in the three groups with different routes to test 
positivity, are shown in Table 2.2.  It should be noted that the majority of cases of 
advanced neoplasia (310/396, 82.2%) were detected in those who had an initial weak 
positive gFOBT result followed by a positive qualitative FIT.  However, this group was 4 
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times larger than the group with an initial strong positive gFOBT result.  A higher 
proportion of participants in the group with an initial strong positive gFOBT result had a 
diagnosis of colorectal cancer than any other route to positivity.  However, the group 
with an initial weak positive gFOBT result followed by a positive qualitative FIT had a 
higher proportion of higher-risk adenoma than any other route to positivity.  For 
completeness, Table 2.2 includes outcomes of those who arrived at their positive 
screening result with a positive qualtitative FIT following an initial untestable gFOBT.  
Since this group are not relevant in terms of the current analysis of groups of differing 
degrees of faecal Hb concentration detected, this group is not included in Table 2.3, 
which shows the Positive Predictive Value (PPV) for neoplasia within each group, as 
well as proportions of other clinical outcomes, by gender.  Within the group with a 
strong positive gFOBT result, the PPV for colorectal cancer was higher in women than 
in men.  Table 2.4 shows odds ratios for cancer, higher-risk adenoma and advanced 
neoplasia, broken down by gender.  Adjusted odds ratio for colorectal cancer  were 
significantly higher in those  with a strong positive gFOBT than those with a weak 
positive gFOBT followed by a positive qualitative FIT (2.15, 95% CI: 1.41 – 3.27).  This 
was true for both genders, but adjusted odds ratio were higher for women (2.52, 95% 
CI: 1.35 – 4.72) than for men (1.78, 95% CI: 1.00 – 3.16). 
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Table 2.2. Clinical outcomes for participants with positive test results according to route to 
test positivity. 
Outcome Total (%) 
Strong 
positive 
gFOBT 
results (%) 
Weak positive 
gFOBT + 
positive FIT 
results (%) 
Untestable 
gFOBT + 
positive FIT 
results (%) 
Cancer (CRC) 129 (9.9) 38 (15.8) 87 (8.9) 4 (5.2) 
Higher-risk adenoma (HRA) 267 (20.5) 39 (16.2) 223 (22.7) 5 (6.5) 
Advanced neoplasia (CRC + HRA) 396 (30.4) 77 (32.0) 310 (31.5) 9 (11.7) 
Low-risk adenoma (LRA) 145 (11.1) 15 (6.2) 118 (12.0) 10 (13.0) 
Total adenoma 409 (31.4) 54 (22.4) 343 (34.8) 15 (19.5) 
Total neoplasia(CRC + HRA + LRA) 538 (41.4) 92 (38.2) 428 (43.5) 19 (24.6) 
Other outcomes: 763 (58.6) 149 (61.8) 555 (56.5) 58 (75.4) 
    Hyperplastic polyps 80 (6.1) 15 (6.2) 63 (6.4) 2 (2.6) 
    Other non-neoplastic 
pathology* 
244 (18.8) 63 (26.1) 166 (16.9) 15 (19.5) 
    No pathology detected 287 (22.1) 43 (17.8) 218 (22.2) 26 (33.8) 
    Did not attend  147 (11.3) 38 (15.8) 94 (9.6) 15 (19.5) 
* - Other non-neoplastic pathology comprise conditions including diverticular disease, haemorrhoids 
and inflammatory bowel disease. 
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Table 2.3. Positive Predictive Values (PPV) for colorectal neoplasia according to route to 
positivity. 
  
Strong positive gFOBT 
results 
Weak positive gFOBT + 
positive FIT results 
  n PPV n PPV 
Cancer (CRC):     
   Total 38 18.7% 87 9.8% 
   Men 19 16.0% 51 9.5% 
   Women 19 22.6% 36 10.3% 
Higher-risk adenoma (HRA):     
   Total 39 19.2% 223 25.1% 
   Men 30 25.2% 158 29.3% 
   Women 9 10.7% 65 18.6% 
Advanced neoplasia (CRC + HRA):    
   Total 77 37.9% 310 34.9% 
   Men 49 41.2% 209 38.8% 
   Women 28 33.3% 101 28.9% 
Total adenoma (HRA + LRA + unclassified adenoma):  
   Total 54 26.6% 340 38.3% 
   Men 38 31.9% 246 45.6% 
   Women 16 19.0% 94 26.9% 
Total neoplasia (CRC + total adenoma):    
   Total 92 45.3% 427 48.1% 
   Men 57 47.9% 297 55.1% 
   Women 35 41.7% 130 37.2% 
Non-neoplastic pathology* + low-risk adenoma:   
   Total 83 40.9% 360 40.5% 
   Men 50 42.0% 225 41.7% 
   Women 33 39.3% 135 38.7% 
No pathology detected:    
   Total 43 21.2% 218 24.5% 
   Men 20 16.8% 105 19.5% 
   Women 23 27.4% 113 32.4% 
* - Non-neoplastic pathology comprises of hyperplastic polyps and other conditions including 
diverticular disease, haemorrhoids and inflammatory bowel disease. 
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Table 2.4. Unadjusted and adjusted odds ratios with 95% confidence intervals (CI) for 
significant neoplasia in those with a strong positive guaiac faecal occult blood test (gFOBT) 
result, using those with an initial weak positive gFOBT result as the reference category.  
 
Strong 
positive 
 gFOBT result 
PPV 
Weak positive 
gFOBT +  
positive FIT  
result  
PPV 
Odds ratio 
(95% CI)* 
Adjusted odds 
ratio 
(95% CI)*,** 
Cancer (CRC): 
 
18.7% 9.8% 2.12 (1.40 - 3.22) 2.15 (1.41 - 3.27) 
   Men 16.0% 9.5% 1.81 (1.03 - 3.21) 1.78 (1.00 - 3.16) 
   Women 22.6% 10.3% 2.54 (1.37 - 4.71) 2.52 (1.35 - 4.72) 
Higher-risk adenoma  
(HRA): 19.2% 25.1% 0.71 (0.48 - 1.04) 0.72 (0.49 - 1.05) 
   Men 25.2% 29.3% 0.81 (0.52 - 1.28) 0.83 (0.52 - 1.30) 
   Women 10.7% 18.6% 0.52 (0.25 - 1.10) 0.52 (0.25 - 1.10) 
Advanced neoplasia 
(CRC + HRA): 37.9% 34.9% 1.13 (0.83 - 1.56) 1.15 (0.84 - 1.59) 
   Men 41.2% 38.8% 1.11 (0.74 - 1.66) 1.11 (0.74 - 1.67) 
   Women 33.3% 28.9% 1.23 (0.74 - 2.04) 1.21 (0.73 - 2.03) 
*  Values in bold represent a statistically significant difference (p < 0.05). 
** Totals adjusted for age quintile and gender, and for age quintile only for values for men and women. 
 
 
 
 
From the 106 cancers for which staging was available from the strong positive gFOBT 
result group and the initial weak positive gFOBT then positive FIT result group, Dukes’ 
stage distribution is shown in Table 2.5.  In men, 19 (32.2%), 20 (33.9%), 19 (32.2%) 
and 1 (1.7%) were Dukes’ A, B, C1 and C2 respectively: in women, 14 (29.8%), 7 
(14.9%), 23 (48.9%) and 3 (6.4%) were diagnosed at these stages.  Table 2.6 shows 
the proportion of cancers in each route which are either early stage (Dukes’ stage A or 
B) or late stage (Dukes’ stage C1, C2 or D), with ORs for those with a strong positive 
gFOBT result compared to those with an initial weak positive gFOBT.  Maximum 
tumour diameter was larger in colorectal cancer cases diagnosed following a strong 
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positive gFOBT result compared to those with an initial weak positive gFOBT result (39 
mm, 95% CI: 33 - 44 v. 31 mm, 95% CI: 27 - 34). Table 2.7 displays the site distribution 
of colorectal cancer in both routes to test positivity. 
 
 
Table 2.5. Proportion of cancers at each Dukes’ Stage in each route to test positivity. 
Dukes’ stage 
Total Strong positive gFOBT 
result 
Weak positive gFOBT + 
positive FIT result 
n % n % n % 
A 33 31.1 4 12.5 29 39.2 
B 27 25.5 11 34.4 16 21.6 
C1 42 39.6 16 50.0 26 35.1 
C2 4 3.8 1 3.1 3 4.1 
 
 
 
Table 2.6. Proportion of early and late stage colorectal cancer by route to test positivity, with 
unadjusted and adjusted odds ratios with 95% confidence intervals (CI), using those with an 
initial weak positive guaiac faecal occult blood test (gFOBT) result as the reference category. 
Cancer stage 
Strong 
positive 
gFOBT result 
Weak 
positive 
gFOBT + 
positive FIT 
result 
Odds ratio 
(95% CI)* 
Adjusted Odds 
ratio 
(95% CI)*,** 
 n % n % 
Early (Dukes’ A or B): 16 48.5 47 61.8 1.54 (0.86 - 2.78) 1.56 (0.86 - 2.81) 
   Men 8 50.0 33 73.3 1.13 (0.51 - 2.50) 1.10 (0.49 - 2.46) 
   Women 8 47.1 14 45.2 2.50 (1.01 - 6.18) 2.47 (0.99 - 6.18) 
Late (Dukes’ C): 17 51.5 29 38.2 2.82 (1.54 - 5.17) 2.87 (1.55 - 5.29) 
   Men 8 50.0 12 26.7 3.22 (1.29 - 8.07) 3.17 (1.26 - 8.02) 
   Women 9 52.9 17 54.8 2.50 (1.11 - 5.65) 2.48 (1.09 - 5.66) 
*  Values in bold represent a statistically significant difference (p < 0.05). 
** Totals adjusted for age quintile and gender, and for age quintile only for values for men and women. 
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Table 2.7. Site distribution of colorectal cancers in each route to test positivity. 
Colorectal 
cancer site* 
Total Strong positive 
 gFOBT result 
Weak positive gFOBT 
+ positive FIT result 
n % n % n % 
Right-sided 35 29.2 13 35.1 22 26.5 
Left-sided 36 30.0 11 29.7 25 30.1 
Rectum 49 40.8 13 35.1 36 43.4 
Total 120  37  83  
* Right-sided includes region up to and including the splenic flexure; left-sided includes descending and 
sigmoid colon; rectum includes recto-sigmoid junction and rectum. 
 
 
2.4 Discussion 
 
Analysis of the clinical outcomes of these participants provides some insight into the 
relationship between degree of colonic blood loss as indicated by route to test 
positivity, and severity of colorectal disease, with evidence of more severe outcomes in 
those with a strong positive gFOBT result. 
 
Despite the Scottish Bowel Screening Programme currently being gFOBT-based as the 
initial test, the majority of participants with a final positive test result were, in fact, from 
the more analytically sensitive qualitative FIT result.  However, those showing evidence 
of material with peroxidise activity in every faecal sample collected on the initial gFOBT 
card did display greater evidence of colonic bleeding and therefore, more severe 
underlying pathology would be expected. 
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Differences were present between some PPV for neoplasia between the two routes to 
a positive screening result examined.  The PPV for colorectal cancer was higher in 
those who had a strong positive gFOBT result compared with those who had an initial 
weak positive gFOBT result.  This remained true for women when broken down by 
gender, but to a lesser extent for menMcDonald et al. (2012) had shown evidence in a 
population in Scottish of women having lower median faecal Hb concentration than 
men, and this has since been confirmed in other populations worldwide. (Fraser & 
Auge, 2014; Fraser et al., 2014; Symonds et al., 2015b)  It can perhaps be suggested 
that women with sufficient Hb in the faeces to trigger a strong positive gFOBT result 
are more likely than men to have serious underlying pathology.  The results here would 
back up this theory.   
 
Interestingly, fewer adenomas were detected in those with a strong positive gFOBT 
result compared with those who had a weak positive gFOBT then positive FIT result.  It 
was the thesis behind the implementation of undertaking FIT rather than a secondary 
gFOBT in initial weak positive participants that clinical performance would be improved 
due to the better analytical sensitivity and specificity of FIT.  These results are in 
keeping with findings that improved test performance with FIT compared to gFOBT is 
particularly evident for adenoma detection. (Rabeneck et al., 2012)  From the data 
presented here, this was true for men only. 
 
Since the completion of this analysis, similar work has emerged from England showing 
that it is possible to demonstrate that the risk of colorectal cancer is related to the 
number of windows testing positive for Hb on a gFOBT card. (Geraghty et al., 2014)  
colorectal cancer was detected in 21.3% of those with five or six windows showing 
positive test results compared with 5.9% in those with a weak positive test result (p < 
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0.001).  Conversely, fewer intermediate-risk adenomas (3-4 small adenomas or at least 
one adenoma ≥10 mm) were detected in those with five or six windows positive test 
results than in those with a weak positive test result (9.0% v. 13.6%), termed “unclear” 
in the NHS Bowel Screening Programme in England.  This mirrors the findings 
presented here in the Scottish population. 
 
In addition to having a greater proportion of colorectal cancer, odds ratio produced from 
logistic regression analysis showed that those in the strong positive gFOBT result 
group were also more than twice as likely to have late stage colorectal cancer as those 
with an initial weak positive gFOBT followed by a positive FIT result, and only four of 
the 32 staged colorectal cancers (12.5%) in this group were Dukes’ stage A compared 
to 39.2% in the initial weak positive gFOBT then positive FIT result group. 
 
The fact that no substantial differences were detected in colorectal cancer site 
distribution between the two routes to positivity may indicate that there is no general 
difference in the severity of colonic blood loss depending on colorectal cancer location, 
and further logistic regression analysis found this to be true when controlling for tumour 
size and Dukes’ stage.  It does seem significant, however, that strong positive test 
results were triggered by malignant tumours with a larger mean size than those in the 
initial weak positive test result group.  This indicates that larger lesions are associated 
with an elevated degree of blood loss into the colon. 
 
The differences seen in these results between men and women raise some concern.  
Although men had a higher test positivity rate than women, the overall PPV for 
colorectal cancer was higher in women than men in this cohort (10.7% v. 8.9%).  
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Moreover, in both routes to positivity examined, overall Dukes’ stages were later in 
women in than in men, with 32.8% of all colorectal cancer in men being late stage in 
contrast to the 54.2% in women.  Since it has been found that a higher proportion of 
colorectal cancer in women arise as interval cancer, (Brenner et al., 2012; Gill et al., 
2012; Steele et al. 2012) the use of an identical screening strategy for both genders 
perhaps does not provide equality in terms of meeting the primary aim of colorectal 
cancer screening i.e., to reduce colorectal cancer mortality through early detection and 
removal of precursor lesions.  Men did, however, have more adenomas of all types 
than did women, including having than double the PPV for higher-risk adenoma than in 
women in the strong positive gFOBT result group.  Low-risk adenoma, however, are 
less likely to be bleeding enough to trigger a positive test and therefore discovery of 
such lesions at colonoscopy can be deemed largely incidental.  These findings, 
therefore, probably simply reflect the greater prevalence of adenoma in men in the 
general population. 
 
Although the cohort came from the third incidence screening round in NHS Tayside, 
some participants will have been taking part in colorectal screening for the first time, 
such as those aged 50 years and new residents of the NHS Tayside catchment area.  
However, the IT system used by the Scottish Bowel Screening Programme does not 
allow for a bulk download of the screening round status of a cohort of participants and 
these data would require collection on an individual basis.  Therefore, owing to the size 
of the cohort being investigated, it was not feasible to perform analysis according to 
prevalence or incidence screening round.  Since the yield of disease is higher in those 
taking part in prevalence screening, this may represent a limitation to this work, 
although the majority of those invited over the time period used will be taking part in 
incidence screening. 
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Despite the fact that the relationship between faecal Hb concentration and severity of 
disease cannot be directly assessed in this investigation, the comparisons made 
between participants in the two different routes to positivity does provide a useful basis 
for further study on this topic.  The finding that those with strong positive gFOBT result 
are more likely to have colorectal cancer, and moreover, colorectal cancer with a worse 
prognosis, gives general support of the existence of this relationship.  Furthermore, 
gender differences in clinical outcomes between the two routes to positivity appear to 
add weight to the questions being asked regarding the use of a single cut-off faecal Hb 
concentration for men and women.  This requires further study. 
 
Examination of the relationship between faecal Hb concentration obtained using 
quantitative FIT and the underlying pathology responsible is the next logical step in this 
work.
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3. The relationship between faecal haemoglobin 
concentration and severity of colorectal neoplasia 
 
 
 
 
3.1 Introduction 
 
 
In the previous Chapter, evidence was presented showing that participants who display 
increased colonic bleeding have more severe disease.  This came from analysis of 
clinical outcomes according to the number of positive windows on the guaiac faecal 
occult blood test (gFOBT) card in a large cohort of screening participants.  However, 
with gFOBT now deemed obsolete, (Young et al., 2012) what would be far more 
enlightening would be a detailed analysis of how estimation of actual faecal 
haemoglobin (Hb) concentration correlates to pathology detected by the gold standard 
colonoscopy; this can be achieved with quantitative Faecal Immunochemical Tests for 
haemoglobin (FIT). 
 
A clearer understanding of how different features of colorectal pathology are 
associated with varying degrees of colonic blood loss can guide screening programme 
organisers when selecting an appropriate cut-off faecal Hb concentration.  With the key 
aim of screening being the early detection and removal of precursor lesions, identifying 
those adenomas at greatest risk of progressing towards malignancy, rather than small 
polyps that are unlikely to ever progress, would be useful to provide an efficient 
programme that limits exposure of its participants to unnecessary, invasive 
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colonoscopy.  It is known that some histopathological features of adenoma are 
associated with a higher risk of progression to malignancy.  These include adenomas 
displaying villous histology rather than solely tubular features and those showing 
evidence of high-grade dysplasia. (Lieberman et al., 2012)  Evidence showing that 
such characteristics are associated with elevated faecal Hb concentration in 
comparison to that of lower risk pathology would provide important backing to the 
argument that faecal Hb concentration is a strong predictor of colorectal cancer risk. 
 
Few previous studies have demonstrated that faecal Hb concentration increases as 
disease becomes more serious, from the normal colon through low- and high-risk 
adenomatous polyps, to invasive colorectal cancer. (Auge et al., 2014; Ciatto et al., 
2007; Hol et al., 2009; Kovarova et al., 2012; Launoy et al., 2005; Levi et al., 2007; 
Rozen et al., 2009a) The results of these studies were reviewed in detail in the 
Introduction to this work.  To summarise, the evidence shows that those with advanced 
neoplasia have significantly higher median faecal Hb concentration than those with less 
severe findings at colonoscopy. (Auge et al., 2014; Ciatto et al., 2007; Hol et al., 2009; 
Kovarova et al., 2012; Levi et al., 2007)  Liao et al. (2013) performed multiple linear 
regression analysis to reveal a significant association between increasing faecal Hb 
concentration in seven ordinal scales and severity of neoplasia, from adenoma, to 
advanced adenoma, to colorectal cancer, adjusted for age and gender in an average-
risk Taiwanese population.  Launoy et al., (2005) using French colorectal cancer 
screening programme data, reported colonoscopy outcomes within increasing ranges 
of faecal Hb concentration.   The authors found that the majority of those in the lowest 
faecal Hb concentration categories did not have neoplasia, whereas 65.2% of those 
with a faecal Hb concentration above the traditionally used cut-off concentration of 100 
ng Hb/ml buffer, or 20 µg Hb/g faeces, had either colorectal cancer or a large 
adenoma.  Indeed, it has been suggested in expert comment that there may be a 
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continuum of increasing risk as faecal Hb concentration increases from zero. (Fraser, 
2011b) 
 
Varying median faecal Hb concentration according to different adenoma characteristics 
has also been documented, with villous or serrated lesions, and adenomas displaying 
high-grade dysplasia associating with higher faecal Hb concentration than adenomas 
with less severe characteristics. (Ciatto et al., 2007; Levi et al., 2007) However, an 
overriding finding was that lesion size was a strong influencing factor in these results.   
This would suggest that it is not so much the detailed histopathology of the lesion that 
determines the degree of colonic blood loss, but more simply that larger lesions are 
more susceptible to damage to their vasculature by passing faeces, possibly as it is 
more formed.   
 
Mixed evidence exists surrounding the relationship between faecal Hb concentration 
and lesion site.  A very recent study by van Doorn et al. (2015) reported that a finding 
of higher mean faecal Hb concentration in lesions found in the distal colon compared to 
those found proximally was not independent of other factors including lesion size and 
polyp morphology.  Levi et al. (2007) observed no variation in faecal Hb concentration 
between proximally and distally located advanced adenoma,  whereas Ciatto et al. 
(2007) found that although left-sided adenomas were larger than those in the right 
colon, left-sidedness did show independent association with increasing faecal Hb 
concentration in adenomas.   This was speculated by the authors to be due to faeces in 
this section of the colon being better formed and therefore having a greater mechanical 
effect on any polyps with which the faces comes into contact.  Further data are 
required to address the issue of the efficacy of FIT in detecting neoplasia from different 
regions of the colon. 
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The existing evidence on the relationship between faecal Hb concentration and clinical 
outcomes is limited and no clear consensus exists on variation in faecal Hb 
concentration according to the location in the colon of neoplasia.  With some 
publications showing that a higher proportion of interval cancers are right-sided than 
screen-detected colorectal cancer, better understanding of any differences in faecal Hb 
concentration according to lesion site could be important to understanding why some 
cancers are missed by screening.  To date, no studies investigating the relationship 
between faecal Hb concentration and clinical outcomes have been conducted where a 
high cut-off faecal Hb concentration was set for test positivity within a colorectal cancer 
screening programme.  It would be valuable for countries, such as the Scotland and the 
rest of the UK, to have such results at their disposal, this time against a backdrop of 
limited colonoscopy capacity.  In addition, by further documenting that participants with 
elevated faecal Hb concentration are at significantly greater risk than those with low 
faecal Hb concentration, the potential of faecal Hb concentration to add to the 
performance of risk scoring models cannot be ignored. 
 
With this in mind, the aim of this section was to investigate the relationship between 
faecal Hb concentration and disease severity in a cohort of average risk participants 
completing a single sample quantitative FIT within the Scottish Bowel Screening 
Programme. 
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3.2 Materials and methods 
 
From 1 July 2010 to 12 January 2011, The Scottish Bowel Screening Programme 
conducted an evaluation of using quantitative FIT in two of the 14 NHS Boards in 
Scotland.  Termed the ‘FIT as a First-Line Test’ evaluation, this was conducted to 
determine clinical outcomes in a cohort screened with FIT at a high cut-off faecal Hb 
concentration to maintain colonoscopy demand within the limits of the available 
resource, and compare these outcomes with control groups completing the gFOBT/FIT 
two-tier reflex algorithm.  The evaluation also aimed to assess any improvements in 
uptake that may occur when screening with FIT, the overall planning and delivery of 
FIT screening, analytical reproducibility of faecal Hb concentration measurements in 
the laboratory, any technical issues arising with FIT, and consistency and quality of 
reagents.  The results of the evaluation have been described elsewhere. (Steele et al., 
2013) 
 
For the ‘FIT as a First-Line Test’ evaluation, all eligible participants in the Scottish 
Bowel Screening Programme, aged 50–74 years, resident in NHS Tayside and NHS 
Ayrshire & Arran, were sent a quantitative FIT kit pack containing an invitation letter, a 
booklet on colorectal cancer and a thin card wallet with written and pictorial instructions 
for sample collection containing a single faecal sample collection device (Eiken 
Chemical Co., Ltd, Tokyo, Japan) and a small zip-lock plastic bag with integral 
absorbent material and a foil mailing pouch for device return.  On return to the 
Laboratory, receipt of a specimen was captured electronically by the Scottish Bowel 
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Screening System through a barcode.  Gender and age were derived from the bar-
coded CHI number, the 10-digit number used through the health care system in 
Scotland.  The barcode labelled specimen collection tubes were assayed for faecal Hb 
concentration on one of two OC-Sensor Diana automated immunoturbidimetry 
analysers (Eiken Chemical Company, Tokyo, Japan).  Analyses were carried out by 
trained staff: the laboratory had a comprehensive total quality management system and 
International Organization for Standardization (ISO) 15189 based standards by Clinical 
Pathology Accreditation (UK) Ltd. 
 
It has been proposed that all FIT data be expressed as μg Hb/g faeces and a multiplier 
can be applied to each analytical system:(Fraser et al., 2012) for the OC-Sensor Diana, 
ng Hb/ml buffer data are multiplied by 0.2.  Samples with results above the upper 
analytical limit were not diluted and re-assayed but reported as greater than that upper 
concentration limit.   
 
All participants with faecal Hb concentration less than 80 µg Hb/g faeces were reported 
as having a negative screening result and sent an informative letter.  All participants 
with faecal Hb concentration equal to or above 80 µg Hb/g faeces were reported as 
having a positive screening test result and sent an informative letter, the general 
practitioner notified and the individual referred to their NHS Board for colonoscopy.  
The cut-off faecal Hb concentration was chosen based on an estimate of approximately 
2% test positivity to mimic the positivity rate of the existing Screening Programme, 
selected to match the available colonoscopy resource.  Data for colonoscopy outcomes 
and any subsequent pathology were downloaded from the appropriate NHS Tayside 
and NHS Ayrshire & Arran clinical IT systems.  Data on colonoscopy were collected on 
the quality of the investigation (quality of preparation, completeness of colonoscopy) 
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and on the number, size, and localisation of colorectal cancer and adenomas.  Full 
pathological data were collected on all excised/biopsy specimens including polyp type, 
presence or absence of malignancy, Dukes’ stage of any colorectal cancer and, in all 
adenoma, the severity of dysplasia.  Lesion size was recorded from pathology reports 
except when removed piecemeal, when colonoscopy measurement was used. Right-
sided location of colorectal cancer was defined as cancer detected in the region of the 
colon up to and including the splenic flexure, left-sided as the region thereafter up to 
the recto-sigmoid junction, and rectal cancer as cancer located at either the recto-
sigmoid junction or in the rectum. 
 
Faecal Hb concentration was collated into clinical outcome groups according to most 
serious diagnosis.  Faecal Hb concentration from those with adenoma were further 
grouped according to characteristics relating to their most serious lesion: size (small, a 
maximum dimension of <10 mm or large, ≥10 mm), degree of dysplasia (high-grade 
dysplasia or low-grade dysplasia), villous nature (presence or absence) and location as 
already defined for colorectal cancer.  MedCalc (MedCalc Software, Mariakerke, 
Belgium) statistical software was used for all calculations and to generate distribution 
graphs. The Mann–Whitney U test was used for comparison between the groups and 
median lesion size.  Probability of p ≤ 0.05 was considered significant. 
 
For reasons explained in the Discussion section of Chapter 2 (The relationship 
between results with the guaiac faecal occult blood test/Faecal Immunochemical Test 
two-tier reflex screening algorithm and severity of colorectal neoplasia), it was not 
feasible to separate those participating in prevalence screening from incidence 
screening.  This is also relevant for Chapters 4-6. 
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3.3 Results 
 
Table 3.1 summarises the number of participants in the study and their clinical 
outcomes (shown as the most serious diagnosis), using those with completed 
investigations as the denominator for percentages of each outcome found.  Those 
undergoing colonoscopy had a mean age of 62.8 years and 56.4% were men.  Overall, 
28.1% of participants undergoing colonoscopy had advanced neoplasia; this was 
significantly higher in men at 32.5% compared with 22.3% in women (p < 0.01). 
 
Figure 3.1 displays the proportion of participants with colorectal cancer, higher-risk 
adenoma, low-risk adenoma, other pathology and no pathology with increasing faecal 
Hb concentration.  The percentage of participants with colorectal cancer rose from 
4.8% in all of those with faecal Hb concentration above the cut-off for test positivity of 
80 µg Hb/g faeces, to 7.4% in those with faecal Hb concentration at the upper 
analytical limit of over 200 µg Hb/g faeces.  Combining colorectal cancer and higher-
risk adenoma gives a Positive Predictive Value (PPV) for advanced neoplasia of 28.1% 
at 80 µg Hb/g faeces, while 35.7% of those with a faecal Hb concentration of over 200 
µg Hb/g faeces had advanced neoplasia.  The majority of cases of advanced neoplasia 
were associated with faecal Hb concentration of over 200 µg Hb/g faeces, with 74.4% 
of participants with colorectal cancer and 58.1% of those with higher-risk adenoma 
having faecal Hb concentration above this upper limit reported by the analyser.  This 
compared to 35.3% of those with low-risk adenoma. 
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Table 3.1. Study participants and clinical outcomes, by gender. 
            Total Men Women 
  n % n % n % 
Study participants:       
 Invited 66,036  32,245  33,791  
 Responders 38,723 43.5 18,057 56.0 20,666 61.2 
 
 
      
Positive (faecal haemoglobin  
concentration ≥ 80 µg Hb/g faeces): 
942 2.4 532 2.9 410 2.0 
 Completed investigations 818 86.8 461 86.7 357 87.1 
 Declined colonoscopy/unfit 124 13.2 71 13.3 53 12.9 
Clinical outcomes:       
 Cancer (CRC) 39 4.8 23 5.0 16 4.5 
 Higher-risk adenoma (HRA) 191 23.3 127 27.5 64 17.9 
 Advanced neoplasia (CRC + HRA) 230 28.1 150 32.5 80 22.4 
 Low-risk adenoma (LRA) 119 14.5 77 16.7 42 11.8 
 Unclassified risk adenoma 2 0.2 1 0.2 1 0.3 
 Total adenoma  312 38.1 205 44.5 107 30.0 
 Total neoplasia (CRC + total adenoma) 351 42.9 228 49.5 123 34.5 
 Inflammatory bowel disease 47 5.7 30 6.5 17 4.8 
 Diverticular disease 106 13.0 43 9.3 63 17.6 
 Haemorrhoids 72 8.8 38 8.2 34 9.5 
 Miscellaneous pathology* 9 1.1 3 0.7 6 1.7 
 No pathology detected 171 20.9 81 17.6 90 25.2 
* Includes four participants with angiodysplasia, two with a rectal ulcer, one with an anal fissure, one 
with severe melanosis coli and one with intestinal parasite. 
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Figure 3.1. Positive Predictive Values (PPV) for clinical outcomes with rising faecal 
haemoglobin concentration (f-Hb). 
0%
5%
10%
15%
20%
25%
30%
35%
40%
≥80 ≥100 ≥120 ≥140 ≥160 ≥180 ≥200
f-Hb (µg Hb/g faeces)
P
P
V
Cancer
High-risk adenoma
Low-risk adenoma
No pathology
Non-neoplastic
pathology
 
Non-neoplastic pathology comprises of hyperplastic polyps and other conditions including diverticular 
disease, haemorrhoids and inflammatory bowel disease. 
 
 
Table 3.2 shows the median faecal Hb concentration for various clinical outcomes with 
95% confidence intervals (CI) and interquartile ranges (IQR).  Although there is much 
overlap amongst clinical outcomes and wide CI, median faecal Hb concentration in 
those with colorectal cancer was statistically significantly higher than that of all other 
outcomes apart from higher-risk adenoma (p = 0.08).  Those with higher-risk adenoma 
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had median faecal Hb concentration that was higher than in those with low-risk 
adenoma, hyperplastic polyps, diverticular disease and those with no pathology 
detected (all p < 0.03), but not significantly different to those with inflammatory bowel 
disease or haemorrhoids (both p > 0.05).  There was no statistically significant 
difference between the low-risk adenoma group and those without neoplasia (p = 0.06).  
Median faecal Hb concentration in all participants with advanced neoplasia diagnosed 
was very highly significantly greater than in those with all other outcomes (p < 0.0001).  
Figure 3.2 illustrates distribution of individual faecal Hb concentration measurements 
for different clinical outcomes. 
 
Table 3.2. Median faecal haemoglobin concentration (f-Hb) according to clinical outcome 
with 95% confidence intervals (CI) and interquartile ranges (IQR). 
Clinical outcomes n 
Median f-Hb 
(µg Hb/g faeces) 95% CI IQR 
Cancer 39 200 200 – 200 187 – 200 
Higher-risk adenoma 191 200 200 – 200 133 – 200 
Low-risk adenoma 119 145 125 – 167 102 – 200 
Hyperplastic polyps 62 175 136 – 200 107 – 200 
Inflammatory bowel disease 47 184 137 – 200 116 – 200 
Diverticular disease 106 158 139 – 198 113 – 200 
Haemorrhoids 72 200 147 – 200 125 – 200 
No pathology detected 171 170 150 – 200 115 – 200 
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Figure 3.2. Distribution of faecal haemoglobin concentration (f-Hb) according to clinical 
outcome. 
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Horizontal bars represent median f-Hb. 
CRC = colorectal cancer, HRA = higher-risk adenoma, LRA = low-risk adenoma, HPP = hyperplastic 
polyps, IBD = inflammatory bowel disease, DD = diverticular disease. 
 
 
Table 3.3 shows median faecal Hb concentration according to Dukes’ stage, cancer 
site and cancer type.  The differences in median faecal Hb concentration between 
different stages were not statistically significant, nor were the differences in faecal Hb 
concentration by tumour site.  Of the 39 participants with colorectal cancer, 29 had 
faecal Hb concentration of more than 200 µg Hb/g faeces and 10 had faecal Hb 
concentration that could be measured within the analytical working range of 0 – 200 µg 
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Hb/g faeces.  Those within the analytical working range included four participants with 
a confirmed polyp cancer (Dukes’ stage A), two non-polyp Dukes’ A cancers, three 
Dukes’ B and one Dukes’ stage C1 rectal cancer with f Hb of 88 µg Hb/g faeces.  In all, 
36 of the colorectal cancer cases had staging available and 12 (six polyp; 27.3%), 11 
(33.3%), 12 (36.4%) and 1 (3.0%) colorectal cancer cases were Dukes’ A, B, C1 and 
C2, respectively.  Figure 3.3 shows the distribution of faecal Hb concentration 
according to Dukes’ stage. 
 
 
Table 3.3. Median faecal haemoglobin concentration (f-Hb) of cancers, with 95% confidence 
intervals (CI) and interquartile ranges (IQR) and significant differences indicated by the p-
value in bold. 
 n 
Median f-Hb 
(µg Hb/g faeces) 95% CI IQR p-value 
All cancers 39 200 170 – 193 187 – 200  
Dukes' stage:      
 A or B 20 200 160 – 200 147 – 200 
0.133 
 C or higher 13 200 200 – 200 200 – 200 
Tumour site*:     
 
 Right-sided 12 200 200 – 200 200 – 200 
0.410 
 Left-sided 13 200 163 – 200 172 – 200 
 Rectum** 14 200 125 – 200 126 – 200 
 
Cancer type:     
 
 Polyp 6 155 104 – 200 116 – 200 
0.039 
 Other 28 200 200 – 200 200 – 200 
* Right-sided includes region up to and including the splenic flexure; left-sided includes descending and 
sigmoid colon; rectum includes recto-sigmoid junction and rectum. 
**No significant difference in median f-Hb between rectal cancer and right-sided cancers (p = 0.3566) or 
between rectal and left-sided cancers (p = 0.9079) 
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Figure 3.3. Distribution of faecal haemoglobin concentration (f-Hb) according to Dukes’ stage 
of colorectal cancer. 
80
100
120
140
160
180
200
Dukes' stage
f-
H
b
 (
µ
g
 H
b
/g
 f
a
e
c
e
s
)
A B C
 
 
 
Table 3.4 further classifies those with an adenoma detected according to different 
polyp characteristics, along with the median faecal Hb concentration and p-values for 
comparison between these features.  Figure 3.4 shows the distribution of faecal Hb 
concentration according to the different adenoma characteristics examined.  
Statistically significant differences in median faecal Hb concentration were detected 
between adenomas classed as large adenomas (≥ 10 mm maximum diameter) and 
small adenomas (< 10 mm), and between adenomas displaying high-grade dysplasia 
and those with low-grade dysplasia.  Although faecal Hb concentration in those who 
had an adenoma with a villous component was higher than in non-villous adenoma, 
this was not statistically significant (p = 0.07).  The higher median faecal Hb 
concentration associated with adenomas situated in the distal colon (beyond the 
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splenic flexure) compared with those more proximal did not reach statistical 
significance (p = 0.08).  No significant difference in faecal Hb concentration was found 
between those with multiple adenomas (defined as ≥3) and those with only one or two 
adenomas (p = 0.64). 
 
Table 3.4. Median faecal haemoglobin concentration (f-Hb) according to adenoma 
characteristic, with 95% confidence intervals (CI) and interquartile ranges (IQR) and 
significant differences indicated by the p-value in bold. 
Adenoma characteristic n 
Median f-Hb 
(µg Hb/g faeces) 95% CI IQR p-value 
       
Small (< 10 mm max. diameter) 134 151 130 – 169 102 – 200 
   <0.0001 
Large (≥ 10 mm max. diameter) 174 200 200 – 200 135 – 200 
       
< 3 adenomas detected 261 198 164 -200 116 – 200 
0.592 
≥ 3 adenomas detected 51 200 154 – 200 117 – 200 
       
Low-grade dysplasia 252 186 154 – 200 112 – 200 
0.009 
High-grade dysplasia 57 200 200 – 200 152 – 200 
       
Non-villous 123 168 142 – 200 114 – 200 
0.092 
Villous component 156 200 184 – 200 117 – 200 
       
Right-sided* 67 158 127 – 200 105 - 200 
0.077 
Left-sided* 209 200 180 – 200 120 - 200 
Rectum* 32 200 150 – 200 115 - 200  
* Right-sided includes region up to and including the splenic flexure; left-sided includes descending and 
sigmoid colon; rectum includes recto-sigmoid junction and rectum. 
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Figure 3.4. Distribution of faecal haemoglobin concentration (f-Hb) according to adenoma 
characteristics. 
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Horizontal bars represent median f-Hb and error bars show interquartile range. 
LGD = low-grade dysplasia, HGD = high-grade dysplasia, 
 
 
The significant difference in faecal Hb concentration seen between high-grade 
dysplasia and low-grade dysplasia adenomas was not evident when holding size 
constant, with no difference between small (< 10 mm) low-grade dysplasia and high-
grade dysplasia adenomas (p = 0.88), or between large (≥ 10 mm) low-grade dysplasia 
and high-grade dysplasia adenomas (p = 0.09).  Multiple regression analysis including 
size, degree of dysplasia, presence or absence of villous component, site and number 
of adenomas as categorical explanatory variables showed adenoma size was the only 
characteristic to be significantly related to faecal Hb concentration (p < 0.0001; all other 
variables p > 0.1).   
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Table 3.5 shows the median size of lesions in those with hyperplastic polyps, adenoma 
or colorectal cancer detected and p-values for comparisons, with significant differences 
in bold.  Significantly larger median lesion size was seen with any adenoma compared 
with hyperplastic polyps (HPP), higher-risk adenoma compared with low-risk adenoma, 
high-grade dysplasia compared with low-grade dysplasia adenomas, villous compared 
with non-villous adenomas, and more advanced cancers compared with polyp cancers. 
In addition, all cancers were significantly larger than higher-risk adenoma (p < 0.0001) 
and indeed any adenoma (p < 0.0001).  Adenomas in the distal colon were larger than 
in the proximal region, in contrast to cancers, which were larger proximally (both p < 
0.05).  No significant differences were seen in the median size of neoplastic lesions 
detected in the rectum compared with elsewhere in the colon. 
 
Table 3.6 shows the results of multivariate logistic regression on categories of faecal 
Hb concentration, gender and age to give odds ratios for colorectal cancer and 
advanced neoplasia in those undergoing colonoscopy.  Those with faecal Hb 
concentration above the upper analytical limit were significantly more likely to have 
colorectal cancer than those in the lowest category examined (80 - 119 µg Hb/g 
faeces), independent of age and gender; the same was true for advanced neoplasia. 
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Table 3.5. Comparison of median lesion size with 95% confidence intervals (CI) according to 
most severe lesion detected at colonoscopy. 
* Not all lesions had a definitive size recorded, therefore some totals differ from those reported 
elsewhere. 
* Right-sided includes region up to and including the splenic flexure; left-sided includes descending and 
sigmoid colon; rectum includes recto-sigmoid junction and rectum. 
 
 
 n* 
Median 
lesion 
size 
(mm) 95% CI 
Minimum 
(mm) 
Maximum 
(mm) 
p-value 
Hyperplastic polyps 38 3 3 - 5 1 16 
<0.0001 
All adenoma 307 10 10 - 11 1 85 
Low-risk adenoma 118 6 4 - 7 1 9 
<0.0001 
Higher-risk adenoma 189 14 12 - 15 3 85 
Adenoma Histology:       
Low-grade dysplasia 250 10 9 - 10 1 50 
<0.0001 
High-grade dysplasia 56 14 12 - 17 3 85 
Non-villous 127 7 6 - 8 1 35 
<0.0001 
Villous 154 13 12 - 15 2 85 
Adenoma site**:       
Right-sided 66 9 7 - 10 1 85 
0.008 
Left-sided 208 11 10 - 12 2 50 
Rectum 32 10 8 - 10 3 30  
Cancer 37 30 25 - 35 7 90  
Dukes’ Stage:       
A or B 22 26 25 - 34 7 55 
0.161 
C or higher 13 35 27 - 42 22 50 
Tumour site**:       
Right-sided 12 35 31 - 46 25 55 
0.005 
Left-sided 13 25 17 - 29 7 45 
Rectum 12 30 24 - 47 18 90  
Cancer type:       
Polyp 5 18 - 7 26 
0.003 
Other 27 35 25 - 44 9 55 
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Table 3.6. Multivariate logistic regression of faecal haemoglobin concentration (f-Hb) category, gender and age quintile with odds ratios with 95% confidence 
intervals (CI) for colorectal cancer (CRC) and advanced neoplasia (AN).  Significant OR shown in bold. 
Variable 
n % Total CRC % with CRC Odds ratio (95 % CI) Total AN % with AN Odds ratio (95% CI) 
f-Hb category 
(µg Hb/g faeces): 
        
 80.0 – 119.9 219 28.0 4 1.8 1.00 42 19.2 1.00 
 120.0 – 159.9 137 17.5 5 3.6 1.76 (0.46 – 6.72) 30 21.9 1.14 (0.67 – 1.93) 
 160.0 - 199.9 63 8.0 1 1.6 0.82 (0.09 – 7.54) 17 27.0 1.60 (0.83 – 3.09) 
 ≥ 200.0 364 46.5 29 8.0 4.29 (1.48 – 12.42) 141 38.7 2.33 (1.57 – 3.47) 
Gender:         
 Men 461 56.3 23 5.0 1.00 150 32.5 1.00 
 Women 358 43.7 16 4.5 0.97 (0.50 – 1.88) 80 22.3 0.62 (0.45 – 0.85) 
Age quintile (years):        
 50 - 54 128 15.6 6 4.7 1.00 32 25.0 1.00 
 55 - 59 169 20.6 3 1.8 0.37 (0.09 – 1.52) 39 23.1 0.90 (0.52 – 1.56) 
 60 - 64 155 18.9 6 3.9 0.82 (0.26 – 2.64) 47 30.3 1.30 (0.76 – 2.23) 
 65 - 69 184 22.5 11 6.0 1.24 (0.44 – 3.46) 60 32.6 1.42 (0.85 – 2.38) 
 ≥ 70 183 22.3 13 7.1 1.71 (0.62 – 4.66) 52 28.4 1.26 (0.74 – 2.12) 
93 
 
 
3.4 Discussion 
 
A wide distribution of faecal Hb concentration exists above the cut-off selected of 80 µg 
Hb/g faeces, with considerable overlap between groups with different clinical 
outcomes.  However, there is evidence of a relationship between increasing faecal Hb 
concentration and stage in progression of colorectal neoplasia.  In addition to a 
significantly higher median faecal Hb concentration in participants with any neoplasia 
detected compared with those with no, or non-neoplastic pathology, increasing faecal 
Hb concentration is also associated with greater severity of the lesion amongst those 
with neoplasia detected. 
 
As might be expected, median faecal Hb concentration was significantly higher in 
participants with higher-risk adenoma compared to those with low-risk adenoma.  
Furthermore, median faecal Hb concentration in those with low-risk adenoma was 
perhaps surprisingly low in comparison with those with no neoplasia detected; lower in 
fact than in those with hyperplastic polyps (although not statistically significant).  
Indeed, previous studies have found relatively low faecal Hb concentration in non-
advanced adenomas, with most giving a concentration below 15 µg Hb/g faeces. (Levi 
et al., 2007)  This is a significant observation, bearing in mind that only a small number 
of all adenomas will ever progress to malignancy.  The ability of faecal Hb 
concentration to distinguish between those with small low-risk adenoma, and larger 
lesions more likely to associate with a greater degree of dysplastic change is useful in 
avoiding overdiagnosis in those with harmless polyps.  The repeat nature of colorectal 
cancer screening with tests for haemoglobin (Hb) in faeces provides opportunities for 
lesions that do undergo further dysplastic change to be detected at a later screening 
round, although this does rely on consistent participation. 
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To further investigate the significant difference in median faecal Hb concentration 
between higher-risk adenoma and low-risk adenoma, more detailed examinations were 
made, with participants grouped by the two adenoma characteristics used in this 
evaluation to determine risk classification: size and number.  The fact that a higher 
median faecal Hb concentration was observed in participants with a larger adenoma 
compared with those with a small adenoma, but not when comparing participants who 
had multiple adenomas with those with only one or two adenomas detected, 
demonstrates that the difference between the higher-risk adenoma and low-risk 
adenoma group can be attributed to lesion size.  Indeed, the median maximum 
dimension of higher-risk adenoma was over double that of low-risk adenoma and 
statistically significantly greater. 
 
The findings here confirm those of earlier work (Ciatto et al., 2007; Levi et al., 2007) 
and are further supported by a recent publication from Spain presenting detailed 
analysis of variation in faecal Hb concentration by lesion characteristic, with adenomas 
displaying villous features and high grade dysplasia associating with higher median 
faecal Hb concentration than adenomas with less severe histological features. (Garcia 
et al., 2015b)  The evidence showing that adenomas displaying high-grade dysplasia 
have a significantly higher median faecal Hb concentration than those with low-grade 
dysplasia may indicate that the severity dysplastic change can reflect propensity of the 
lesion to bleed.  However, further analysis of this Scottish cohort showed there to be no 
significant difference between high-grade dysplasia and low-grade dysplasia 
adenomas when size was taken into account, and retrospective multiple regression 
modelling demonstrated that adenoma size was the only one of the variables studied 
found to independently related to faecal Hb concentration.  Thus, the relationship 
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between grade of dysplasia and faecal Hb concentration was found to be primarily 
related to adenoma size.  With adenomas displaying high-grade dysplasia being 
significantly larger than those with low-grade dysplasia, and with 27.2% of larger 
adenomas also displaying high-grade dysplasia compared to just 7.5% of smaller 
lesions, then it can be stated that increasing faecal Hb concentration is associated with 
larger lesions, which, in turn, are more likely to display more severe dysplasia.  It is 
worth noting that very recent analysis from the Netherlands (van Doorn et al., 2015) 
reported on multiple linear regression performed on a cohort of 877 participants with a 
lesion detected following a positive screening test result using a cut-off faecal Hb 
concentration of 10 µg Hb/g faeces and found that both size and polyp morphology, 
with faecal Hb concentration highest in polyps with pedunculated shape, to remain 
significantly associated with faecal Hb concentration (p < 0.001 and p< 0.005, 
respectively).  The finding that only adenoma size was independently associated with 
faecal Hb concentration in the cohort from Scotland may be due to the far higher cut-off 
faecal Hb concentration used, above which small polyps are likely to be largely 
incidental findings. 
 
Further evidence of a potential continuum of risk with increasing faecal Hb 
concentration came on investigation of those participants who had colorectal cancer 
detected following their positive screening result.  Although the median faecal Hb 
concentration of participants with colorectal cancer was not significantly different to 
those with higher-risk adenoma, 74.4% of those with colorectal cancer had a faecal Hb 
concentration that was above the upper analytical limit of 200 µg Hb/g faeces, 
compared to 58.1% of those with higher-risk adenoma as their most serious outcome.  
However, it should be stated even when looking only at those with faecal Hb 
concentration > 200 µg Hb/g faeces, the PPV for colorectal cancer was still below 10%, 
and below 40% for advanced neoplasia.  This illustrates the poor specificity of faecal 
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Hb concentration for the detection of significant colorectal neoplasia.  The high number 
of participants with a false positive result in screening is an important issue in terms of 
use of resources, unnecessary worry experiences by the patients along with the risks 
and discomfort associated with colonoscopy.  
 
Within the colorectal cancer group, with the exception of polyp cancers, significant 
differences in median faecal Hb concentration were not seen between early stage and 
late stage tumours.  However, it is of note that 90.0% of the colorectal cancer cases 
that were associated with a faecal Hb concentration within the analytical working range 
(< 200 µg Hb/g faeces), were early stage and that 40.0% were polyp cancers.  This 
compares with 51.7% of colorectal cancer above the limit of the analyser that were 
early stage.  Overall, polyp cancers were significantly smaller than the more invasive 
cancers and had a significantly lower median faecal Hb concentration, being similar in 
this regard to adenomas with high-grade dysplasia. 
 
The mean maximum diameter of all malignant tumours was, as expected, significantly 
greater than all of the various groupings of adenomas studied.  The Dukes’ C1 rectal 
cancer with the relatively low faecal Hb concentration of 88.4 µg Hb/g faeces 
demonstrates the potential anomalies in the relationship between faecal Hb 
concentration and neoplastic disease stage that may occur.  This particular tumour had 
a maximum diameter that was smaller than the median, with a maximum dimension of 
25 mm reported, further giving weight to the argument that it is the size of the lesion 
rather than its Dukes’ stage that is related to the degree of lower gastrointestinal blood 
loss. This is in keeping with the findings of Levi et al. (2007) who found that small 
proximal cancers had low faecal Hb concentration.  
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It has been demonstrated that, like gFOBT, FIT is less effective at detecting lesions 
located in the proximal region of the colon than those found distally. (Haug et al., 2011)  
77.8% of adenomas and 69.2% of cancers in this cohort were located in the distal 
colon or rectum.  However, the location of lesions missed by FIT screening is not 
known and this may simply reflect the true anatomical distribution of colorectal 
neoplasia.  The results of similar investigations by Levi et al. (2007) involving subjects 
from an increased risk population have also shown that median faecal Hb 
concentration was similar between participants with advanced adenomas detected in 
the proximal colon and those found distally.  Despite distal adenomas in this cohort 
being significantly larger than those located in the proximal colon, and median faecal 
Hb concentration appearing to be higher in those with distal adenomas, the findings of 
this study were in keeping with the observations by Levi et al. (2007) in that the 
difference was not statistically significant (p = 0.08). 
 
In addition to previously discussed work which provides mixed conclusions with regard 
to the relationship between faecal Hb concentration and lesion site, (Ciatto et al., 2007; 
Levi et al., 2007; van Doorn et al., 2015) a very recent study from Australia has now 
shown that test positivity with a cut-off faecal Hb concentration of 20 µg Hb/g faeces 
was significantly more likely in those with distal neoplasia compared with those who 
had proximal neoplasia detected (odds ratio = 2.10, 95% CI: 1.17 - 3.78), but did not 
present results of variation in median faecal Hb concentration between the two groups. 
(Symonds et al., 2015b).  However, the finding in the cohort presented in this Chapter 
that there was no significant difference in median faecal Hb concentration in 
participants with colorectal cancer detected in different regions of the colon, regardless 
of the fact that the proximal tumours were significantly larger than those found distally, 
supports the argument that the success of FIT in screening for colorectal neoplasia 
depends on its efficacy in detecting Hb from different parts of the colon. (Allison, 2010)  
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It has been suggested in previous literature that there may be gender differences in 
test sensitivity with gFOBT, (Brenner et al., 2010) and that a slower colonic transit time 
in women may be partly responsible for this.  If this is the case, it might be expected 
that proximal colorectal cancer in women would have a lower median faecal Hb 
concentration than in men, owing to the greater time window for Hb degradation to 
occur from the site of the lesion to when the faeces is sampled.  Unfortunately, the 
numbers in this cohort are too small to allow conclusions to be drawn from more 
detailed analysis of variation in faecal Hb concentration according to site and gender, 
but this is an interesting area for future research. 
 
Some evidence exists that when screening with tests for Hb in faeces, interval cancers 
may occur more regularly in the rectum than screen-detected colorectal cancer, 
(Jensen et al., 1992; Steele et al., 2012; Tazi et al., 1999) with the speculated reasons 
for this finding being faster tumour growth rates (Launoy et al., 1997) and non-
haemolysed erythrocytes from rectal tumours not yielding positive FIT or gFOBT.  For 
this reason, median faecal Hb concentration in those with lesions arising in the rectum 
was analysed separately to that of lesions situated in regions of the colon categorised 
as proximal or distal.  This gives a novel insight compared to other studies that have 
included the rectum in their definition of the distal colon.  However, no significant 
variation was observed in faecal Hb concentration or lesion size in those with rectal 
advanced neoplasia compared with elsewhere in the colon.  It is of note, however that 
the late stage cancer with the surprisingly low faecal Hb concentration of 88.4 µg Hb/g 
faeces was a rectal tumour. 
 
It is also of interest that non-neoplastic pathology, particularly diverticular disease, was 
not associated with faecal Hb concentration that was significantly different from that 
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found in those with no pathology was detected.  This is an important observation, since 
it indicates that false positive test resulting from benign disease are likely to be no more 
common than false positive test results in the absence of any colonoscopic 
abnormality. 
 
These findings, taken together, may be generally interpreted as follows: faecal Hb 
concentration can be a predictor of lesion size, with larger lesions more likely to carry 
features further along the pathway to malignancy, namely high-grade dysplasia and 
villousness, up to colorectal cancer itself. 
 
This work has important limitations.  Firstly, analysis of the distributions of faecal Hb 
concentration collected was confounded by the upper analytical limit of 200 µg Hb/g 
faeces.  Of the 818 participants who were included in this analysis, 393 had a faecal 
Hb concentration greater than 200 µg Hb/g faeces.  Therefore, an exact quantitative 
estimate of faecal Hb concentration was not recorded for 48.0% of participants.  It is 
possible that those participants who had large malignant tumours detected had faecal 
Hb concentration far higher than 200 µg Hb/g faeces, and that median faecal Hb 
concentration was considerably underestimated in this group.  This might explain why 
there was not a statistically significant difference in median faecal Hb concentration 
between the colorectal cancer group and the higher-risk adenoma group, despite the 
malignant lesions being significantly larger.   
 
Another limitation relating to the distribution of faecal Hb concentration is that the 
conclusions drawn from comparisons made between groups with differing clinical 
findings come with the caveat that some of the median values had relatively wide 95% 
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CI.  This was evident in some groups with small numbers of participants; for example, 
those with polyp cancers where there were only six confirmed cases. 
 
Thirdly, since this is observational research from results of a screening evaluation, only 
participants with a positive result were referred for colonoscopy.  This meant that 
analysis of the relationship between faecal Hb concentration and disease could only be 
carried out on those with a faecal Hb concentration above the cut-off for test positivity 
of 80 µg Hb/g faeces.  There will, therefore, have been false negative test results for 
which faecal Hb concentration has not been taken into account when calculating the 
median values for each group.  This issue will, in part, be addressed in the next 
Chapter of this thesis through analysis of interval cancer identified in this cohort. 
 
It is possible that the results may have been strengthened by the collection of more 
than one sample from each participant, as advocated in several studies for improving 
neoplasia detection. (Grazzini et al., 2009; Guittet et al., 2009; Levi et al., 2007; 
Lieberman & Weiss, 2001; Nakama et al., 1999; Park et al., 2010; Rozen et al., 2010; 
van Roon et al., 2011)  This might have gone some way to eliminate the effect of 
intermittent bleeding, or bleeding at different rates on different days, causing some 
lesions to associate with lower than expected faecal Hb concentration.  This is possibly 
demonstrated here by the late stage rectal cancer that gave rise to the relatively low 
faecal Hb concentration of 88.4 µg Hb/g faeces although, as described earlier, other 
possibilities are plausible.  However, a more recent study by Oort et al. (2011) found 
two-test strategies not to be superior to a single test for the detection of colorectal 
neoplasia.  
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These findings from ostensibly healthy, asymptomatic individuals have potential 
ramifications for future selection of optimum cut-off faecal Hb concentration for test 
positivity in colorectal cancer screening using FIT, particularly when colonoscopy 
capacity is limited. 
 
It has been documented that positivity rates are affected by factors such as age and 
gender, (Moss et al., 2012; Steele et al., 2009; Steele et al., 2010) with both having 
been shown to have an effect on faecal Hb concentration, (Khalid-de Bakker et al., 
2011; McDonald et al., 2012) and studies are emerging with focus on potential use of 
risk scoring models in colorectal cancer screening programmes. (Aniwan et al., 2015; 
Auge et al., 2014; Chen et al., 2014; Driver et al., 2007; Kaminski et al., 2014; Omata 
et al., 2011; Stegeman et al., 2014; Wang et al., 2014; Wong et al., 2014; Yeoh et al., 
2011)  The findings here could be used to further support the inclusion of faecal Hb 
concentration in risk scoring systems.  With the aim of colorectal cancer screening 
being to detect colorectal cancer and its precursors, these results reinforce the 
argument for the use of quantitative FIT with an adjustable cut-off in screening 
programmes by showing that dysplastic change is more likely to arise in lesions that 
are larger, and more prone to bleed.
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4. The relationship between faecal haemoglobin 
concentration and interval cancers 
 
 
 
 
4.1 Introduction 
 
Interval cancers are a significant issue in colorectal cancer screening programmes.  
The Expert Working Group for Right-Sided Lesions and Interval Cancers, World 
Endoscopy Organization, recently recommended a standardised nomenclature for 
interval cancer across all colorectal cancer screening modalities and colonoscopy 
surveillance, providing a definition of interval cancer as: colorectal cancer diagnosed 
after a screening test or examination in which no cancer is detected and before the 
date of the next recommended examination. (Sanduleanu et al., 2015)   
 
Minimising the proportion of missed colorectal cancer is crucial to the success of 
colorectal cancer screening programmes in meeting their primary goal of reducing 
colorectal cancer mortality.  Screening programmes, by nature, only allow 
measurement of clinical outcomes for those undergoing colonoscopy following a 
positive screening test result.  As a result, it is not possible to directly assess test 
sensitivity within the screening setting since the prevalence of disease in participants 
below the cut-off concentration is not known.  However, identification of colorectal 
cancer detected in the interval following a negative test result can allow for calculation 
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of the proportion of interval cancer; this can act as surrogate measure for test 
sensitivity and therefore, the effectiveness of the screening programme. 
 
Evidence exists that interval cancers are diagnosed at a later stage and therefore have 
a worse prognosis than screen-detected colorectal cancer (Tazi et al., 1999, Jensen et 
al., 1992).  Additionally, Steele et al., (2012) found that although interval cancer had a 
less favourable stage distribution than screen-detected colorectal cancer, interval 
cancer had a relatively good prognosis compared to those colorectal cancer cases 
arising in the group not offered screening over the time period of the three pilot rounds 
of the Scottish Bowel Screening Programme.  This would suggest that despite poor test 
sensitivity, screening with gFOBT still offers a protective effect even in those with 
missed colorectal cancer in comparison to no screening. 
 
Although randomised controlled trials (RCT) have shown that guaiac faecal occult 
blood test (gFOBT) utility in colorectal cancer screening is proven to reduce mortality, 
(Towler et al., 1998) high proportions of all colorectal cancer diagnosed in the screened 
population that were interval cancers, here referred to as the interval cancer proportion, 
are commonly reported.  Results from large scale RCT of gFOBT screening in England 
(Hardcastle et al., 1996) and Denmark (Kronborg et al., 1996) reveal interval cancer 
proportions of 51.3% and 55.2% respectively.  A large non-randomised trial of gFOBT 
effectiveness conducted in Burgundy calculated the interval cancer proportion higher 
still at 59.3% (Faivre et al., 1991).  Further studies from Denmark (Jensen et al., 1992), 
Scotland (Steele et al., 2012) and France (Tazi et al., 1999) have also provided 
evidence that interval cancers consistently account for more than half of colorectal 
cancer detected in populations screened biennially with gFOBT, indicating poor test 
sensitivity. 
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Previously published work has also identified some characteristics more associated 
with interval cancers than gFOBT screen-detected colorectal cancer.  Higher 
proportions of interval cancer are found in women compared with screen-detected 
colorectal cancer (Gill et al., 2012; Steele et al., 2012) and significantly more interval 
cancers have been demonstrated to arise in the right colon than do screen-detected 
colorectal cancer (Brenner et al., 2012; Cooper et al., 2012; Farrar et al., 2006; Gill et 
al., 2014; Gill et al., 2012; Hosokawa et al., 2003; Singh et al., 2010; Singh et al., 2006; 
Steele et al., 2012).  Assuming advanced neoplasia was present at the time of the 
negative gFOBT, these findings suggest that gFOBT may tend to be more likely to 
detect pathology in men and in the left side of the colon.  Furthermore, rectal cancers 
have been found to be more common amongst interval cancer cases than screen-
detected colorectal cancer  (Garcia et al., 2015a; Jensen et al., 1992; Steele et al., 
2012; Tazi et al., 1999)  This may tie in with findings that tumour growth rates vary 
according to subsite, with Launoy et al. (1997) reporting growth to be fastest for rectal 
cancer .  It may be that some interval cancer cases arising in the rectum are more likely 
to be the result of significant progression towards malignancy of what was perhaps a 
relatively small precursor lesion at the time of the negative screening test.  Another 
plausible explanation is that the erythrocytes in any blood originating in the rectum 
have not been haemolysed and the still intact erythrocytes do not yield positive results 
with either gFOBT or Faecal Immunochemical Tests for haemoglobin (FIT).  Interval 
cancers have also been associated with a worse prognosis, with larger, later stage 
tumours more frequently reported for interval cancer compared with screen-detected 
colorectal cancer. (Steele et al., 2012) 
 
With countries worldwide now introducing FIT to replace gFOBT in colorectal cancer 
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screening programmes due to their various advantages (Fraser, 2011a) and numerous 
studies demonstrating FIT to be a more sensitive test, particularly for advanced 
adenoma detection than gFOBT (Rabeneck et al., 2012), it is likely that FIT have the 
potential, at least over time, to reduce interval cancer proportions.  Moreover, 
quantitative FIT allows programme organisers to select a cut-off faecal haemoglobin 
(Hb) concentration most appropriate for their programme.  However, this poses 
considerable challenges for countries with limited colonoscopy capacity.  To secure a 
low test positivity rate that matches colonoscopy capacity, high cut-off faecal Hb 
concentration must be used.  This may negate the improved sensitivity offered by FIT 
over gFOBT; this has been demonstrated by the results of an evaluation of quantitative 
FIT in Scotland at a cut-off faecal Hb concentration of 80 µg Hb/g faeces in which the 
Positive Predictive Values (PPV) for advanced neoplasia were no better than with 
gFOBT. (Steele et al., 2013) 
 
Thus, it is important to establish the interval cancer proportions associated with the use 
of FIT at a cut-off giving a test positivity rate equivalent to gFOBT and to find out if 
characteristics such as female gender and location in the proximal colon continue to 
show positive associations with interval cancer.  However, data on interval cancer 
proportions with population screening with FIT are lacking; these would provide 
essential insights into how quantitative FIT can be utilised in countries with limited 
colonoscopy capacity to minimise interval cancer proportions and address the gender 
inequalities that exist with gFOBT screening.  Furthermore, the quantitative nature of 
modern FIT means that, for the first time, analysis can be performed on faecal Hb 
concentration of participants at the time of the negative test before diagnosis of interval 
cancer to assess the value of faecal Hb concentration as a predictor of risk.  It would 
be hoped that this can provide a greater insight into how quantitative FIT can be 
utilised in countries with limited colonoscopy capacity to minimise interval cancer 
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proportions and address the gender inequalities that appear to exist with gFOBT 
screening.  For these reasons, the consequences of FIT using a faecal Hb 
concentration cut-off of 80 µg Hb/g faeces (set to give ca. 2% test positivity rate) were 
assessed in terms of interval cancer within an established colorectal cancer screening 
programme.  The aims of this analysis were to determine the interval cancer proportion 
in the group participating in the ‘FIT as a First Line Test’ evaluation in Scotland to allow 
comparison with the ca. 50% commonly seen in colorectal cancer screening 
programmes using gFOBT.  Furthermore, it was hoped that the cut-off faecal Hb 
concentration at which all interval cancers would have been detected could be 
identified along with the positivity rate that this threshold would have generated. 
 
 
4.2 Materials and methods 
 
 
The study cohort was derived from the participants of the ‘FIT as a First-Line Test’ 
evaluation, the full process of which was described in the previous Chapter (Chapter 3: 
The relationship between faecal haemoglobin concentration and severity of colorectal 
neoplasia). 
 
Linkage with the Scottish Cancer Registry was performed  by Information Services 
Division (ISD) Scotland to identify interval cancer cases (defined as colorectal cancer 
diagnosed after a negative screening test result with FIT and before the invite to the 
subsequent screening round after the two year interval used in the Scottish Bowel 
Screening Programme). Comparison of factors including faecal Hb concentration and 
gender distribution of colorectal cancer between the group with interval cancer and 
those with screen-detected colorectal cancer was performed.  Interval cancer data 
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were available for interval cancers diagnosed up to 31 December 2012, meaning that 
the analysis included only participants with a negative screening result date up to 31 
December 2010 and participants with a later result date were excluded from the 
analysis.  The linkage was completed using IBM SPSS statistical software version 21.0 
(SPSS Inc., Chicago, IL, USA).  Colorectal cancer arising within two years of a 
negative colonoscopy were referred to as “missed” cancers and not interval cancers. 
 
Deprivation was categorized from individual postcodes using population weighted 
Scottish Index of Multiple Deprivation (SIMD) 2012 quintiles for analysis of screening 
outcomes by deprivation. (Information Services Division (ISD) Scotland, 2015b)  SIMD 
identifies small area concentrations of multiple deprivation based on income level, 
employment, health, education, skills and training, housing, geographical access and 
crime.  The most recent 2012 update has improvements to indicators and methodology 
from SIMD 2009. 
 
MedCalc (MedCalc Software, Mariakerke, Belgium) statistical software was used for all 
calculations.  The Mann-Whitney U test was used for comparison of median faecal Hb 
concentration between different groups.  Probability of p < 0.05 was considered 
significant.  Logistic regression analysis was performed to calculate odds ratio for 
interval cancer amongst different demographic groups, both unadjusted and adjusted 
for confounding variables. 
 
4.3 Results 
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Over the six month screening period for which interval cancer data were available, a 
total of 30,893 participants in the two NHS Boards responded to screening, with 30,140 
participants having a negative test result and 753 having a faecal Hb concentration 
above the 80 µg Hb/g cut-off faecal Hb concentration for a positive test result. Table 
4.1 shows the demographic details of those invited and responding to screening. 
 
104 participants with a positive FIT result did not complete follow-up investigations due 
to either non-attendance, recently performed colonoscopy, or being deemed unfit for 
invasive procedures, and were excluded from further analysis.  Of 649 participants 
completing investigations as a result of their positive FIT result, 30 had screen-detected 
colorectal cancer. 31 cases of interval cancer were identified from follow-up of 
participants with a negative screening test result to give an interval cancer proportion of 
50.8%.  Table 4.2 displays characteristics associated with interval cancer and screen-
detected colorectal cancer.  The numbers of cases of screen-detected colorectal 
cancer and interval cancer were insufficient to allow for further subgroup analysis by 
gender. 
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Table 4.1. Screening outcome of invitees, according to gender, age quintile and Scottish 
Index of Multiple Deprivation (SIMD) quintile. 
  
Invited Responded 
Positive  
test result 
Negative  
test result 
  n % n % n % n % 
Gender         
 Men 21,213 48.2 14,459 46.8 432 57.4 14,027 46.5 
 Women 22,825 51.8 16,434 53.2 321 42.6 16,113 53.5 
Age (years)         
 50-54 11,491 26.1 7,321 23.7 111 14.7 7,210 23.9 
 55-59 9,943 22.6 6,820 22.1 158 21.0 6,662 22.1 
 60-64 9,429 21.4 7,027 22.7 133 17.7 6,894 22.9 
 65-69 6,389 14.5 4,871 15.8 161 21.4 4,710 15.6 
 70-74 6,786 15.4 4,854 15.7 190 25.2 4,664 15.5 
SIMD quintile         
 
1 (most 
deprived) 7,327 16.6 4,386 14.2 146 19.4 4,240 14.1 
 2 9,428 21.4 6,094 19.7 166 22.0 5,928 19.7 
 3 7,699 17.5 5,443 17.6 128 17.0 5,315 17.6 
 4 10,956 24.9 8,127 26.3 186 24.7 7,941 26.3 
 
5 (least 
deprived) 8,572 19.5 6,809 22.0 127 16.9 6,682 22.2 
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Table 4.2. Characteristics of interval colorectal cancers and screen-detected colorectal 
cancer. 
    Interval cancers Screen-detected cancers 
p-value 
    n % n % 
Total cases 31 50.8 30 49.2  
Gender:       
 Men 15 48.4 16 51.6 
0.90 
 Women 16 53.3 14 46.7 
Age quintile (years)*:       
 50-54 0 0.0 4 100 
0.22 
 55-59 3 50.0 3 50.0 
 60-64 8 66.7 4 33.3 
 65-69 5 38.5 8 61.5 
 70-74 15 57.7 11 42.3 
Cancer site**:       
 Right-sided 13 50.0 13 50.0 
0.99  Left-sided 5 50.0 5 50.0 
 Rectum 13 52.0 12 48.0 
Dukes' stage:       
 A 6 42.9 8 57.1 
0.07 
 B 10 50.0 10 50.0 
 C 7 43.8 9 56.3 
 D 7 100 0 0.0 
  Not known 1 25.0 3 75.0   
* Age at time of invite. 
** Right-sided CRC includes region up to and including the splenic flexure; left-sided includes descending 
and sigmoid colon; rectum includes recto-sigmoid junction and rectum. 
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Table 4.3 shows median faecal Hb concentration and corresponding interquartile range 
(IQR) at the time of screening in those who were subsequently found to have an 
interval cancer, allowing comparison of faecal Hb concentration according to gender, 
colorectal cancer stage, site and time to diagnosis following screening.  No statistically 
significant differences were detected within these categories. 
 
Table 4.3. Median faecal haemoglobin concentration (f-Hb) and interquartile range (IQR) at 
time of negative screening test in those who had interval cancer. 
  n Median f-Hb 
(µg Hb/g faeces) 
IQR p-value 
All  31 2.8 0.4 - 13.5  
Gender:      
   Men  15 12.6 0.1 - 12.9 
0.440 
   Women  16 0.5 0.4 - 11.7 
Stage:      
   Total early  16 3.1 0.4 - 12.1 
0.466 
   Total late  14 2.5 0.4 – 6.8 
Site*:      
   Right-sided  13 1.4 0.0 – 11.8 
0.298 
   Left-sided  5 15.2 2.3 – 31.1 
   Rectum 13 2.8 0.4 – 6.1  
Time to diagnosis:     
   within 1 year 8 4.1 0.2 – 7.5 
0.786 
   1-2 years  23 2.8 0.4 – 15.9 
* Right-sided CRC includes region up to and including the splenic flexure; left-sided includes descending 
and sigmoid colon; rectum includes recto-sigmoid junction and rectum. 
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46.9% of colorectal cancer cases in men were interval cancers compared with 55.2% in 
women.  Median age in those with an interval cancer was 68 years (95% CI: 64 - 72) 
compared with 67 years (95% CI: 61 - 71) for screen-detected colorectal cancer cases. 
 
Table 4.4 shows the effect on test positivity rate and interval cancer proportion of 
lowering the faecal Hb concentration cut-off to various concentrations and Figure 4.1 
displays the same data in graphical form.  Figure 4.2 shows the number of 
colonoscopies that would have been required at different faecal Hb concentration cut-
offs alongside the associated proportions of interval cancer and screen-detected 
colorectal cancer.  Halving the cut-off faecal Hb concentration to 40 µg Hb/g faeces 
would have detected 10% more colorectal cancer (assuming lesions would be detected 
at colonoscopy), reduced the interval cancer proportion from 50.8% to 45.9% but with a 
significant 58.6% increase in the number of colonoscopies required.   
 
Table 4.4. Effect of lowering the cut-off faecal haemoglobin concentration (f-Hb) on test 
positivity rate and interval cancer proportion. 
Cut-off f-Hb 
(µg Hb/g faeces) 
 
Positivity rate 
Interval cancers Screen-detected cancers 
n % n % 
80 2.5% 31 50.8 30 49.2 
60 3.0% 29 47.5 32 52.5 
40 3.9% 28 45.9 33 54.1 
20 6.3% 26 42.6 35 57.4 
15 7.6% 23 37.7 38 62.3 
10 9.5% 23 37.7 38 62.3 
2 24.7% 12 19.3 49 80.3 
> 0 48.3% 6 9.8 55 90.2 
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Figure 4.1. Effect of lowering the cut-off faecal haemoglobin concentration (f-Hb) on test 
positivity rate and interval cancer proportion.  
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Figure 4.2. Effect of lowering the cut-off faecal haemoglobin (f-Hb) on proportions of interval 
cancer and screen-detected colorectal cancers (CRC) and number of colonoscopies required. 
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Figure 4.3 shows the faecal Hb concentration distribution of all colorectal cancer cases.  
Of the 31 interval cancer cases, 23 had faecal Hb concentration less than 10 µg Hb/g 
faeces at the time of their negative screening test, meaning that over a third of 
colorectal cancer cases would still have been missed if this cut-off faecal Hb 
concentration had been adopted.  Furthermore, six of these 23 cases had completely 
undetectable faecal Hb concentration.  With 53.0% of all participants having 
undetectable faecal Hb concentration, the proportion of interval cancers arising in this 
group was calculated.  This group was used as a reference category when producing 
odds ratios for IC compared with those with higher faecal Hb concentration.  Odds 
ratios were also calculated for men compared with women, and for 60-69 year olds and 
those over 70 years old compared with those aged 50-59 years.  These results along 
with odds ratio also adjusted for age and gender are displayed in Table 4.5.  Figure 4.4 
demonstrates the increasing proportion of interval cancers diagnosed at increasing 
ranges of faecal Hb concentration. 
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Figure 4.3. Faecal haemoglobin concentration (f-Hb) distribution of all cancers in the 
screened population. 
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Dashed line represents cut-off of 80 µg Hb/g faeces 
 
Figure 4.4. Proportion of interval cancers (IC) diagnosed in participants with different ranges 
of faecal haemoglobin concentration (f-Hb). 
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Table 4.5. Proportion of interval cancers by faecal haemoglobin concentration (f-Hb), gender 
and age with adjusted odds ratios with 95% confidence intervals (CI). 
   Odds ratio 
  
% with interval 
cancer Non-adjusted (95% CI) Adjusted (95% CI)* 
f-Hb (µg Hb/g faeces):    
 0.0 0.04 1.00 1.00 
 1.0 - 9.9 0.17 3.57 (1.41 - 9.06) 3.17 (1.25 - 8.05) 
 10.0 - 19.9 0.38 8.11 (2.02 - 32.46) 5.95 (1.48 - 24.00) 
 20.0 - 39.9 0.44 7.03 (1.42 - 34.91) 5.29 (1.06 - 26.40) 
 40.0 - 59.9 0.75 10.52 (1.26 - 87.73) 8.20 (0.98 - 68.91) 
 60.0 - 79.9 1.31 34.42 (6.89 - 171.93) 23.91 (4.73 - 120.81) 
Gender:    
 Women 0.10 1.00 1.00 
 Men 0.11 1.07 (0.53 - 2.16) 1.01 (0.50 - 2.04) 
Age (years):    
 50 – 59 0.02 1.00 1.00 
 60 – 69 0.11 5.15 (1.47 - 18.09) 4.69 (1.33 - 16.47) 
 ≥ 70 0.32 14.61 (4.23 - 50.48) 12.16 (3.50 - 42.26) 
*Adjusted for age and gender as applicable. 
 
 
 
4.4 Discussion 
 
These results provide unique insights into interval cancer proportions using FIT with a 
high cut-off faecal Hb concentration in an established screening programme with 
limited colonoscopy capacity (80 µg Hb/g faeces) and how these rates could be 
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influenced by varying the cut-off faecal Hb concentration.  The interval cancer 
proportion found was no different to the rates of around 50% commonly reported in 
literature from screening programmes using traditional gFOBT.  It was, however, much 
higher than the 14.4% interval cancer proportion found in Italy with a cut-off faecal Hb 
concentration of 20 µg Hb/g faeces. (Zorzi et al., 2011)  This indicates that the use of a 
high cut-off faecal Hb concentration not only limits the improved sensitivity for 
significant neoplasia offered by FIT but increases the interval cancer proportion.  
However, assuming these cancers were present and would have been detected at 
colonoscopy at least in the form of significant precursor lesions at the time of the 
negative screening test, an interval cancer proportion at a cut-off faecal Hb 
concentration of 20 µg Hb/g faeces of 42.6% was calculated.  Even at this markedly 
lower cut-off faecal Hb concentration than that used in this evaluation, the interval 
cancer proportion would still be almost three-times higher than that identified with FIT 
in Italy.  A potential reason for this may be that the region of Italy studied has been 
offering FIT screening since 2002.  With the improved sensitivity for advanced 
neoplasia demonstrated by FIT compared with gFOBT appearing to be particularly 
attributable to detection of pre-malignant polyps, (Rabeneck et al., 2012) it may be that 
removal of such precursor lesions over multiple screening rounds has limited the 
number of interval cancers in Italy. 
 
It should be mentioned that the calculation of yield of screen-detected colorectal cancer 
at different cut-off faecal Hb concentration is likely to be a slight underestimation.  In 
addition to avoided interval cancer, a lower cut-off faecal Hb concentration may also 
have led to detection of colorectal cancer that would arise as screen-detected 
colorectal cancer at the subsequent screening round as well as a small proportion of 
over-diagnosed cancers.  Therefore, in reality the interval cancer proportion may be 
lower than reported here, although this is difficult to quantify. 
 
118 
 
 
Our results back up previous findings that women have a higher interval cancer 
proportion than men.  In attempting to explain this, characteristics associated with 
colorectal cancer between the genders were analysed.  In contrast to results of 
previous studies investigating interval cancer in gFOBT screening programmes, this did 
not reveal an association with location in the proximal colon for interval cancer in 
women, with just a quarter of cases in women located from the caecum up to and 
including the splenic flexure.  This compared with 38.5% of screen-detected colorectal 
cancer in women being right-sided.  Furthermore, it was in fact the case that most 
interval cancers in men were right-sided.  What was revealed was that over half of 
cancers (53.3%) diagnosed in women, both interval cancers and screen-detected, were 
located in the rectum, whereas rectal cancers accounted for a much lower proportion of 
all colorectal cancer cases in men (29.0%).  It can be speculated that this discrepancy 
in colorectal cancer site distribution between men and women may be contributing 
towards the inequality in sensitivity of FIT between the sexes.  Overall colorectal 
cancer statistics for Scotland do not echo this pattern of site distribution, with 
proportions of colorectal cancer located in the rectum or at the recto-sigmoid junction 
diagnosed in 50-74 year olds in 2011 being 36.8% and 31.2% for men and women, 
respectively. (Information Services Division (ISD) Scotland, 2015a)  Nonetheless, using 
this cohort, it can be proposed that interval cancer cases in men were mostly 
attributable to lesions located in the proximal colon that were not bleeding enough to 
produce a positive FIT result.  With rectal colorectal cancer however, the cause for 
missed lesions may tie in with previously findings of Launoy et al. (1997) that 
progression to malignancy is faster in the rectum than in precursor lesions arising 
elsewhere in the colon.   Smaller precursor lesions that are not bleeding enough at the 
time of FIT screening to trigger a positive test result may be rapidly becoming 
malignant before the next screening round.  With rectal colorectal cancer much more 
prevalent in women than men in this cohort, a greater proportion of aggressive rectal 
neoplasia may offer some explanation for the inequalities seen in the interval cancer 
119 
 
 
proportion.  Incidentally, analysis of adenoma site distribution amongst participants with 
a positive FIT result attending for colonoscopy shows rectal adenomas to only account 
for a small proportion of the total adenomas detected in both men and women.  
However, rectal adenomas were most likely to display villous features and show high-
grade dysplasia than adenomas located elsewhere.  This is an area requiring further 
study. 
 
The more advanced stage distribution of interval cancer highlights the need for 
measures to be taken to improve colorectal cancer detection with screening.  Lowering 
the cut-off faecal Hb concentration would be an obvious solution, but the resultant 
increase in demand for colonoscopy may not be supported by the available resources.  
This problem could be counteracted by screening at a low cut-off faecal Hb 
concentration, but alongside a longer interval between screening rounds than the two 
years currently implemented.  This is an interesting area for future research to 
investigate the impact of such a strategy on interval cancer proportions. 
 
A concern is that almost 20% of interval cancer cases in this cohort had undetectable 
faecal Hb concentration meaning that a significant proportion of colorectal cancer 
would always be missed, even with drastic lowering of the cut-off faecal Hb 
concentration.  Although participants who had undetectable Hb in their sample 
accounted for over half of the screened population, the proportion of interval cancer in 
this group was relatively small – over 35 times lower than the proportion of interval 
cancer identified in those with faecal Hb concentration in the range 60.0 - 79.9 µg Hb/g 
faeces, who constituted just 0.5% of the cohort.  Adjusted odds ratios demonstrate an 
increasing risk of interval cancer with increasing faecal Hb concentration and perhaps 
indicate a need for participants with elevated faecal Hb concentration to be offered 
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more regular screening.  This ties in with the work by Chen et al. (2011) showing that 
the higher the initial faecal Hb concentration, the sooner the interval cancer would be 
found.   These results also support the inclusion of faecal Hb concentration in risk 
scoring models increasingly being documented within colorectal cancer screening 
populations worldwide. 
 
Another area for future research is better understanding of the potential biological 
differences between interval cancer and screen-detected colorectal cancer.  Recent 
data from the NHS Bowel Cancer Screening Programme revealed that those with 
Dukes’ stage C and D screen-detected colorectal cancer had superior survival rates in 
comparison to stage-matched interval cancer (p < 0.05). (Gill et al., 2014)  The authors 
stated that the worse prognosis observed for those with an interval cancer, despite an 
apparently similar degree of disease severity, suggests that some biological difference 
may exist between interval cancers and screen-detected colorectal cancer.  Existing 
literature has explored association of interval cancer following negative colonoscopy 
with molecular features such as BRAF and KRAS mutations, chromosomal instability 
and microsatellite instability, as documented in the 2014 review by Cisyk et al.(2014)  
However, there is a lack of research into the biological features of interval cancers in 
populations screened with tests for the presence of Hb in faeces that relate to a 
lesion’s propensity to bleed if a false negative, or to undergo rapid growth if a de novo 
colorectal cancer which at the time of screening was a true negative case. 
 
Many other laboratory tests utilise varying reference values partitioned according to 
factors such as age and gender to reflect the differences in values seen in these 
demographic groups.  Evidence of inequalities in faecal Hb concentration distribution 
between the genders and with age (Fraser & Auge, 2014; Fraser et al., 2014; 
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McDonald et al., 2012; Symonds et al., 2015b) raises the question of whether it may be 
advantageous to adopt a similar strategy in colorectal cancer screening with 
quantitative FIT.  However, men having higher median faecal Hb concentration than 
women and faecal Hb concentration increasing with age may simply reflect the fact that 
disease is more prevalent in these groups.  Some may be of the opinion that owing to 
the fact that men have more colorectal neoplasia, a lower cut-off faecal Hb 
concentration should be used in men than women.  Our results would suggest that this 
approach would widen the inequality seen in interval cancer proportions between men 
and women.  Although it was shown using adjusted odds ratios that overall, women are 
no more likely than men to have an interval cancer (due to a lower overall percentage 
of colorectal cancer than in men), women who do have colorectal cancer or advanced 
precursor lesions are more likely to have faecal Hb concentration below the cut-off and 
therefore not be referred for colonoscopy to detect and remove the lesion.  With 
interval cancer being associated with worse prognosis, it appears that women may be 
disadvantaged by the use of one cut-off faecal Hb concentration for all and therefore 
better individualised use of FIT in colorectal cancer screening should be considered.
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5. The relationship between faecal haemoglobin 
concentration and detection of advanced colorectal 
neoplasia in the subsequent screening round 
 
 
 
 
5.1 Introduction 
 
 
It has been established in the previous Chapter that colorectal cancer screening 
programme participants with elevated faecal haemoglobin (Hb) concentration, although 
still below the selected cut-off concentration for a positive test result, are more likely to 
be diagnosed with an interval cancer than those with undetectable haemoglobin (Hb) in 
their screening sample.  Further knowledge of the predictive power of faecal Hb 
concentration in colorectal cancer screening may be obtained from retrospective 
analysis of faecal Hb concentration in participants who have had neoplasia detected 
following a positive screening test result in the round subsequent to a negative test 
result.  Such analysis could provide evidence to support future modification of protocol 
to improve the effectiveness of the screening programme. For example, those at 
elevated risk of having advanced neoplasia, despite their negative screening test 
result, could be prioritised for future repeat screening at a shorter interval than the 
current biennial invitation.  Conversely, those deemed very unlikely to have a later 
diagnosis of advanced neoplasia might not require such frequent invitation to 
screening.  Since it has already been established that those with undetectable faecal 
Hb concentration account for around half of all participants in this large cohort 
completing a single Faecal Immunochemical Test for Hb (FIT) as a first-line test, this 
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strategy could potentially significantly reduce the number of overall referrals to 
colonoscopy.  This, in turn, could pave the way for lowering of the cut-off faecal Hb 
concentration to improve test sensitivity and therefore reduce the interval cancer 
proportion.  This is a particularly important consideration in a country such as Scotland 
where it has been necessary to adopt a cut-off faecal Hb concentration that is 
significantly higher than that used elsewhere, due to the limited capacity of the 
colonoscopy resource.  
 
The existing literature provides evidence that a trend exists between increasing faecal 
Hb concentration and more severe colorectal findings being detected at follow-up to a 
positive screening test result, as reviewed in Chapter 3 (Faecal haemoglobin 
concentration is related to severity of colorectal neoplasia), and further supported by 
the new findings reported in the results that followed.  What has been more rarely 
documented, however, is the relationship between faecal Hb concentration that is 
below the cut-off and treated as a baseline measurement, and clinical outcomes in the 
longer term to determine the role of faecal Hb concentration as a predictor of future risk 
of advanced neoplasia.  One important study that does investigate this is the 
longitudinal follow-up of colorectal cancer screening participants in Taiwan by Chen et 
al. (2011)  The authors followed-up a cohort of 44,324 participants aged 40 - 69 years 
with faecal Hb concentration below the cut-off concentration of 20 µg Hb/g faeces) for a 
median of 4.39 years (interquartile range 2.53 - 6.12).  Incidence rates and hazard 
ratios for advanced neoplasia in those with baseline faecal Hb concentration within 
incremental ranges up to the cut-off faecal Hb concentration were calculated.  The 
incidence of advanced neoplasia rose from 1.75/1000 person-years for those with 
faecal Hb concentration 0.2 – 3.9 µg Hb/g faeces to 7.08/1000 person-years in those 
closest to the cut-off concentration with faecal Hb concentration between 16.0 and 19.9 
µg Hb/g faeces.  Moreover, relative to those with faecal Hb concentration 0.2 – 3.9 µg 
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Hb/g faeces, adjusted hazard ratios for advanced neoplasia were calculated as 3.41 
(95% confidence interval [CI] 2.02 - 5.75) for those with faecal Hb concentration in the 
category closest to the cut-off faecal Hb concentration used.  This trend indicates that 
the higher the baseline faecal Hb concentration, the greater the likelihood of a future 
diagnosis of advanced neoplasia.  Another interesting finding was that analysis of 
participants for whom faecal Hb concentration was measured in subsequent screening 
rounds following the baseline faecal Hb concentration showed that the group who were 
eventually diagnosed with colorectal neoplasia displayed a trend of rising median 
faecal Hb concentration across three screening rounds.  This was in contrast to a less 
pronounced general trend of decreasing faecal Hb concentration in the second and 
third rounds in those with no diagnosis of colorectal neoplasia.  From these data arises 
the interesting concept of monitoring change in participant’s found faecal Hb 
concentration across screening rounds to identify those at greater risk.  Implementation 
of such a strategy in practice may be complicated, but the evidence from this novel 
study yet again highlights the numerous opportunities for more efficient and effective 
screening facilitated by the replacement of guaiac faecal occult blood tests (gFOBT) 
with FIT. 
 
A recent update of this group’s work is given by the paper published by Yen et al., 
(2014) where results of their regression modelling work are presented to further 
establish the value of faecal Hb concentration as a predictor for colorectal neoplasia.  
54,921 participants invited between 2001 and 2007 were followed up in the annual FIT 
screening programme to identify those diagnosed with interval cancer, screen-detected 
colorectal cancer and adenoma.  In addition to follow-up of participants with a negative 
FIT result at baseline, participants with an initial faecal Hb concentration above the cut-
off concentration of 20 µg Hb/g faeces were also included in the model.  As with the 
study by Chen et al., (2011) a trend of increasing hazard ratios for colorectal neoplasia 
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with increasing baseline faecal Hb concentration was demonstrated, but this time 
extended well above the selected cut-off faecal Hb concentration with the inclusion of 
these extra data.  The area under the curve for the model to assess the risk of 
colorectal cancer rose from 0.67 (95% CI: 0.64 - 0.70) when only including 
conventional risk factors such as gender, family history, smoking and Body Mass 
Index, to 0.84 (95% CI: 0.82 - 0.87) when faecal Hb concentration was incorporated 
into the model, with the relationship stronger in men than women. 
 
Literature around the topic of the value of faecal Hb concentration as a predictor of 
future risk is scarce, with only two studies identified, both concerning the same 
Taiwanese population.  It is accepted that due to variation in available resources and in 
the distribution of faecal Hb concentration across geography, countries using FIT as 
the initial screening investigation must conduct their own evaluation into the predictive 
value of faecal Hb concentration for future diagnosis of advanced neoplasia, if seeking 
to incorporate into their screening programmes more creative strategies to improve 
detection rates and programme efficiency.  With the aim of not exceeding the capacity 
of the available colonoscopy resource, organisers of the Scottish Bowel Screening 
Programme selected a cut-off faecal Hb concentration for the evaluation of using FIT 
as a first-line test that was far higher than that used elsewhere, meaning that many 
participants with a test result below the cut-off faecal Hb concentration would have 
been deemed to have a positive test result and followed up with colonoscopy if 
screened in these other countries.  As a result, it can be expected that a reasonable 
proportion of participants with faecal Hb concentration below the cut-off concentration 
in the Scottish FIT evaluation cohort would have advanced neoplasia diagnosed at the 
subsequent screening round. 
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The aim of this section was to investigate the relationship between faecal Hb 
concentration at the time of the negative screening test result during the FIT evaluation 
and the screening test result at the subsequent screening round.  It was also hoped to 
determine ifthose with faecal Hb concentration closest to the cut-off were more likely to 
be subsequently diagnosed with advanced neoplasia.  If this is the case, further 
evidence of the predictive power of faecal Hb concentration in colorectal cancer 
screening will be provided and consideration of closer surveillance of participants with 
elevated faecal Hb concentration, although below the cut-off concentration, may be 
warranted. 
 
 
5.2 Materials and methods 
 
 
The study cohort was again derived from the participants of the ‘FIT as a First-Line 
Test’ evaluation, the full process of which was previously described in the previous 
Chapter (Chapter 3: The relationship between faecal haemoglobin concentration and 
severity of colorectal neoplasia). 
 
Following completion of the ‘FIT as a First-Line Test’ evaluation, the Scottish Bowel 
Screening Programme returned to the two-tier reflex gFOBT/FIT screening algorithm, 
which has been described in Chapter 2: The relationship between results with the 
gFOBT/FIT two-tier reflex screening algorithm and severity of colorectal neoplasia. 
 
The screening test results for all of those eligible to take part in the subsequent 
screening round after the FIT evaluation and resident in either NHS Tayside or NHS 
Ayrshire & Arran were examined.  Data for colonoscopy outcomes and any subsequent 
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pathology for those with a positive gFOBT/FIT screening test result were downloaded 
and collated as described previously in this work. 
 
MedCalc (MedCalc Software, Mariakerke, Belgium) statistical software was used for all 
calculations in this analysis.  The Mann-Whitney U test was used for comparison of 
median faecal Hb concentration between groups.  Probability of p < 0.05 was 
considered significant.  Logistic regression analysis was performed to calculate odds 
ratios for diagnosis of advanced neoplasia at the next screening round amongst those 
in different faecal Hb concentration categories and different demographic groups, both 
unadjusted and adjusted for age and gender as known confounding variables. 
 
 
5.3 Results 
 
 
37,780 participants had faecal Hb concentration below the cut-off used of 80 µg Hb/g 
faeces.  92.7% were invited for screening with the gFOBT algorithm in the next round; 
the majority of those not invited were above the age range of the screening 
programme, with others having died or no longer being resident in Scotland.  30,849 
participants completed both the FIT evaluation and the subsequent screening round 
when the programme had reverted to the gFOBT/FIT two-tier reflex algorithm.  Table 
5.1 details the screening outcomes of all participants who had faecal Hb concentration 
below the 80 µg Hb/g faeces cut-off used in the FIT evaluation, by age and gender. 
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Table 5.1. Subsequent screening result of participants with negative test result. 
   Total Men Women 
   n % n % N % 
Total with faecal haemoglobin 
concentration <80 µg Hb/g faeces 37,780  17,525  20,255  
Result in subsequent round: 
      
 Positive test 556 1.5 339 1.9 217 1.1 
 Negative test 30,293 80.2 13,910 79.4 16,383 80.9 
 Non-responder 4,165 11.0 1,976 11.3 2,189 1.8 
 Excluded 2,766 7.3 1,300 7.4 1,466 7.2 
 
 
A total of 556 (1.5%) participants went on to have a positive test result in the 
subsequent screening round, and 30,293 (80.2%) were again deemed to have a 
negative screening test result.  The median faecal Hb concentration was statistically 
significantly higher in those who had a positive test result in the subsequent round than 
those who again had a negative test result (2.1 µg Hb/g faeces, IQR 0.0 - 13.2 v. 0.0 
µg Hb/g faeces, IQR 0.0 - 1.4; p < 0.0001). 
 
Table 5.2 displays the clinical outcomes with median faecal Hb concentration of 
participants who had a positive result in the subsequent screening round.   
 
The majority, 96.6%, of participants of both rounds had an initial faecal Hb 
concentration in the lowest category, that is 0.0 - 19.9 µg Hb/g faeces.  Of those 
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undergoing follow-up to a positive test result in the subsequent screening round, 87.4% 
of participants who did not have advanced neoplasia detected were in this low faecal 
Hb concentration group, compared to only 56.8% of those with advanced neoplasia 
having had their previous faecal Hb concentration in this lowest category examined.  
The proportion of participants who had faecal Hb concentration within different 
categories of faecal Hb concentration, by their final outcome at the subsequent 
screening round, are shown in Table 5.3. 
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Table 5.2. Clinical outcomes and median baseline faecal haemoglobin concentration (f-Hb) with interquartile range (IQR) in participants with a positive 
screening test result in the subsequent screening round.  
 All  Men  Women 
  n % 
median f-Hb 
(µg Hb/g 
faeces) 
IQR 
 
n % 
median f-Hb 
(µg Hb/g 
faeces) 
IQR 
 
n % 
median f-Hb 
(µg Hb/g 
faeces) 
IQR 
Total with a positive 
screening test result in 
the subsequent 
screening round 556  2.1 0.0 - 13.0 
 
339  1.6 1.2 - 3.0 
 
217  2.4 0.0 - 12.9 
Cancer (CRC) 26 4.7 16.7 1.2 - 31.6  19 5.6 21 0.5 - 36.3  7 3.2 10.2 2.5 - 24.0 
Higher-risk adenoma 
(HRA) 85 15.3 13.6 1.2 - 38.5 
 
63 18.6 9.6 0.9 - 38.8 
 
22 10.1 16.6 1.8 - 35.2 
Advanced neoplasia 
(CRC + HRA) 
111 20.0 13.6 1.2 - 37.6  82 24.2 14.7 0.8 - 38.8  29 13.4 13.6 1.8 - 35.2 
Low-risk adenoma 65 11.7 1.7 0.0 - 8.5  42 12.4 1.6 0.0 - 10.9  23 10.6 1.8 0.0 - 7.0 
Non-neoplastic 
pathology* 131 23.6 1.6 0.0 - 7.4 
 
72 21.2 0.7 0.0 - 5.8 
 
59 27.2 3.4 0.1 - 15.1 
No pathology detected 169 30.4 1.4 0.0 - 6.2  93 27.4 0.3 0.0 - 5.6  76 35.0 2.0 0.0 - 7.3 
 
* - Non-neoplastic pathology comprises of hyperplastic polyps and other conditions including diverticular disease, haemorrhoids and inflammatory bowel disease. 
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Table 5.3. Proportion of participants in each faecal haemoglobin (Hb) concentration 
category, by final outcome. 
 Faecal Hb concentration (µg Hb/g faeces) 
 0.0 - 19.9 20.0 - 39.9 40.0 - 59.9 60.0 - 79.9 
 n % n % n % n % 
Negative screening test result 29,049 96.6 661 2.2 227 0.8 125 0.4 
Positive screening test result 449 80.8 59 10.6 26 4.7 22 4.0 
Cancer (CRC) 14 53.8 7 26.9 1 3.8 4 15.4 
Higher-risk adenoma (HRA) 49 57.6 17 20.0 10 11.8 9 10.6 
Total advanced neoplasia 
(CRC + HRA) 
63 56.8 24 21.6 11 9.9 13 11.7 
Low-risk adenoma 58 85.3 8 11.8 2 2.9 0 0.0 
Non-neoplastic pathology* 115 87.8 6 4.6 7 5.3 3 2.3 
No pathology detected 147 88.0 14 8.4 2 1.2 4 2.4 
* - Non-neoplastic pathology comprises of hyperplastic polyps and other conditions including 
diverticular disease, haemorrhoids and inflammatory bowel disease. 
 
 
Table 5.4 shows the proportion of participants with different clinical outcomes 
according to which category of faecal Hb concentration they fell into at the previous 
screening round with FIT.  The majority of participants with a positive screening test 
result who had previously low concentrations of faecal Hb concentration (< 60 µg Hb/g 
faeces) did not have advanced neoplasia detected at the next round. However, the 
opposite was true with rising faecal Hb concentration.  This can be visualised in Figure 
5.1.  Figure 5.2 shows the percentage of participants in each faecal Hb concentration 
category with or without advanced neoplasia detected at the subsequent screening 
round, this time presented as a proportion of all participants of both rounds. 
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Table 5.4. Clinical outcomes expressed as the proportion of participants with follow-up 
complete after a positive screening result in the subsequent round, by faecal haemoglobin 
concentration (faecal Hb concentration) category. 
 Faecal haemoglobin concentration (µg Hb/g faeces) 
 0.0 - 19.9 20.0 - 39.9 40.0 - 59.9 60.0 - 79.9 
 n % n % n % n % 
Follow-up complete 383  52  22  20  
Cancer (CRC) 14 3.7 7 13.5 1 4.5 4 20.0 
Higher-risk adenoma (HRA) 49 12.8 17 32.7 10 45.5 9 45.0 
Advanced neoplasia (CRC + HRA) 63 16.4 24 46.2 11 50.0 13 65.0 
Low-risk adenoma 58 15.1 8 15.4 2 9.1 0 0.0 
Non-neoplastic pathology* 115 30.0 6 11.5 7 31.8 3 15.0 
No pathology detected 147 38.4 14 26.9 2 9.1 4 20.0 
 
* - Non-neoplastic pathology comprises of hyperplastic polyps and other conditions including 
diverticular disease, haemorrhoids and inflammatory bowel disease. 
 
 
Figure 5.1. Proportion of participants with a positive screening test result completing follow-
up who had advanced neoplasia or less severe outcomes, according to previous faecal 
haemoglobin concentration (f-Hb) category. 
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LRA = low-risk adenoma; Non-neoplastic pathology comprises of hyperplastic polyps and other 
conditions including diverticular disease, haemorrhoids and inflammatory bowel disease. 
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Figure 5.2. Proportion of participants of both rounds who had advanced neoplasia or less 
severe outcomes, according to previous faecal haemoglobin concentration (f-Hb) category. 
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LRA = low-risk adenoma; Non-neoplastic pathology comprises of hyperplastic polyps and other 
conditions including diverticular disease, haemorrhoids and inflammatory bowel disease. 
 
 
The proportion of all participants of both rounds who had advanced neoplasia detected 
following a positive test result rose with each increasing category of faecal Hb 
concentration at the previous round.  Logistic regression analysis, summarised in Table 
5.5, showed very high adjusted odds ratios for advanced neoplasia even in those with 
faecal Hb concentration 20.0 - 39.9 µg Hb/g faeces, using those with faecal Hb 
concentration 0.0 - 19.9 µg Hb/g faeces as the reference group (adjusted odds ratio = 
14.3, 95% CI: 8.9 - 23.1).  Almost 9% of all participants who had faecal Hb 
concentration within the highest faecal Hb concentration range examined, 60.0 - 79.9 
µg/g faeces, and participated in the subsequent round, had advanced neoplasia 
detected at the follow-up investigations of a positive test result.  Advanced neoplasia 
was over 40-times more prevalent in this group than those with faecal Hb concentration 
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previously 0.0 - 19.9 µg/g faeces, of whom 0.21% had advanced neoplasia.  The 
adjusted odds ratio for advanced neoplasia in the highest range of faecal Hb 
concentration was calculated to be 38.0 (95% CI: 20.2 - 71.2). 
 
 
Table 5.5. Odds ratios (both unadjusted and adjusted for age and gender) with 95% 
confidence interval (CI) for advanced neoplasia (AN) according to faecal haemoglobin 
concentration (f-Hb) category. 
f-Hb (µg Hb/g faeces) 
% with AN 
detected 
Odds ratio 
Non-adjusted Adjusted 
(95% CI) (95% CI) 
0.0 - 19.9 0.21 1.0 1.0 
20.0 - 39.9 3.37 16.2 (10.1 - 26.2) 14.3 (8.9 - 23.1) 
40.0 - 59.9 4.42 21.5 (11.2 - 41.4) 17.7 (9.2 - 34.2) 
60.0 - 79.9 8.97 45.9 (24.7 - 85.4) 38.0 (20.2 - 71.2) 
 
 
 
5.4 Discussion 
 
 
With studies in this area scarce, these results have important implications for future 
screening strategy.  The finding that a far higher proportion of participants with a 
previous faecal Hb concentration approaching the cut-off used had advanced neoplasia 
detected at the next round provides further evidence that faecal Hb concentration is a 
strong predictor of future risk. 
 
The test positivity rate in those participants who, in the previous round, had faecal Hb 
concentration below the cut-off faecal Hb concentration for positivity of 80 µg/g faeces 
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was 1.5%.  This was lower than the overall test positivity rate seen in the programme 
with the gFOBT/FIT two-tier reflex algorithm of around 2%. (Steele et al., 2009)  This 
suggests that even with a relatively high cut-off faecal Hb concentration, those who 
have previously had a negative screening test result are less likely to have a positive 
test result in the next screening round.  This is compared with the overall population 
invited for screening, which would include first-time participants and repeat participants 
who have previously had a positive test result.  This finding supports very recently 
published work from Spain showing that test positivity rate in the second round was 
significantly lower than in the first round, using a cut-off faecal Hb concentration of 20 
µg Hb/g faeces (4.8% v. 6.9%, respectively, p < 0.0005). (Bujanda et al., 2015) 
 
Despite a lower risk of having a positive test result than the general screening 
population, it is without doubt that a greater risk of advanced neoplasia is seen in those 
who had faecal Hb concentration approaching the cut-off used in the previous round.  
Faecal Hb concentration was significantly elevated, not only in those who would go on 
to have a positive screening test result in the next round compared to those who again 
had a negative test result, but also in those who had advanced neoplasia detected at 
follow-up investigations compared with those with no pathology (both p < 0.0001). 
These findings further enhance the status of faecal Hb concentration as a valuable 
predictor of risk of advanced neoplasia.  Furthermore, one in five participants who had 
faecal Hb concentration in the category closest to the cut-off, then had a positive test 
result in the subsequent screening round, were diagnosed with colorectal cancer.  This 
compares with one in 27 participants in the lowest faecal Hb concentration category 
examined, meaning those with an elevated faecal Hb concentration who go on to have 
a positive test screening result in the next round are over five times more likely to have 
colorectal cancer detected.  When also taking into account detection of higher-risk 
adenoma, 65% of those participants with a positive screening test result who previously 
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had faecal Hb concentration in the highest category examined had advanced neoplasia 
diagnosed, compared to just 16.4% in the lowest category.  Moreover, a trend exists of 
an increasing proportion of advanced neoplasia diagnosed in participants from each of 
the four increasing ranges of faecal Hb concentration.  From these data, the odds of 
having advanced neoplasia detected following a positive screening test result are even 
in those with previous faecal Hb concentration between 40.0 and 59.9 µg/g faeces.  
After this point, it is more likely that not that advanced neoplasia will be present at 
follow-up investigations in those with a positive screening test result in the subsequent 
round.  When taking into account not just those with a subsequent positive screening 
test result, but all participants of both screening rounds examined in this analysis, it 
was seen that almost 1 in 10 of all participants with faecal Hb concentration 
approaching the cut-off used went on to have advanced neoplasia detected, 
representing a 40-fold increase in the risk in those in the lowest faecal Hb 
concentration category.  This finding is important when considering faecal Hb 
concentration as a predictor of future risk of advanced neoplasia at the time of a 
negative screening test result.  Not only is strong evidence provided for the value of 
faecal Hb concentration as a risk factor for advanced neoplasia being detected at 
follow-up investigations of participants going on to have a positive test result, but also 
for predicting future test positivity and the subsequent detection of advanced neoplasia. 
 
There are different ways in which these results can impact on screening strategy.  Risk 
scoring models are becoming increasingly developed for use in colorectal cancer 
screening programmes, with an escalation in published studies in recent years.                                                                                               
(Aniwan et al., 2015; Auge et al., 2014; Chen et al., 2014; Stegeman et al., 2014; Wang 
et al., 2014; Wong et al., 2014; Kaminski et al., 2014; Chong et al., 2013; Omata et al., 
2011; Yeoh et al., 2011; Driver et al., 2007)  The results in this Chapter indicate that 
programmes using FIT and looking to utilise such systems should certainly incorporate 
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faecal Hb concentration into the models to improve their predictive power.  Further 
potential for application of this finding into screening lies in the idea of using faecal Hb 
concentration as a determinant of the length of time until the next screening invite.  
Participants with a negative screening test result, but with faecal Hb concentration 
close to the cut-off used, could be recalled for screening at a shorter interval than those 
with very low faecal Hb concentration, whose next invite could be delayed, backed by 
the evidence that their risk of advanced neoplasia is substantially reduced.  Such 
prioritisation of screening participants according to risk has the potential to improve the 
performance of screening programmes by targeting resources more effectively.   
 
It can be deduced from the results that more individuals with false positive test results 
occur at the subsequent screening round in those whose previous faecal Hb 
concentration was low.  This may suggest that the bleeding that producing the positive 
test result is more likely to be the result of a short term cause such as infection, or 
haemorrhoids, for example.  On the other hand, those with a positive test result, who 
have previously exhibited an elevated concentration of Hb in the faeces are more likely 
to have disease.  Consideration may be given to targeting the colonoscopy resource 
towards such participants who have exhibited high faecal Hb concentration in 
consecutive screening rounds and are, according to the findings of this study, far more 
likely to have advanced neoplasia.  However, such a strategy would come with the 
caveat that, as documented in the previous Chapter, a proportion of interval cancers 
are associated with undetectable faecal Hb concentration. 
 
An interesting observation, worthy of further discussion, is that median faecal Hb 
concentration of participants with colorectal cancer detected at the next screening 
round was higher in men than in women, but the opposite was apparent for higher-risk 
138 
 
 
adenoma.  In fact, previous median faecal Hb concentration for women with colorectal 
cancer was very similar to previous median faecal Hb concentration of men with 
higher-risk adenoma.  This may further demonstrate the variation in faecal Hb 
concentration by gender as now documented using data from various countries, 
(Fraser & Auge, 2014; Fraser et al., 2014; McDonald et al., 2012; Symonds et al., 
2015b) and also by the results discussed in previous Chapters showing that women 
with advanced neoplasia had lower median faecal Hb concentration than men.  A 
number of theories can be hypothesised here, including gender differences in site 
distribution, lesion size, colonic transit time and tumour growth rates.  Data on site 
distribution and lesion size at the time following the positive test result in the 
subsequent round are available, but with only 19 cases of colorectal cancer in men and 
seven in women, the sample size is not sufficient to draw robust conclusions.  It would 
be interesting to further study why median faecal Hb concentration at the previous 
round for women with colorectal cancer equates to that of men with the less severe 
diagnosis of higher-risk adenoma. 
 
An obvious weakness of this analysis is that different screening tests were employed in 
the two rounds examined.  As a result, the findings should be interpreted with the 
caveat that the cohort of participants with a positive test result at the subsequent 
screening round may have been different if FIT with a cut off of 80 µg Hb/g faeces was 
the initial screening test in both rounds.  It would be of interest to conduct a similar 
study where quantitative FIT was used consecutively to allow the variation in faecal Hb 
concentration over time, according to clinical outcomes to be investigated.  Chen et al. 
(2011) documented how, in their cohort, those who had an eventual diagnosis of 
colorectal neoplasia had a trend of increasing mean faecal Hb concentration over time, 
whereas the mean faecal Hb concentration of those without neoplasia showed a slight 
overall decrease across screening rounds.  It would have been interesting to test if this 
139 
 
 
result is echoed in the Scottish population; published data on intra-participant faecal Hb 
concentration variability are limited and may have implications for future individualised 
risk assessment using FIT.  In addition, the number of colorectal cancer cases is low, 
limiting detailed analysis by sub-groups such as age, gender and lesion site for 
example. 
 
Previous Chapters have discussed the relationship between faecal Hb concentration 
and severity of colorectal disease at immediate follow-up investigations, and also the 
risk of diagnosis of interval cancer.  With the addition of this work, further support has 
been provided for the case of using faecal Hb concentration as a risk factor, not only at 
the time of screening, but now also as a longer term predictor of risk.  Individuals 
identified as being at greater risk, although having a screening test result that is 
negative according to the selected cut-off faecal Hb concentration, could receive their 
repeat invite for screening at a shorter interval than those who consistently return 
samples with undetectable faecal Hb concentration, for example.  In addition, providing 
screening participants who have elevated faecal Hb concentration with the knowledge 
that they are at greater risk of future diagnosis of advanced neoplasia may be 
beneficial to adherence to subsequent screening invites and awareness of any 
symptoms arising between invites.
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6. The relationship between faecal haemoglobin 
concentration and degree of deprivation 
 
 
 
 
6.1 Introduction 
 
 
There is a well-established relationship between deprivation and cancer mortality.  
Using guaiac faecal occult blood tests (gFOBT) in screening programmes, 
considerable evidence accumulated that deprivation as well as male sex and older age 
is associated with an increased incidence of colorectal cancer. (Mansouri et al., 2013; 
Moss et al., 2012; Steele et al., 2010)  The most recent whole-population colorectal 
cancer statistics for Scotland show a slight trend of rising colorectal cancer incidence 
with increasing degree of deprivation, while colorectal cancer mortality shows a more 
marked association (Information Services Division (ISD) Scotland, 2014).  Where 
previous UK evidence had revealed affluence to show association with colorectal 
cancer incidence in both sexes in the 1980s, this trend faded into the 1990s before 
beginning to demonstrate a reversal of this relationship. (Oliphant et al., 2011)   Age-
standardised incidence rates prior to commencement of the Scottish Bowel Screening 
Programme in the West of Scotland revealed an effect of increasing colorectal cancer 
incidence with increasing degree of deprivation only in men, cited as being attributable 
to a fall in colorectal cancer incidence in men in affluent groups rather than a rise in 
incidence rates in the more deprived.  More convincing evidence of an association 
between increasing deprivation and higher rates of colorectal cancer incidence, 
independent of other risk factors, comes from the US. (Doubeni et al., 2012) 
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Interestingly, in this instance, the association was strongest for cancer arising in the 
rectum and weakest for right-sided colorectal cancer, perhaps indicating the 
involvement of a particular biological factor driving the relationship.  The exact factors 
causing the associations generally seen between deprivation and colorectal cancer 
incidence and mortality are unclear, but are commonly suggested to include varying 
exposures to modifiable lifestyle-related risk-factors, as well as inequalities in access to 
colonoscopies and screening.  Cancer preventability estimates are available for the UK 
according to various lifestyle-related factors including consumption of red meat, 
processed meat, alcohol intake, physical activity and body fatness, contributing to a 
total of 47% of colorectal cancer considered as preventable through eating healthily, 
being physically active and maintaining a healthy weight (World Cancer Research Fund 
International (WCRF), 2014).  Another study has this figure as high as 54.4%, with the 
effect greater in men, and meat consumption accounting for the largest proportion of 
preventable colorectal cancer cases overall of all lifestyle-related exposures examined, 
at 21.1% (Parkin et al., 2011).  With less desirable lifestyle choices being associated 
with those with higher degree of deprivation in Scotland (Bromley et al., 2010), it 
follows that more preventable cancers may be occurring in the most deprived.  
Moreover, Ellis et al. (2012) calculated that 11% of overall cancer-related deaths a year 
in England between 2004 and 2006 would have been avoided if three-year survival had 
been as high for all patients as in the most affluent groups .  It is also widely-known that 
screening participation is poorer in the most deprived (Steele et al., 2013) and it can be 
projected that this disparity will widen any pre-existing elevated colorectal cancer risk 
and deficits in survival rates in this group. 
 
It is important to consider in detail how the introduction of screening programmes may 
affect the observed relationship between deprivation in colorectal cancer incidence and 
mortality.  Studies have shown degree of deprivation to impact on various stages 
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throughout the colorectal cancer screening process.  In Scotland, increasing 
deprivation is associated with lower uptake, higher test positivity rates, poorer 
attendance at follow-up colonoscopy and lower Positive Predictive Values (PPV) for 
neoplasia.  Following multivariate analysis, the relationship between increasing 
deprivation and lower PPV for detection of neoplasia has been shown to remain only in 
males.  Moreover, deprivation impacted on a number of outcomes in those with 
colorectal cancer with more deprived groups demonstrating poorer cancer specific and 
overall survival (Mansouri et al., 2013). 
 
Dietary factors are often cited as contributing towards some of the individuals with false 
positive test results in colorectal cancer screening with guaiac faecal occult blood test 
(gFOBT), with detection of haem from red meat consumption, for example.  It would be 
interesting to investigate whether or not evidence of false positive test result rates 
being higher in the more deprived is still observed when screening with Faecal 
Immunochemical Test for haemoglobin (FIT) as the initial test, since these tests are not 
subject to dietary interference.  At the time of the analysis presented in this Chapter, of 
the various studies investigating the impact of deprivation at various stages of the 
colorectal cancer screening process, none had assessed the relationship with faecal 
haemoglobin (Hb) concentration when using quantitative FIT. 
 
In the recent assessment of FIT as a first-line test in Scotland, (Steele et al., 2013) it 
was documented that faecal Hb concentration was higher in men than in women, and 
increased with age in both genders. (McDonald et al., 2012)  It was stated that these 
data were vital considerations for screening programme design, more tailored 
strategies were needed and faecal Hb concentration could be included in individual 
risk-scores along with gender and age.  In consequence, since deprivation is of 
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considerable relevance to colorectal cancer, including test uptake and positivity rates in 
screening programmes, it is important to also consider the relevance of deprivation as 
a risk factor.  With this in mind, the aim of this Chapter was to investigate the 
relationship between deprivation and faecal Hb concentration and how this may relate 
to findings at colonoscopy.  
 
 
6.2 Materials and methods 
 
 
The study cohort was again derived from the participants of the ‘FIT as a First-Line 
Test’ evaluation, the full process of which was previously described in a previous 
Chapter (Chapter 3: The relationship between faecal haemoglobin concentration and 
severity of colorectal neoplasia). 
 
Deprivation was categorized as described in Chapter 4: The relationship between 
faecal haemoglobin concentration and interval cancers.  Distributions of faecal Hb 
concentration were calculated overall and for men and women in deprivation quintiles. 
MedCalc (MedCalc Software, Mariakerke, Belgium) statistical software was used for all 
calculations.  
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6.3 Results 
 
 
Of the 66,725 men and women invited, aged 50 to 74 years, faecal Hb concentration 
was measured on single samples from 38,439 participants who had degree of 
deprivation calculated, with 48.8% men and 53.3% women.  Table 6.1 shows the 
number in each Scottish Index of Multiple Deprivation (SIMD) quintile, further broken 
down by gender and age.  There were no significant differences in the gender or age 
distributions in each deprivation quintile (p > 0.05). 
 
Table 6.1. Number of participants in each Scottish Index of Multiple Deprivation (SIMD) 
quintile. 
  Deprivation  
  SIMD 1 
(most 
deprived) 
SIMD 2 SIMD 3 SIMD 4 SIMD 5 
(least 
deprived) 
Total 
  n (%) n (%) n (%) n (%) n (%) n 
Total  5,450 (14.2) 7,604 (19.8) 6,780 (17.6) 9,962 (25.9) 8,643 (22.5) 38,439 
Gender: 
 Men 2,556 (14.3) 3,572 (19.9) 3,171 (17.7) 4,667 (26.0) 3,968 (22.1) 17,934 
 Women 2,894 (14.1) 4,032 (19.7) 3,609 (17.6) 5,295 (25.8) 4,675 (22.8) 20,505 
Age (years): 
 50-54 1,473 (16.7) 1,609 (18.2) 1,443 (16.3) 2,497 (28.2) 1,821 (20.6) 8,843 
 55-59 1,226 (14.1) 1,751 (20.2) 1,602 (18.4) 2,228 (25.7) 1,877 (21.6) 8,684 
 60-64 1,115 (12.6) 1,806 (20.5) 1,515 (17.2) 2,207 (25.0) 2,176 (24.7) 8,819 
 65-69 766 (12.6) 1,228 (20.2) 1,149 (18.9) 1,537 (25.3) 1,385 (22.8) 6,065 
 70-74 870 (14.4) 1,210 (20.1) 1,071 (17.8) 1,493 (24.8) 1,384 (23.0) 6,028 
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For men and women and for all deprivation quintiles, none of the distributions of faecal 
Hb concentration were Gaussian (D’Agostino-Pearson test, p < 0.0001) and the 
coefficients of skewness and kurtosis were significantly > 1 (p < 0.0001).  Of particular 
note was that the distribution of faecal Hb concentration was highly positively skewed: 
51.9% of all participants had no detectable faecal Hb concentration.  A significantly 
greater proportion of those in the least deprived quintile (56.5%) had no detectable 
faecal Hb concentration than those in the most deprived quintile (45.5%, p < 0.0001).  
Distributions of faecal Hb concentration for each deprivation quintile are displayed as 
percentiles with conventional 95% confidence interval (CI) in Tables 6.2 and 6.3 for 
men and women, respectively.  The 97.5% percentile represents the potential non-
parametric upper reference limit (URL) of the 0.95 inter-fractile reference interval and 
90% CI are given as recommended in Clinical and Laboratory Standards Institute 
(CLSI) EP28-A3c guidelines for derivation of population-based reference values. 
(Wayne, 2008) 
146 
 
 
1
4
6
 
Table 6.2. Percentiles, with 95% confidence intervals (CI), of faecal haemoglobin concentration (µg Hb/g faeces) in men and potential upper 
reference limits (URL) with 90% CI. 
 
Deprivation n (%) 25th (95% CI) 50th (95% CI) 75th (95% CI) 90th (95% CI) 95th (95% CI) 97.5th URL (90% CI) 
Total 17,934 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.2) 2.3 (2.2 - 2.4) 12.2 (11.4 - 13.4) 37.2 (34.0 - 40.6) 104 (93.8 - 116.2) 
SIMD 1 
(most deprived) 
2,556 (14.3) 0.0 (0.0 - 0.0) 0.4 (0.4 - 0.6) 3.2 (2.8 - 3.6) 18.8 (14.8 - 21.4) 49.6 (39.4 - 67.0) 120.8 (101.4 - 149.8) 
SIMD 2 3,572 (19.9) 0.0 (0.0 - 0.0) 0.4 (0.2 - 0.4) 3.0 (2.6 - 3.6) 17.6 (15.0 - 21.4) 51.4 (40.6 - 63.4) 141.6 (107.8 - 199.6) 
SIMD 3 3,171 (17.7) 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.2) 2.2 (2.0 - 2.6) 12.8 (10.6 - 15.0) 39.2 (30.2 - 47.4) 103.6 (72.2 - 143.6) 
SIMD 4 4,667 (26.0) 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.0) 1.8 (1.6 - 2.0) 9.0 (8.0 - 10.4) 29.2 (23.8 - 36.4) 96.2 (77.0 - 116.2) 
SIMD 5 
(least deprived) 
3,968 (22.1) 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.0) 1.6 (1.4 - 1.6) 8.8 (7.4 - 10.8) 29.2 (24.0 - 34.0) 78.2 (62.0 - 96.4) 
 
Table 6.3. Percentiles, with 95% confidence intervals (CI), of faecal haemoglobin concentration (µg Hb/g faeces) in women and potential upper 
reference limits (URL) with 90% CI. 
 
Deprivation n (%) 25th (95% CI) 50th (95% CI) 75th (95% CI) 90th (95% CI) 95th (95% CI) 97.5th URL (90% CI) 
Total 20,505 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.0) 1.6 (1.6 - 1.8) 7.0 (6.6 - 7.4) 21.8 (20.2 - 23.4) 55.6 (50.6 - 62.4) 
SIMD 1 
(most deprived) 
2,894 (14.1) 0.0 (0.0 - 0.0) 0.2 (0.2 - 0.4) 2.4 (2.2 - 2.6) 11.6 (10.0 - 14.8) 33.4 (26.4 - 41.4) 101.2 (71.6 - 126.6) 
SIMD 2 4,032 (19.7) 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.2) 2.0 (1.8 - 2.0) 8.4 (17.2 - 10.0) 24.8 (20.4 - 29.4) 72.8 (53.2 - 85.6) 
SIMD 3 3,609 (17.6) 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.0) 1.6 (1.4 - 1.8) 6.4 (5.6 - 7.4) 19.2 (15.8 - 23.4) 42.4 (32.6 - 58.6) 
SIMD 4 5,295 (25.8) 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.0) 1.4 (1.4 - 1.6) 6.0 (5.6 - 6.6) 20.0 (16.0 - 23.4) 52.8 (39.4 - 63.4) 
SIMD 5 
(least deprived) 
4,675 (22.8) 0.0 (0.0 - 0.0) 0.0 (0.0 - 0.0) 1.2 (1.2 - 1.4) 5.6 (5.0 - 6.4) 15.6 (13.0 - 19.2) 40.4 (31.0 - 51.8) 
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The Krusall-Wallis non-parametric analysis of variance (ANOVA) showed that highly 
statistically significant variation existed in faecal Hb concentration across deprivation 
quintiles (p < 0.000001), with median faecal Hb concentration increasing as deprivation 
increased.  Post-hoc analysis revealed that those in the least and the second least 
deprived quintiles had significantly higher median faecal Hb concentration than those in 
each of the three remaining less deprived quintiles (p < 0.0001 for all comparisons). 
 
Table 6.4 shows the proportion of participants with faecal Hb concentration above 
different cut-off concentrations for a positive test result commonly used in screening 
programmes, for each deprivation quintile, for men and women.  Also estimated were 
the cut-off faecal Hb concentration that would generate a test positivity rate of 2.0% in 
each deprivation quintile, as this is the level deemed desirable for referral to 
colonoscopy for the Screening Programme in Scotland, within the limits of the available 
colonoscopy resource.  The test positivity rate with the cut-off faecal Hb concentration 
used in the Scottish ‘FIT as a First-Line Test’ evaluation of 80 µg Hb/g faeces would 
range from 1.96% in the least deprived up to 3.21% in the most deprived and would be 
higher in men than women.  Logistic regression analysis showed that participants in the 
most deprived group were more likely to have a faecal Hb concentration above the cut-
off faecal Hb concentration for test positivity compared with the least deprived group, 
independent of gender and age (adjusted odds ratio = 1.70, 95% CI: 1.37 - 2.11).  
Odds ratios for test positivity across the different degrees of deprivation are displayed 
in Table 6.5, both non-adjusted and adjusted for gender and age. 
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Table 6.4. Test positivity rates (%) at commonly used cut-off faecal haemoglobin (Hb) 
concentrations and cut-off to attain 2.0 % positivity for men and women. 
Gender Deprivation Faecal Hb concentration 
(µg Hb/g faeces) 
Cut-off for 2% 
positivity 
(µg Hb/g faeces) 10 15 20 40 80 
Men: Total 11.2 9.0 7.6 4.7 3.0 136 
 SIMD 1 
(most deprived) 
13.7 11.2 9.5 5.8 3.6 148 
 SIMD 2 13.6 11.1 9.4 5.8 3.5 > 200 
 SIMD 3 11.4 9.1 7.5 4.9 2.9 150 
 SIMD 4 9.4 7.4 6.4 4.0 2.8 124 
 SIMD 5 
(least deprived) 
9.6 7.7 6.1 3.9 2.3 104 
Women: Total 8.1 6.2 4.6 3.3 2.0 80 
 SIMD 1 
(most deprived) 
11.2 8.9 7.6 4.3 2.9 126 
 SIMD 2 9.2 6.9 4.9 3.5 2.2 92 
 SIMD 3 7.7 6.0 4.4 3.2 1.7 66 
 SIMD 4 7.1 5.2 3.9 3.2 1.9 70 
 SIMD 5 
(least deprived) 
6.8 5.2 3.7 2.6 1.6 58 
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Table 6.5. Odds ratios with 95% confidence interval (CI) for test positivity for each Scottish 
Index of Multiple Deprivation (SIMD) quintile. 
Deprivation Positivity rate Odds ratio 
  Non-adjusted (95% CI) Adjusted (95% CI)* 
Total:    
SIMD 1 (most deprived) 3.21% 1.66 (1.34 - 2.06) 1.70 (1.37 - 2.11) 
SIMD 2 2.83% 1.46 (1.19 - 1.79) 1.46 (1.19 - 1.79) 
SIMD 3 2.23% 1.14 (0.91 - 1.43) 1.14 (0.91 - 1.42) 
SIMD 4 2.33% 1.20 (0.98 - 1.46) 1.21 (0.99 - 1.48) 
SIMD 5 (least deprived) 1.96% 1.00 1.00 
    
Men:    
SIMD 1 (most deprived) 3.56% 1.54 (1.15 - 2.06) 1.60 (1.19 - 2.15) 
SIMD 2 3.50% 1.51 (1.15 - 1.98) 1.53 (1.16 - 2.01) 
SIMD 3 2.87% 1.23 (0.92 - 1.65) 1.24 (0.92 - 1.66) 
SIMD 4 2.83% 1.21 (0.93 - 1.57) 1.21 (0.95 -1.62) 
SIMD 5 (least deprived) 2.34% 1.00 1.00 
    
Women:    
SIMD 1 (most deprived) 2.90% 1.81 (1.32 - 2.48) 1.83 (1.33 - 2.50) 
SIMD 2 2.23% 1.38 (1.02 - 1.88) 1.37 (1.01 - 1.86) 
SIMD 3 1.66% 1.02 (0.73 - 1.44) 1.02 (0.73 - 1.44) 
SIMD 4 1.89% 1.16 (0.86 - 1.57) 1.18 (0.88 - 1.48) 
SIMD 5 (least deprived) 1.66% 1.00 1.00 
* - adjusted for gender and age quintile, as appropriate. 
 
 
Detection of advanced neoplasia in participants with a faecal Hb concentration above 
the cut-off adopted was also examined.  Analysis of all screening participants show that 
the odds ratio for having a positive test result and then having advanced neoplasia 
detected rose with each increasing deprivation quintile compared with the least 
deprived, albeit not to statistical significance (adjusted odds ratio in most deprived: 1.48 
(95% CI: 0.99 - 2.22).  However, no trend at all was apparent for increasing likelihood 
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of advanced neoplasia detection with participants with a positive test result.  This 
translates as no association existing between deprivation and PPV for advanced 
neoplasia, and, as such, no association with the number of false positive test results.  
Table 6.6 shows PPV for colorectal cancer, higher-risk adenoma, and other pathology 
calculated for each deprivation quintile, by gender.  Overall PPV for advanced 
neoplasia were slightly higher in the least deprived, but the differences did not reach 
statistical significance (p > 0.05). 
 
Table 6.6. Positive Predictive Values (PPV) for each deprivation quintile, by gender. 
SIMD 
1 
(most deprived) 
2 3 4 
5 
(least deprived) 
  n PPV n PPV n PPV n PPV n PPV 
All positive test results:         
 All 153  183  130  194  154  
 Men 80  105  78  112  84  
 Women 73  78  52  82  70  
Cancer (CRC):           
 All 8 5.2% 4 2.2% 10 7.7% 7 3.6% 10 6.5% 
 Men 5 6.3% 3 2.9% 6 7.7% 3 2.7% 6 7.1% 
 Women 3 4.1% 1 1.3% 4 7.7% 4 4.9% 4 5.7% 
Higher-risk adenoma (HRA):          
 All 36 23.5% 42 23.0% 36 27.7% 39 20.1% 37 24.0% 
 Men 22 27.5% 28 26.7% 22 28.2% 30 26.8% 25 29.8% 
 Women 14 19.2% 14 17.9% 14 26.9% 9 11.0% 12 17.1% 
Advanced neoplasia (CRC + HRA):         
 All 44 28.8% 46 25.1% 46 35.4% 46 23.7% 47 30.5% 
 Men 27 33.8% 31 29.5% 28 35.9% 33 29.5% 31 36.9% 
 Women 17 23.3% 15 19.2% 18 34.6% 13 15.9% 16 22.9% 
Non-neoplastic pathology*/no pathology detected:       
 All 108 70.6% 136 74.3% 83 63.8% 145 74.7% 107 69.5% 
 Men 52 65.0% 73 69.5% 50 64.1% 78 69.6% 53 63.1% 
 Women 56 76.7% 63 80.8% 33 63.5% 67 81.7% 54 77.1% 
* - Non-neoplastic pathology comprises of hyperplastic polyps and other conditions including 
diverticular disease, haemorrhoids and inflammatory bowel disease. 
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6.4 Discussion 
 
 
Deprivation and faecal Hb concentration was examined in a large group of ostensibly 
asymptomatic people aged 50 – 74 years.    As degree of deprivation increased, 
median faecal Hb concentration increased.  Although men had higher concentrations 
than women in all deprivation quintiles, the trend for increasing odds ratio for faecal Hb 
concentration above the cut-off of 80 µg Hb/g faeces with increasing deprivation 
seemed slightly stronger in women. 
The relationship between faecal Hb concentration and deprivation is reflected by those 
in the more deprived groups having a higher proportion of participants with faecal Hb 
concentration above the cut-off used in the ‘FIT as a First-Line Test’ evaluation in 
Scotland (Steele et al., 2013), in men and in women.  The same was seen at all four of 
the other commonly-used screening cut-off faecal Hb concentration examined, in men 
and in women, showing that the findings would apply in the same way if lower cut-off 
faecal Hb concentration were implemented rather than the relatively high 80 µg Hb/g 
faeces cut-off adopted in the evaluation.  This cut-off was deliberately selected with an 
aim to generate an overall test positivity rate of around 2%, but in reality resulted in the 
referral of a slightly higher 2.44% of participants to colonoscopy.  However, test 
positivity rates ranged from 1.96% to 3.21% between the lowest and highest quintile of 
deprivation, respectively; this in real terms would represent a sizeable difference in the 
number of people referred from the different deprivation quintiles if taking into account 
the entire screening population. 
 
If equality of test positivity rates were to be achieved across deprivation groups, varying 
cut-off faecal Hb concentration would have to be employed for each group.  This 
seems particularly evident in women in this analysis, with the cut-off faecal Hb 
152 
 
 
concentration required to generate 2% test positivity in the most deprived women being 
more than double the concentration that would give this same referral rate in least 
deprived women.  Crucially though, it would not be the case that adapting the cut-off 
faecal Hb concentration for these different groups is an appropriate strategy to address 
any inequalities between in terms of colorectal cancer incidence and mortality.  What is 
of paramount importance is minimising numbers of missed cases of advanced 
neoplasia in each group while limiting the number of screening participants being 
referred for unnecessary colonoscopy.  Therefore, measures of sensitivity and 
specificity for men and women in the varying degrees of deprivation would allow a 
more comprehensive analysis of how any group might be disadvantaged by the use of 
a single cut-off faecal Hb concentration for all.  Since colorectal disease status was 
known only for those attending follow-up for positive screening test results, and not 
those with faecal Hb concentration below the cut-off concentration, such analysis was 
not possible.  What could be examined, however, were the PPV for neoplasia in each 
deprivation quintile. 
 
In contrast to results of previous studies showing lower PPV for neoplasia and, in turn, 
higher false positive rates in more deprived groups participating in gFOBT screening 
(Mansouri et al., 2013) no significant differences in these rates were detected between 
the deprivation quintile in those with a positive test result in this cohort.  It could be 
speculated that the variation in false positive rates by deprivation when screening with 
gFOBT was in part attributable to a greater consumption of red meat, for example, in 
the more deprived.  Since FIT are not at all subject to dietary interference, this driving 
mechanism may be have been negated in this cohort.  Indeed, our results are now 
supported by very up-to-date work from Australia, (Symonds et al., 2015b) albeit with a 
much lower cut-off faecal Hb concentration used than in the Scottish evaluation.  
Symonds et al. (2015b) observed a trend of increasing faecal Hb concentration with 
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increasing deprivation, and reported that those in the lowest socioeconomic status 
quintile had a significantly lower odds ratio for test positivity with a cut-off faecal Hb 
concentration of 20 µg Hb/g faeces than those in the most deprived group (odds ratio = 
0.65, 95% CI: 0.53 – 0.80, p < 0.001).  No significant differences were seen in false 
positive rates, defined as the absence of any neoplasia, between the deprivation 
quintiles.  The same study also reported that faecal Hb concentration and test positivity 
were significantly higher in those who had previously participated in colorectal cancer 
screening (p < 0.05), although false positivity rates showed no association with 
previous screening.  Since the number of false positive test results will fall with 
increasing cut-off faecal Hb concentration, the work presented in this Chapter provides 
further evidence of this relationship in a country with limited colonoscopy capacity and 
may be of concern to screening programme organisers. 
 
A plausible explanation is that the more deprived experience more colonic bleeding 
than the least deprived, whether it is arising from neoplastic lesions or for other less 
serious reasons.  It may be that colorectal cancer incidence is higher in all participants 
in the most deprived quintiles, and this coupled with bleeding perhaps arising as a 
result of lifestyle choices associated with deprivation such as a low fibre diet and 
increased alcohol intake for example, contributes to the higher test positivity rates seen 
in these groups.  A further contributing factor to higher test positivity rates in the more 
deprived could be pointed to by the trend of decreasing uptake of screening with 
increasing deprivation (Digby et al., 2013).  Delayed participation may therefore be a 
factor, with more participants in the more deprived groups responding to screening for 
the first time, or responding less regularly than the less deprived groups.  Modification 
of the cut-off concentration to achieve equality of test positivity rates would be 
detrimental to improving colorectal cancer detection in this case.  Raising the cut-off 
faecal Hb concentration for the most deprived may miss cases of neoplasia in that 
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group, with no benefit to the least deprived.  Likewise, lowering of the cut-off faecal Hb 
concentration for the least deprived may result in improved disease detection rates in 
this group, but would offer no corresponding benefit to the most deprived and therefore 
possibly only act to widen an already existing disparity in colorectal cancer mortality 
between deprivation quintiles. 
 
Since sensitivity and specificity measures cannot be calculated here, the results from 
this cohort cannot form any firm basis for recommendations regarding tailoring of cut-
off faecal Hb concentration according to degree of deprivation.  However, the trend of 
increasing odds of having a positive screening test result, then having advanced 
neoplasia detected, with increasing degree of deprivation (controlling for the 
confounding effects of age and gender) came very close to reaching statistical 
significance.  This is perhaps enough to merit at least the consideration of the inclusion 
of degree of deprivation into risk-scoring models, despite the absence of an increase in 
PPV at the cut-off faecal Hb concentration adopted.  It is important that such modelling 
be kept as simple as possible so as to be feasible and acceptable to those involved in 
the delivery of the screening programme as an efficient way of prioritising those at 
greatest risk of disease.  More obvious factors for inclusion might include easily 
obtainable variables such as age and gender.  However, if degree of deprivation could 
be easily incorporated, it may improve the predictive qualities of such a model. 
 
In addition to interpretation of these results in terms of colorectal cancer detection in 
the screening setting, they may also add some further backing to the evidence base for 
colorectal cancer prevention.  As discussed, changes in the relationship between 
colorectal cancer incidence and deprivation in men in Scotland have been attributable 
to those in the least deprived groups improving their lifestyle choices, whereas the 
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most deprived did not (Oliphant et al., 2011).  Campaigns incorporating lifestyle change 
with the aim of colorectal cancer prevention may wish to target deprived groups in 
particular with the rationale that they exhibit a greater degree of faecal Hb 
concentration, which in turn is related to increased severity of colorectal neoplasia.  
Furthermore, the relationship between faecal Hb concentration and all-cause mortality 
shown in the important paper by Chen et al. (2013) may imply that faecal Hb 
concentration is representative of overall state of health, with poorer health outcomes 
in the most deprived reflecting this. 
 
A limitation of this work is that SIMD is an area-based measurement meaning that 
assumptions may be made of individuals residing in each SIMD “datazone”.  It is 
important to mindful of this when interpreting the findings that individual screening 
participants cannot be labelled as deprived or not based on the area they live in.  SIMD 
more simply reports the relative deprivation of one area compared to another.  
However, since gathering individual level data on health behaviours, e.g. via 
questionnaire, would be unfeasible in the setting of population screening, the SIMD 
index is the best measure available and reasonable conclusions can still be drawn from 
this analysis. 
 
To summarise, a clear relationship exists between degree of deprivation and faecal Hb 
concentration. Although likely related to lifestyle factors associated with increasing 
deprivation, further work is warranted to investigate the mechanisms.  With some 
association existing between deprivation and increased colorectal cancer incidence 
and poorer outcomes, these data further highlight the need for further work to assist 
consideration of the adoption of better strategies for setting cut-off faecal Hb 
concentration, albeit without full knowledge of disease prevalence in participants with 
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faecal Hb concentration below the cut-off selected for a positive test result.  Moreover, 
these findings show that there is potential for deprivation to be included, along with 
faecal Hb concentration, gender and age, in the risk-scoring models that are of ever-
growing interest.  However, it is important to state that although these results in a large 
cohort document statistically significance variation in faecal Hb concentration according 
to degree of deprivation, their clinical significance in population screening must be 
further tested. 
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7. Faecal haemoglobin concentration as an indicator of 
significant colorectal disease in patients presenting to 
primary care with colorectal symptoms 
 
 
 
 
7.1 Introduction 
 
Colorectal symptoms such as diarrhoea, rectal bleeding and abdominal pain are 
common reasons for patients to present to their general practitioner (GP) in the United 
Kingdom, with one study reporting that these complaints to account for 10% of all of the 
clinical work of the NHS (Jones et al., 2009).  National Institute for Health and Care 
Excellence (NICE) (2015) guidelines highlight the symptoms most suggestive of the 
presence of serious pathology and in need of further investigation by endoscopy.  
These include rectal bleeding, a mass on examination, iron-deficiency anaemia, but 
also non-specific symptoms such as a persistent change in bowel habit. However, the 
same symptoms can often be associated with much less serious causes such as 
haemorrhoids and irritable bowel syndrome (IBS).  The latest revisions of the NICE 
guidelines (2015) now concede that symptoms have a Positive Predictive Value (PPV) 
for colorectal cancer of only 3-4%.  Indeed, such symptoms alone have been shown in 
the detailed review and meta-analysis performed by Jellema et al. (2010) to show poor 
diagnostic performance as predictors of colorectal cancer.   Only weight loss and iron-
deficiency anaemia showed fairly high values for specificity (median 89%, range 72 - 
96 and median 92%, range 83 - 95, respectively) but sensitivity was lacking.  
Therefore, it is difficult for GP to make decisions on which patients are most likely to 
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have significant colorectal disease encompassing colorectal cancer, higher-risk 
adenoma and inflammatory bowel disease, and as such should be prioritised for 
referral for further investigations. 
 
Recent campaigns have run in the United Kingdom with the aim of earlier detection of 
colorectal cancer.  Analysis of the impact of the “Be Clear on Cancer” campaign in 
England has highlighted the problems associated with placing an emphasis on urgent 
referral of patients presenting with large bowel symptoms, despite evidence of their 
poor predictive value. (Peacock et al., 2013)  An escalation in the number of referrals 
for investigation was reported with an increase of 60%, but no increase in colorectal 
cancer detection was observed, nor was there a stage shift towards earlier diagnosis.  
In addition, the cost of diagnosing a case of colorectal cancer was calculated to have 
increased by 30%.  A similar campaign exists in Scotland, namely “Detect Cancer 
Early”, with a key aim to encourage those with potential symptoms of colorectal cancer 
to attend their GP at the earliest opportunity. (Scottish Government, 2014) 
 
In NHS Tayside, the number of referrals for investigation of colorectal symptoms 
increased from 1,200 per year in 2007 to 4,200 per year in 2013. (Personal 
communication, Mowat C., 2015)   Again, the rapid increase in referrals did not 
associate with a greater number of colorectal cancer cases diagnosed.  Around 35-
40% of referrals in NHS Tayside are marked as “Urgent”, or “Urgent Suspected 
Cancer” and, following triage by Consultant Gastroenterologists, around 75% of all 
referrals are brought straight to investigation with the remainder being assessed in out-
patient clinics.  Local audit data have revealed a diagnostic yield of colorectal cancer in 
patients undergoing colonoscopy at just 2%, and 5% for inflammatory bowel disease.  
Clearly, the trend of increasing referrals over time is placing a burden on endoscopy 
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services that is not sustainable, particularly in terms of increasing costs without any 
improvement in disease outcomes.  Moreover, waiting times in those who do have 
significant colorectal disease are being lengthened by the escalating number of 
negative “urgent” colonoscopies. 
 
Clearly it would be beneficial to identify new means of reducing the number of 
unnecessary colonoscopies performed in symptomatic patients.  Providing GP with a 
tool to distinguish between those patients in whom a policy of watchful waiting or 
referral for a specialist opinion may be more appropriate and those who require 
prioritisation for investigation is urgently required. 
  
The Faecal Immunochemical Test for haemoglobin (FIT) may represent such a tool 
with a potential role in this context.  Detection of haemoglobin (Hb) in faeces is well 
established in colorectal cancer screening programmes and the merits of FIT over 
guaiac faecal occult blood tests (gFOBT) and the potential for faecal Hb concentration 
to act as a predictor of risk have been discussed at length in this work.  When using 
tests for Hb in faeces for colorectal cancer screening in a healthy population, 
participants with a negative test result are often advised that cancers can be missed, to 
be aware of symptoms and attend their GP if concerned.  However, in patients 
presenting with symptoms in primary care, it would be unacceptable for patients to be 
reassured when there is a reasonable possibility of a false negative test result.  
Therefore, test sensitivity has far higher importance than in the screening setting and 
as a result, earlier recommendations have indicated that gFOBT has no context in 
primary care owing to its poor sensitivity. (National Institute for Health and Care 
Excellence (NICE), 2011; Scottish Intercollegiate Guidelines Network (SIGN), 2011)  
However, lacking in the literature is evidence of test performance of FIT in primary care 
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as a rule-out test for significant colorectal disease, evident when the systematic review 
by Jellema et al. (2010) reporting on the value diagnostic tests for colorectal cancer in 
primary care did not identify any studies involving FIT in this setting.  However, since 
this publication in 2010, some studies have emerged in this field. 
 
Only one of these, from Scotland, (McDonald et al., 2013) assessed test performance 
for detecting colorectal cancer, higher-risk adenoma and inflammatory bowel disease, 
and an overall Negative Predictive Value (NPV) of 88.1% was reported with a cut-off 
concentration of 10 µg Hb/g faeces in 280 patients awaiting colonoscopy.  No 
individuals with colorectal cancer were associated with faecal Hb concentration below 
this threshold, although a total of only six cases were diagnosed in the cohort.  A recent 
study from Spain compared the diagnostic accuracy of FIT for colorectal cancer 
detection with the expert guidelines for referral from NICE and the Scottish 
Intercollegiate Guidelines Network (SIGN). (Cubiella et al., 2014)  With a cohort of 787 
patients including 97 colorectal cancer cases, the authors showed a NPV of 97.8% for 
colorectal cancer when using a cut-off concentration of 20 µg Hb/g faeces, with which a 
test positivity rate of 30.6% was observed.  Parente et al. (2012) studied 280 patients 
awaiting colonoscopy for suspicion of colorectal cancer, with an faecal Hb 
concentration cut-off equivalent to 20 µg Hb/g faeces and reported a NPV for colorectal 
cancer of 92.0%.  
 
A retrospective population-based study from Sweden described the impact of a 
qualitative FIT used in primary care in 215 patients with colorectal cancer and 
adenomas exhibiting high-grade dysplasia and concluded that a negative test result 
delayed further investigation and missed around 15% of colorectal cancer cases. 
(Hogberg et al., 2013)  Another study investigating the use of a qualitative FIT in 
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primary care was performed in England in 126 patients referred via the ‘rapid access’ 
colorectal service.  Although the authors concentrated on FIT as a rule-in test for 
colorectal cancer, the NPV was 100% for the 17 colorectal cancer cases in the cohort. 
(Kaul et al., 2013)  Kalimutho et al. (2011) examined performance of qualitative FIT and 
faecal calprotectin testing in comparison to faecal DNA test performance in 204 
consecutive symptomatic patients referred for colonoscopy.  NPV was not reported, but 
sensitivity and specificity for colorectal cancer detection were 51.9% and 97.9%, 
respectively.   Kok et al. (2012) also examined qualitative FIT in combination with 
faecal calprotectin testing.  With the cut-off faecal Hb concentration as equivalent to 8 
µg Hb/g faeces, NPV for significant colorectal disease was 94% (95% CI: 91 - 96) but 
the study was limited by small numbers with only 19 cases of colorectal cancer, and 
diverticular disease was included in the definition of significant colorectal disease.  
 
In summary, previous studies reporting results on the use of FIT in symptomatic 
patients provide some evidence that faecal Hb concentration may perform well as a 
rule-out test for significant colorectal disease, with high NPV documented, although 
many of the sample sizes are small.  What is missing, however, is an evaluation of the 
use of faecal Hb concentration at the point of GP referral for endoscopy, rather than in 
those awaiting colonoscopy.  If promising results were available for such an analysis, 
they could be translated directly into practice to better target colonoscopy towards 
those at greatest risk of significant colorectal disease.  Such evidence could provide 
GP with the confidence to utilise faecal Hb concentration as a rule-out test for 
significant colorectal disease, inclusive of higher-risk adenoma and inflammatory bowel 
disease in addition to colorectal cancer which is mainly reported alone in the literature. 
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The existing studies discussed here, other than those of McDonald et al., (2013) and 
Cubiella et al., (2014) have focussed solely on test performance without considering 
the potential reduction in referral rate.  It would be of great value to identify appropriate 
cut-off faecal Hb concentration for FIT in primary care that would allow a significant 
reduction in referral rates and subsequently ease the current strain on resources, 
without missing an unacceptable number of cases of significant colorectal disease.  
With this in mind, the aim of this study was to assess the diagnostic accuracy of 
quantitative FIT in patients presenting to primary care with colorectal symptoms and to 
identify an appropriate cut-off faecal Hb concentration to rule out significant colorectal 
disease. 
 
 
7.2 Materials and methods 
 
 
This prospective study gained the full support of NHS Tayside GP and was conducted 
following the STAndards for the Reporting of Diagnostic accuracy studies (STARD) 
guidelines. (2015)  All adult patients referred for investigation of colorectal symptoms in 
NHS Tayside over a six month period from October 2013 to March 2014 were eligible.  
The NHS Tayside Colorectal Pathway is a unique, single electronic portal of entry for 
new referrals with daily vetting by consultant gastroenterologists to triage patients 
either straight to endoscopy or to the appropriate out-patient clinic.  At the point of 
referring patients to the Colorectal Pathway, GP were prompted to request faecal Hb 
concentration alongside full blood count, urea and electrolytes and C-reactive protein 
and record the presenting symptoms via the NHS Tayside electronic test requesting 
software.  If patients had more than one presenting symptom, for the purposes of the 
present analysis they were attributed only one, in order of decreasing clinical 
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importance as follows: rectal bleeding, anaemia, diarrhoea, altered bowel habit, 
abdominal pain, weight loss. The total number of referrals and their urgency were 
recorded on the referral management software.  Practice nurses distributed an OC-
Sensor FIT specimen collection device (Eiken Chemical Company, Tokyo, Japan), and 
a pictorial patient instruction sheet to each participant.  Patients were instructed to 
collect samples from a single faeces and to return the sample immediately to the GP 
surgery.  The samples were returned at room temperature via the GP surgery routine 
sample collection service (a daily van courier service) to Blood Sciences, Ninewells 
Hospital and Medical School, and stored at 4oC prior to analysis to ensure stability. 
 
Faecal Hb concentration measurement was performed using a single OC-Sensor io 
analyser, (Eiken Chemical Co., Ltd, Tokyo, Japan). Inter-run imprecision was assessed 
with quality control materials (Eiken) in each run: coefficients of variation were 4.6% at 
25 µg Hb/g faeces and 3.9% at 93 µg Hb/g faeces over the period of this study.  Any 
faecal Hb concentration sample which was reported by the analytical system as a 
positive numerical result greater than zero µg Hb/g faeces was considered as a 
“detectable faecal Hb concentration”.  Samples with results above the upper analytical 
limit were not diluted and re-assayed but reported as greater than that upper 
concentration limit of 200 µg Hb/g faeces.  Faecal Hb concentration results were 
converted from the instrument generated ng Hb/ml buffer to the internationally 
recommended unit of µg Hb/g faeces by multiplication by 0.2. (Fraser et al., 2012)  The 
laboratory had a total quality management system in place and was accredited to 
International Organization for Standardization (ISO) 15189 based standards. 
 
Patients referred to endoscopy were investigated within six weeks of referral.  The NHS 
Tayside endoscopy units participate in the accreditation scheme of the Joint 
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Accreditation Group on GI Endoscopy.  Participating clinicians and endoscopists were 
blind to the faecal test results.  All findings were recorded on the endoscopy reporting 
system by the endoscopist.  The diagnoses of colorectal cancer, higher-risk adenoma 
and inflammatory bowel disease were confirmed following assessment by a 
gastrointestinal pathologist.  Clinical outcomes were collected for all patients who 
completed the tests and the diagnostic accuracies of faecal Hb concentration for 
identification of significant colorectal disease were examined.  MedCalc statistical 
software (MedCalc Software, Mariakerke, Belgium) was used for all calculations and to 
produce distribution plots for faecal Hb concentration.  The study was approved by the 
East of Scotland research ethics committee. 
 
7.3 Results 
 
Over the six-month study period, 2,189 patients were referred for investigation from 
primary care to the NHS Tayside Colorectal Service, with 1,032 marked as either 
“urgent” or “urgent suspected cancer”.  Of those referred, 1,043 patients returned a FIT 
specimen collection devices.  Table 7.1 summarises the details of the final study cohort 
of 1,023 with a faecal Hb concentration measurement.  55.6% of this group were 
women and median age was 64 years (range 16-95, [interquartile range] IQR 51 - 74). 
 
Table 7.2 shows median faecal Hb concentration according to gender and age, and 
proportions of patients above increasing cut-off faecal Hb concentration.  Median faecal 
Hb concentration was significantly higher in those aged 70 years old and over 
compared with those under 40 years old (p < 0.02).  More women than men and more 
younger patients than older patients had undetectable faecal Hb concentration in their 
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sample.  Using a cut-off faecal Hb concentration-off of 10 µg Hb/g faeces, the test 
result was positive in 22.3% of samples. 
 
 
Table 7.1. Summary of study cohort with number of participants returning a sample for 
faecal haemoglobin concentration measurement. 
 Total Men Women 
 n % n % n % 
Total referrals to NHS Tayside Colorectal 
Service during the study period 
2,189      
Urgent referrals* 1,032 47.1 ** ** ** ** 
       
Returned samples 1,043 47.6 465 ** 578 ** 
       
Excluded:       
Specimen not suitable for analysis 15 1.4 6 1.3 9 1.6 
Specimen returned out with study period 4 0.4 2 0.4 2 0.3 
Previous diagnosis of significant bowel disease 1 0.1 0 0.0 1*** 0.2 
       
Included in final study cohort: 1,023  457 44.7 566 55.3 
* Referrals marked “urgent” or “urgent suspected cancer”. 
** Data not available for number of urgent referrals by gender. 
*** Previous diagnosis of ulcerative colitis. 
 
 
The prevalences of referred symptoms in the cohort were altered bowel habit (42.7%), 
rectal bleeding (33.9%), diarrhoea (16.8%), abdominal pain (11.0%), iron-deficiency 
anaemia (8.7%), weight loss (0.9%) and a palpable mass (0.3%). 
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A total of 750 patients (54.7% female, median age 64 years, range: 16 - 90, IQR: 52 - 
73) had faecal Hb concentration available and completed bowel investigations and 
were therefore included in the analysis of test performance. The most common findings 
at colonoscopy were: normal in 240 (32.0%), diverticular disease in 188 (25.1%), 
haemorrhoids in 97 (12.9%), low-risk adenoma in 65 (8.7%), higher-risk adenoma in 40 
(5.3%), inflammatory bowel disease in 34 (4.5%) and colorectal cancer in 28 patients 
(3.7%). 
 
Table 7.3 shows the number of patients with each outcome according to the referral 
symptom, with PPV also shown for each symptom.  
 
Figure 7.1 shows the distribution of the 1,023 faecal Hb concentrations, by clinical 
outcome, along with those who did not complete bowel investigations.  Three patients 
with colorectal cancer had a faecal Hb concentration below 10 µg Hb/g faeces.  Median 
faecal Hb concentration was significantly higher in those with colorectal cancer 
compared to those with all other outcomes combined (130.1 µg Hb/g faeces, IQR 35.1 
- 200.0 v. 0.4 µg Hb/g faeces, IQR 0.0 - 5.8, p < 0.0001), higher-risk adenoma 
compared with all other non-neoplastic outcomes combined, (6.4 µg Hb/g faeces, IQR 
1.3 - 190.8 v. 0.4 µg Hb/g faeces, IQR 0.0 - 4.2, p < 0.0001), and inflammatory bowel 
disease compared with all non-neoplastic outcomes (84.0 µg Hb/g faeces, IQR 3.8 - 
200.0 v. 0.3 µg Hb/g faeces, IQR 0.0 - 3.8, p < 0.0001). 
 
Since three cases of colorectal cancer were associated with low faecal Hb 
concentration (< 10 µg Hb/g faeces), and it would be generally considered 
unacceptable for colorectal cancer to be missed in symptomatic patients presenting in 
167 
 
 
primary care, performance characteristics of faecal Hb concentration for detection of 
significant colorectal disease was assessed using a cut-off faecal Hb concentration of 
any detectable faecal Hb concentration, in addition to performance at 10 µg Hb/g 
faeces.  Table 7.4 displays test performance at both of these cut-off faecal Hb 
concentration. 
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Table 7.2.  Number of patients with undetectable faecal haemoglobin concentration (f-Hb), and f-Hb above increasing cut-offs according to gender and age. 
 Total 
Median f-Hb 
(µg Hb/g faeces), 
(IQR) 
0 µg Hb/g 
faeces 
> 0 µg Hb/g 
faeces 
≥10 µg Hb/g 
faeces 
≥15 µg Hb/g 
faeces 
≥20 µg Hb/g 
faeces 
≥30 µg Hb/g 
faeces 
≥200 µg Hb/g 
faeces 
   n % n % n % n % n % n % n % 
Total 1,023 0.4 (0.0-6.6) 434 42.4 589 57.6 228 22.3 198 19.4 174 17.0 153 15.0 70 6.8 
   Men 457 0.6 (0.0-7.6) 183 40.0 274 60.0 109 23.9 93 20.4 84 18.4 75 16.4 42 9.2 
   Women 566 0.4 (0.0-6.0) 251 44.3 315 55.7 119 21.0 105 18.6 90 15.9 78 13.8 28 4.9 
Age category  (years): 
              
   < 40 85 0.2 (0.0-2.7) 40 47.1 45 52.9 17 20.0 15 17.6 13 15.3 12 14.1 7 8.2 
   40-49 138 0.4 (0.0-2.8) 63 45.7 75 54.3 22 15.9 19 13.8 15 10.9 13 9.4 5 3.6 
   50-59 190 0.3 (0.0-7.2) 89 46.8 101 53.2 42 22.1 38 20.0 34 17.9 33 17.4 18 9.5 
   60-69 253 0.4 (0.0-5.9) 116 45.8 137 54.2 54 21.3 42 16.6 36 14.2 29 11.5 15 5.9 
   ≥ 70 357 1.2 (0.0-11.6) 126 35.3 231 64.7 93 26.1 84 23.5 76 21.3 66 18.5 25 7.0 
 
169 
 
 
1
6
9
 
Table 7.3. Symptom prevalence and Positive Predictive Values (PPV) for colorectal cancer (CRC), higher-risk adenoma (HRA), inflammatory bowel disease (IBD) 
and significant colorectal disease (SCD). 
Symptoms Total  
CRC 
 
HRA 
 
IBD 
 
SCD = CRC+HRA+IBD 
 
 n %  n % PPV n % PPV n % PPV n % PPV 
Altered bowel habit 322 42.9  7 25.0 2.2% 13 32.5 4.0% 7 20.6 2.2% 27 26.7 8.4% 
Rectal bleeding 256 34.1  11 39.3 4.3% 20 50.0 7.8% 23 67.6 9.0% 54 53.5 21.1% 
Diarrhoea 126 16.8  3 10.7 2.4% 6 15.0 4.8% 9 26.5 7.1% 18 17.8 14.3% 
Iron-deficiency anaemia 66 8.8  6 21.4 9.1% 1 2.5 1.5% 2 5.9 3.0% 9 8.9 13.6% 
Abdominal pain 83 11.1  3 10.7 3.6% 5 12.5 6.0% 2 5.9 2.4% 10 9.9 12.0% 
Weight loss 7 0.9  1 3.6 14.3% 0 0.0 0.0% 0 0.0 0.0% 1 1.0 14.3% 
Mass 2 0.3  1 3.6 50.0% 0 0.0 0.0% 0 0.0 0.0% 1 1.0 50.0% 
Total 750     28     40     34     101*     
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Figure 7.1.  Distribution of faecal haemoglobin concentration by clinical outcome. 
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NNP = Non-neoplastic pathology; IBD = inflammatory bowel disease; HRA = higher-risk adenoma. 
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Table 7.4. Performance of faecal haemoglobin concentration (f-Hb) in the detection of 
colorectal cancer (CRC), higher-risk adenoma (HRA), all neoplasia (AN), inflammatory bowel 
disease (IBD) and significant colorectal disease (SCD) using two different cut-off 
concentrations. 
  CRC HRA 
AN 
= CRC+HRA IBD 
SCD 
= CRC+HRA+IBD 
f-Hb cut-off ≥10 µg Hb/g faeces:     
 Positivity rate:  23.5%      
 Number 28  40 68 34 102 
 True positive results 25 20 45 25 70 
 False negative results 3 20 23 9 32 
 False positive results 151 156 131 151 106 
 True negative results 571 554 551 565 542 
 Positive Predictive Value 14.2% 11.4% 25.6% 14.2% 39.8% 
 
Negative Predictive 
Value 99.5% 96.5% 96.0% 98.4% 94.4% 
 Sensitivity 89.3% 50.0% 66.2% 73.5% 68.6% 
 Specificity 79.1% 78.0% 80.8% 78.9% 83.6% 
f-Hb cut-off any detectable blood:     
 Positivity rate:  58.3%      
 Number 28 40 68 34 102 
 True positive results 28 33 61 29 90 
 False negative results 0 7 7 5 12 
 False positive results 409 404 376 408 347 
 True negative results 313 306 306 308 301 
 Positive Predictive Value 6.4% 7.6% 14.0% 6.7% 20.6% 
 
Negative Predictive 
Value 100% 97.8% 97.8% 98.4% 96.2% 
 Sensitivity 100% 82.5% 89.7% 85.3% 88.2% 
 Specificity 43.4% 43.1% 44.9% 43.0% 46.4% 
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Whilst only small numbers were available, some analysis of test performance by 
gender was possible.  At a cut-off faecal Hb concentration of any detectable Hb, test 
positivity rate would be higher in men than in women (60.9% v. 56.0%).  Using this 
criteria for referral would give a PPV for colorectal cancer of 6.3% in men and 6.6% in 
women.  However, overall PPV for colorectal cancer, higher-risk adenoma and 
inflammatory bowel disease would be higher in men, at 22.6%, compared with 18.3% 
in women.  This was due to higher proportions of both higher-risk adenoma and 
inflammatory bowel disease in men with detectable Hb in their sample compared to 
women.  Interestingly, all three of the colorectal cancer cases with faecal Hb 
concentration below the other cut-off faecal Hb concentration examined of ≥ 10 µg 
Hb/g faeces occurred in women.  No colorectal cancer would be therefore have been 
missed in this cohort using this higher cut-off faecal Hb concentration in men, although 
12 patients with higher-risk adenoma and five with inflammatory bowel disease would 
not have been urgently referred compared to seven and fives cases of higher-risk 
adenoma and inflammatory bowel disease, respectively, in men using the cut-off faecal 
Hb concentration of any detectable Hb. 
 
Interestingly, 256 of the 755 patients described rectal bleeding, but 87 (34.0%) of these 
had undetectable faecal Hb concentration. In this subgroup, only 3.4% had significant 
colorectal disease (two with higher-risk adenoma, one with inflammatory bowel 
disease), and the most common finding was haemorrhoids, the most severe diagnosis 
in 32 patients reporting rectal bleeding but having undetectable faecal Hb concentration 
(36.8%).  
 
Of the 28 patients diagnosed with colorectal cancer, eight were situated in the proximal 
colon (28.6%), six in the distal colon (21.4%) and 14 in the rectum (50.0%).  Although 
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the numbers are too small to draw any conclusions, no significant differences in 
median faecal Hb concentration were observed between patients with colorectal cancer 
located in different regions of the colorectum.  All three of the cases of colorectal 
cancer with a faecal Hb concentration < 10 µg Hb/g faeces were Dukes’ stage C.  Two 
were located in the sigmoid colon, with maximum tumour diameters of 20 mm and 50 
mm, with the other a 38 mm rectal tumour. 
 
No significant difference was detected in median faecal Hb concentration between 
those with early stage colorectal cancer compared with late stage colorectal cancer, 
nor was there a correlation found between faecal Hb concentration and tumour size. 
 
 
7.4 Discussion 
 
 
The results of this study demonstrate that faecal Hb concentration can be used in a 
symptomatic population presenting to primary care with colorectal symptoms to help 
identify those in need of further investigation.  Using detectable faecal Hb concentration 
as the criterion for referral identified 58.3% of patients as having a positive test result 
and a PPV for significant colorectal disease of 20.6%.  The significant reduction in 
referral rate is promising in light of the current strain on endoscopy resource in 
Scotland, but vitally important for GP making decisions on which patients to refer for 
colonoscopy is that no cases of colorectal cancer are missed.  The data from this 
cohort indicate that GP can use faecal Hb concentration as a decision aid with the 
confidence that colorectal cancer is effectively ruled out in patients with no detectable 
faecal Hb concentration, with no cases identified in this cohort using this criterion.  
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Some cases of higher-risk adenoma and inflammatory bowel disease were diagnosed 
in patients with undetectable faecal Hb concentration, although this was rare. 
 
Test performance was assessed at the cut-off of any detectable faecal Hb 
concentration due to three colorectal cancer cases, all late stage, in the cohort having 
faecal Hb concentration below the more commonly adopted cut-off faecal Hb 
concentration of 10 µg Hb/g faeces, and missing any colorectal cancer cases in 
patients reporting colorectal symptoms in primary care would be unacceptable.  In 
keeping with previous findings from colorectal cancer screening data that median 
faecal Hb concentration is higher in men than in women, and in older than in younger 
participants, (Fraser & Auge, 2014; Fraser et al., 2014; McDonald et al., 2012; 
Symonds et al., 2015b) more women than men had undetectable faecal Hb 
concentration and likewise for younger compared with older patients.  Some studies 
have shown that women have a higher proportion of interval cancer diagnosed in 
screened populations. (Brenner et al., 2012; Gill et al., 2012; Steele et al., 2012).  
Therefore, it is perhaps not surprising that all three of the colorectal cancer cases with 
very low faecal Hb concentration occurred in female patients.  This is significant in that 
it may suggest that colorectal cancer can be ruled out at different cut-off faecal Hb 
concentration for men and women.  Increasing the cut-off faecal Hb concentration from 
any detectable faecal Hb concentration to ≥ 10 µg Hb/g faeces would greatly reduce 
the referral rate in men from 60.9% to 25.6%, while improving specificity for all 
significant colorectal disease from 44.1% to 81.3%.  However, these improvements 
would be associated with a loss in sensitivity from 88.7% to 69.9% and a drop in NPV 
from 95.5% to 93.2%.  Of 22 higher-risk adenoma cases, the number missed would 
triple from four (18.1%) to 12 (54.5%), and of 18 cases of inflammatory bowel disease, 
five would be missed (27.8%) rather than just two (11.1%) when using any detectable 
Hb as the referral criteria. 
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When considering the impact of undiagnosed higher-risk adenoma in the symptomatic 
population, it is important to reiterate that not all adenomas will progress to colorectal 
cancer.  In addition, with exception to large adenomas in the rectum, it is unlikely that 
higher-risk adenoma are responsible for the symptoms that cause patients to present 
at primary care.  Therefore, it could be said that the discovery of higher-risk adenoma 
in symptomatic populations are largely incidental.  In any case, it should be 
emphasised when proposing that FIT should be used as a decision tool in primary care 
that this does not mean patients with faecal Hb concentration below the chosen cut-off 
faecal Hb concentration would never be offered colonoscopy.  Patients could 
potentially complete a repeat test at a later date, with the reasoning that an higher-risk 
adenoma progressing toward malignancy may associate with colonic blood loss at this 
time, or that an intermittently bleeding lesion is more likely to be detected at a second 
testing opportunity.  Moreover, a wait-and-wait policy should be implemented in those 
with an undetectable faecal Hb concentration, where patients can be referred if 
symptoms persist in the longer term.  This is perhaps more relevant for inflammatory 
bowel disease, since symptoms in these patients are more likely to be a direct result of 
the condition.  Based on symptoms and other aspects relating to the patient, the GP 
can refer a patient with an undetectable faecal Hb concentration for further assessment 
at gastrointestinal (GI) clinics in secondary care, and, further to this, a referral to 
colonoscopy may still made.  Therefore, the use of FIT in primary care should not act 
as a barrier to GP using their own discretion when referring patients in the case of a 
negative test result at the applied cut-off faecal Hb concentration. 
 
In keeping with comparison of clinical outcomes in screening participants as 
documented previously in this work, those with colorectal cancer, higher-risk adenoma, 
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or inflammatory bowel disease had significantly higher median faecal Hb concentration 
than those with less severe outcomes.  This demonstrates that this variation also 
occurs in a symptomatic population with a cut-off of undetectable faecal Hb 
concentration applied. 
 
As expected from results of other published studies and the systematic review 
conducted by Jellema et al., (2010) symptoms were poor predictors of underlying 
pathology.  For example, iron-deficiency anaemia showed good specificity for 
colorectal cancer at 91.6%, however sensitivity was very poor at 27.3%.  However, 
some further thought on perhaps using symptoms in conjunction with faecal Hb 
concentration in primary care is warranted.  Although possibly incidental, half of all 
higher-risk adenoma in this cohort were associated with rectal bleeding.  Furthermore, 
rectal bleeding was the most common referral symptom in those with colorectal cancer 
(39.3%), and occurred in the majority of those who went on to have a new diagnosis of 
inflammatory bowel disease (67.6%).  With the majority of patients with significant 
colorectal disease reporting rectal bleeding, its status as a “red flag” symptom is 
seemingly supported.  It could be reasonably expected that those reporting rectal 
bleeding would be least likely to have undetectable faecal Hb concentration in their 
faeces.  However, over a third of these patients had undetectable faecal Hb 
concentration and a very low proportion of significant colorectal disease was present in 
this subgroup.  This may suggest that reporting of this symptom in primary care is non-
specific and the use of faecal Hb concentration in patients with rectal bleeding may still 
be warranted. 
 
Rectal cancers accounted for half of all colorectal cancer cases.  This is a higher 
proportion than that observed in the screening population discussed in an earlier 
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Chapter of this work at 35.9%.  This might suggest that rectal cancers are more likely 
to trigger symptoms prompting a patient to attend their GP surgery.  An intriguing 
observation when analysing site distribution of both interval cancer and screen-
detected colorectal cancer was that a higher proportion of rectal colorectal cancer 
occurred in women than men, with 53.3% of all colorectal cancer in women arising at 
this site compared with 29.0% in men.  In the symptomatic population examined here, 
11 of the 14 rectal cancers occurred in female patients (78.6%), with 73.3% of all 
colorectal cancer in women occurring in the rectum compared with just 23.0% in men.  
With the caveat that numbers are small, this may further indicate that rectal cancers 
are more prevalent in women than in men.  Drawing conclusions from these results is 
complicated, and further work is required into which biological mechanisms may be 
driving this trend. 
 
Less than half of the population referred to NHS Tayside’s Colorectal Service over the 
six-month study period returned a sample.  Since it was not mandatory for GP to 
request the test when referring patients for investigation, some GP will have made a 
personal choice not to provide patients with the kit.  As a result, it is not known how 
many patients did not receive a kit to complete and how many were provided with the 
opportunity to provide a sample of faeces but were non-compliant.  The reduction in 
referral rate of over 40% if using a cut-off faecal Hb concentration of any detectable 
faecal Hb concentration in this study was calculated when only taking into account 
those patients referred for investigations who had submitted a sample.  Achieving a 
similar reduction in primary care if implemented as mandatory to complete the referral 
would rely on patient compliance.  It is a positive finding that, in keeping with 
observations from the Scottish Bowel Screening Programme’s evaluation of 
quantitative FIT, (Steele et al., 2013) only a small number of samples were unsuitable 
for analysis.  An opportunity to repeat the test could be provided to these patients. 
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This study adds to the existing investigations into the role of quantitative FIT in primary 
care, an area that, in comparison to the available literature on test performance in 
screening populations, is scarce.  At the time of this work, only three other studies in 
this field were identified (Cubiella et al., 2014; McDonald et al., 2013; Parente et al., 
2012), with only the last conducted with a reasonably large cohort.  More recently, two 
further studies have emerged, both from Catalonia, Spain, confirming our findings that 
FIT has a role as a strong rule-out test in symptomatic patients.  Auge et al. (2015) 
performed analysis of faecal samples using the HM-JACKarc quantitative FIT system 
(Kyowa Medex Co., Ltd, Tokyo, Japan) from 208 symptomatic patients undergoing 
colonoscopy.  NPV for advanced neoplasia were calculated as 95.0% and 89.2% using 
cut-off faecal Hb concentration of detectable blood and 10 µg Hb/g faeces, 
respectively.  The associated test positivity rates at these respective cut-off faecal Hb 
concentration, however, were rather different to those presented in the work of this 
Chapter at 90.4% and 15.8%, owing to the analytical system used in the Spanish study 
having a lower analytical detection limit.  Only two cases of colorectal cancer were 
diagnosed in the cohort, and the authors have confirmed in personal correspondence 
that neither were associated with undetectable faecal Hb concentration.  The other 
recent study from Catalonia by Rodriguez-Alonso et al. (2015) compared test 
performance of OC-Sensor FIT at various cut-off faecal Hb concentrations with current 
guidelines for urgent referral in 1,054 patients referred for colonoscopy.  NPV of 94.1% 
and 93.4% were reported at hypothetical cut-off faecal Hb concentration of detectable 
faecal Hb concentration and 10 µg Hb/g faeces, respectively, with no patients who had 
colorectal cancer diagnosed having an undetectable faecal Hb concentration.  These 
new studies enhance the small but growing evidence base supporting the role of faecal 
Hb concentration in symptomatic patients and confirm the results presented in this 
Chapter.  In addition, the results here provide unique data on the use of FIT at the point 
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of GP referral, therefore allowing for direct implementation of this strategy as a fully-
rolled out decision tool, backed up by the knowledge of its feasibility in this setting. 
 
Further, analysis may be of interest concerning the development of algorithms to 
improve specificity of the referral process using faecal Hb concentration, for example 
taking into account the age of the patient, bearing in mind that colorectal cancer is very 
rare in those aged below 50 years, with the youngest patient in the cohort with 
colorectal cancer being 56 years old.  More detailed work is also still required into the 
use of faecal Hb concentration in combination with symptoms, as well as other risk 
factors for significant colorectal disease.  Although undetectable faecal Hb 
concentration seems to perform well as a rule-out biomarker for colorectal cancer, and 
does not miss many higher-risk adenoma and inflammatory bowel disease cases, 
specificity is poor at 46.4% and only 20.6% of those with detectable faecal Hb 
concentration had significant colorectal disease.  Therefore, a large number of 
investigations would still be performed in those without demonstrable significant 
colorectal disease using this criteria.  With risk scoring systems now increasingly 
emerging for use in screening populations, similar models can be developed for 
implementation in primary care for triage of symptomatic patients for urgent 
investigation.  Such models would need to avoid over complication of the referral 
process to promote agreeability to their use on the part of GP, with easily-obtainable 
variables.  This is the next step for research into the role of faecal Hb concentration in 
primary care to reduce the burden on colonoscopy resource caused by unnecessary 
invasive investigations. 
 
Finally, these findings may have important ramifications in context of the debate 
surrounding the very recent update to the NICE guidelines for recognition and referral 
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of suspected colorectal cancer. (National Institute for Health and Care Excellence 
(NICE), 2015)  Previously, the NICE guidelines made no mention of tests for the 
presence of Hb in the faeces (National Institute for Health and Care Excellence (NICE), 
2011) and the advice from SIGN on diagnosis of colorectal cancer was that gFOBT are 
not indicated for use in the primary care setting and should not impact on the need to 
investigate symptoms. (Scottish Intercollegiate Guidelines Network (SIGN), 2011)  New 
Healthcare Improvement Scotland (HIS) referral guidelines for suspected cancer, 
however, state that “a recent negative faecal occult blood test should not rule out the 
need to refer”. (Healthcare Improvement Scotland (HIS), 2015)  Contrary to the body’s 
previous advice, the new NICE guidelines (2015) now recommend that faecal tests are 
used, in the absence of overt rectal bleeding, in those aged 50 years and over with 
unexplained abdominal pain or weight loss, those aged below 60 years with altered 
bowel habit or iron-deficiency anaemia, or those aged 60 years and over who have 
anaemia even in the absence of iron-deficiency anaemia.   Urgent referral for 
suspected cancer, according to the guidelines, should be made in patients whose 
“tests show occult blood in their faeces”. 
 
Several serious reservations were raised by a large group of multidisciplinary figures in 
response to the updated NICE guidance, (Steele et al., 2015) with one major concern 
being that it is not stated which faecal test should be utilised.  Further concerns were 
raised by Benton et al. (2015) around the number of false negative test results that 
would occur using gFOBT in primary care and the assumption that such patients would 
re-present within a year was rejected.  An objection was made that the guidelines were 
based around the PPV of gFOBT for colorectal cancer with not enough emphasis given 
to the NPV, which has been shown to be as low as 16% with gFOBT in primary care. 
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The various benefits offered by FIT over gFOBT have been outlined in detail 
throughout this thesis, with a standout advantage in the context of symptomatic 
patients being the improved sensitivity that quantitative FIT can offer by way of the 
option to lower the faecal Hb concentration cut-off to such that can effectively rule-out 
colorectal cancer whilst significantly reducing the burden on endoscopic resource.  For 
this to be achieved in the cohort described in this Chapter, a far lower cut-off faecal Hb 
concentration was required than that commonly used in colorectal cancer screening 
programmes, to eliminate patients with false negative test results who it would be 
unacceptable to falsely reassure in primary care.  Worryingly, this is not possible using 
gFOBT, with which interval cancer proportions in colorectal cancer screening 
programmes have been repeatedly demonstrated at upwards of 50%. (Digby et al., 
2015; Steele et al., 2012; Tazi et al., 1999; Hardcastle et al., 1996; Kronborg et al., 
1996; Faivre et al., 1991)  Moreover, symptomatic patients by nature represent a 
higher risk group than asymptomatic screening populations. 
 
In response to the negative correspondence received, the authors of the updated NICE 
guidelines stated that it was not specified which test is to be used since FIT did not, at 
the time of the development of the advice, have any supportive studies in symptomatic 
patients in primary care. (Hamilton et al., 2015)  The evidence supporting the use of 
FIT as a rule-out test for colorectal cancer at a cut-off faecal Hb concentration of any 
detectable faecal Hb concentration presented in this Chapter surely supports the 
argument that quantitative FIT, owing to the feature of an adjustable cut-off faecal Hb 
concentration, must be the test of choice if faecal tests are to be used to aid the 
decision of whether or not to refer patients with colorectal symptoms presenting at 
primary care.  Indeed, a very recent editorial by Fraser & Strachan, (2015) also 
expressing reservations towards the updated NICE guidelines, explained that the 
growing evidence showing FIT to have applicability to assessment of symptomatic 
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patients presenting to primary care, including a publication resulting from the work 
presented in this Chapter, has emerged mainly during and after the publication of the 
new NICE guidelines.  The debate around the current referral guidance will persist for 
the time being, and more studies demonstrating the value of using quantitative FIT in 
symptomatic patients in primary care are required to build the evidence base desired 
by the authors of the guidelines for a revision to be considered.
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8. Summary and Conclusions 
 
 
 
 
8.1 Summary of key findings 
 
 
The findings of this work support the use of faecal haemoglobin (Hb) concentration as 
an important predictor of significant colorectal neoplasia. Detailed analysis of data 
arising from the Scottish Bowel Screening Programme’s ‘FIT as a First-Line Test’ 
evaluation gives backing to the thesis is that faecal Hb concentration can be better 
optimised in colorectal cancer screening programmes than simply implementing as a 
binary test with one cut-off faecal Hb concentration used for all.  To summarise, median 
faecal Hb concentration was higher in those with advanced neoplasia than those with 
less severe outcomes in those with a positive screening test result and that in those 
with a negative screening test result, an elevated faecal Hb concentration associated 
with a greater likelihood of a future diagnosis of AN, either as an interval cancer or at 
the subsequent screening round.  A novel finding that faecal Hb concentration shows 
an independent relationship with degree of deprivation was also demonstrated in the 
screening population examined. .  It was also considered that the use of faecal Hb 
concentration in primary care would be supported by evidence of high Negative 
Predictive Values (NPVs) for significant colorectal disease.  This was indeed the case, 
with potential to cut the number of endoscopy referrals by up to 40% based on the 
absence of detectable faecal Hb, whilst ruling out colorectal cancer in the symptomatic 
patients studied 
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8.2 Relationship between faecal haemoglobin concentration and severity of 
colorectal neoplasia 
 
The results presented in this work further support the existing literature documenting a 
continuum of risk of colorectal disease with increasing faecal Hb concentration.  Using 
a strong positive guaiac faecal occult blood test (gFOBT) result as an indicator of an 
elevated concentration of haemoglobin (Hb) in the faeces, evidence of more severe 
clinical outcomes were observed in comparison to those with less windows on the test 
card producing a reaction that was positive for the haem component of Hb.  Bearing in 
mind an important area of debate in colorectal cancer screening is whether or not 
women may be disadvantaged by the use of faecal tests, the gender differences 
uncovered in the analysis  may be significant, particularly with regard to women in both 
routes to test positivity having later stage colorectal cancer than men.  If this points 
towards earlier stage colorectal cancer being more likely to be missed in women, this 
may tie in with previous work showing women to have higher interval cancer 
proportions than men. 
 
More relevant, given the direction that screening programmes are now moving 
worldwide to use of quantitative Faecal Immunochemical Tests for Hb (FIT), is the 
exploration of faecal Hb concentration in relation to clinical outcomes.  The overall 
findings in the current work is that faecal Hb concentration relates to lesion size, which 
in turn relates to risk of malignancy.  Although overlap was evident, there was some 
distinction between the distribution patterns of faecal Hb concentration in the group 
with advanced neoplasia and those with low-risk adenoma.  Although a relatively high 
cut-off faecal Hb concentration was adopted in this cohort, this finding is promising in 
terms of the inclination to avoid overdiagnosis of those with small polyps unlikely to 
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progress to colorectal cancer.  It can be speculated that many more such lesions were 
present in those below the cut-off faecal Hb concentration used.  Future work may be 
warranted on gender and age differences in the relationship between faecal Hb 
concentration and severity of colorectal neoplasia; this was not possible with the 
sample size available for analysis.   
 
Even using a relatively high cut-off faecal Hb concentration compared with other 
studies investigating the relationship between faecal Hb concentration and clinical 
outcomes, the value of faecal Hb concentration as a predictor of colorectal neoplasia 
has been further demonstrated.  This has implications for programme organisers in 
countries with a limited colonoscopy resource who may wish to look at targeting 
colonoscopy towards those considered at greatest risk according to their faceal Hb 
concentration. 
 
8.3 Faecal haemoglobin concentration as a predictor of interval cancer and 
advanced neoplasia at the subsequent screening round 
 
With FIT now widely accepted as a more analytically and clinically sensitive test than 
gFOBT, it would be hoped that FIT could go some way to reducing the high interval 
cancer proportions commonly reported with gFOBT at around 50%.  It seems from the 
data presented in this work, however, that the use of high cut-off faecal Hb 
concentration may negate any potential improvements in sensitivity, since an interval 
cancer proportion of 50.8% was found.  The later stage distribution of interval cancer 
compared with screen-detected colorectal cancer does highlight the benefit of lowering 
the cut-off faecal Hb concentration, but the fact that almost a fifth of those with an 
interval cancer diagnosed had undetectable faecal Hb concentration illustrates that 
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even drastic reductions in the cut-off faecal Hb concentration will not solve the problem 
of interval cancer within screening programmes using faecal tests for blood. 
 
Further analysis of participants with a negative screening test result was performed to 
investigate the relationship between faecal Hb concentration and clinical outcomes in 
the subsequent screening round.  The results supported the hypothesis that those with 
a faecal Hb concentration closer to the cut-off applied were more likely to have 
advanced neoplasia diagnosed at the subsequent screening round than those with a 
very low faecal Hb concentration at baseline.  This provides further evidence of the 
predictive power of faecal Hb concentration and perhaps advocates closer future 
surveillance of participants with a faecal Hb concentration closer to the cut-off.  The 
finding that more false positive test results occurred in those with a previously low f-Hb 
indicates that colorectal cancer screening programmes may improve their efficiency by 
prioritising investigation in participants who have elevated f-Hb over consecutive 
rounds.  A clear weakness of this work was that FIT was not the screening test used in 
the subsequent round in question, since the Scottish Bowel Screening Programme had 
reverted to the gFOBT/FIT two-tier reflex algorithm following the FIT evaluation.  
However, with the introduction of FIT now approved in Scotland and due for full roll-out 
in the near future, an exciting opportunity will exist for investigation of intra-participant 
variation in f-Hb, and how variation in f-Hb relates to disease status. 
 
8.4 The relationship between faecal haemoglobin concentration and degree 
of deprivation 
 
With existing evidence linking lower socioeconomic status with increased colorectal 
cancer mortality, it was of interest to investigate where faecal Hb concentration fits into 
the relationship.  An independent trend of increasing faecal Hb concentration with 
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increasing degree of deprivation was uncovered.  Participants in the most deprived 
group were more likely to have faecal Hb concentration above the cut-off chosen for 
the ‘FIT as a First-Line Test’ evaluation of 80 µg Hb/g faeces, but the higher odds ratio 
for advanced neoplasia in those in the more deprived groups did not reach statistical 
significance.  Although some potential exists for the inclusion of deprivation as a risk 
factor in risk scoring models in colorectal cancer screening, its clinical significance is 
not clear from these findings.  It is vital that any risk scoring models are as simple as 
possible, and the use of deprivation may be an unnecessary complication in this 
context.  A more important focus with regard to deprivation may be better targeting of 
initiatives to improve uptake in those in more deprived areas, with participation 
consistently lowest in this demographic.  Since faecal Hb concentration is related to all-
cause mortality, it might be that the association of faecal Hb concentration and 
deprivation might reflect overall health; the interesting possibility that faecal Hb 
concentration may be a modifiable biomarker of this would be very interesting to 
investigate. 
 
8.5 The role of faecal haemoglobin concentration in primary care 
 
The use of FIT in primary care to distinguish between those with significant colorectal 
disease and those with less severe, or no pathology is still controversial.  Differences in 
the acceptability of the test exist in this setting of individual testing as opposed to in 
population screening.  The harms associated with a false positive test result such as 
complications arising at colonoscopy will be more tolerable in a symptomatic population 
reporting to GP with a view to such investigations than those who perceive themselves 
to be healthy up until notification of a positive test result. Therefore, a very low cut-off 
generating a high positivity rate can be introduced in the symptomatic population, that 
would be considered to upset the balance of harms and benfits of screening.  In 
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addition, false negative test results if found to exhibit a very low chance of false 
negative test result in a patient with colorectal cancer. However, due to the 
unsustainable burden being placed on investigative services in the UK as a result of 
the escalating numbers of urgent referrals from primary care, with a low yield of 
significant bowel disease, the findings presented in this work support the argument that 
FIT has a very significant role to play.  In simple terms, it was demonstrated that using 
a cut-off of any detectable faecal Hb concentration would have reduced the referral rate 
by over 40%, whilst providing general practitioners (GP) with confidence that no cases 
of colorectal cancer would have been missed.  FIT also performed well as a rule-out 
test for higher-risk adenoma and inflammatory bowel disease, despite some cases 
having an undetectable faecal Hb concentration.  In real terms, such patients may still 
undergo endoscopy if symptoms persist, and in some cases the FIT test may be 
bypassed where patients have particularly worrying symptoms to expedite the referral 
process.   
 
These are very promising results, and it is hoped that they can guide decision makers 
to incorporate FIT into the referral process for patients presenting at primary care with 
colorectal symptoms.  However, opportunity for further work in this area exists.  
Although the use of FIT in primary care would make a significant contribution towards 
alleviating some of the burden on investigative services, a large number of 
unnecessary colonoscopies would still be performed as demonstrated by the large 
number of patients who had a detectable faecal Hb concentration, but had no diagnosis 
of clinically important disease; the PPV for significant colorectal disease using a cut-off 
of any detectable faecal Hb concentration was just 20.6%.  The next step is 
development of a model to allow more sophisticated stratification of risk than that 
afforded with faecal Hb concentration alone.  Easily obtainable risk factors such as 
age, gender, specific symptoms and indices from full blood count could be combined 
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with data on lifestyle and Body Mass Index (BMI), for example, to allow development of 
a practical scoring tool to identify patients most likely to harbour significant colorectal 
disease.  This may help to distinguish between the very small number of patients with a 
low or undetectable faecal Hb concentration who had significant colorectal disease and 
those in whom invasive investigations are unnecessary.  Further work to clarify several 
important issues regarding potential use of FIT in assessment of the symptomatic was 
called for in a very recently published editorial article (Fraser & Strachan, 2015) in light 
of the updated National Institute for Health and Care Excellence (NICE) guidelines for 
recognition and referral of suspected colorectal cancer. (National Institute for Health 
and Care Excellence (NICE), 2015)  The issues raised included how clinical outcomes 
might differ using different quantitative FIT analytical systems, whether or not the focus 
should be on detection (rule-in) or eliminating (rule-out) colorectal disease, the role of 
faecal Hb concentration in clinical pathways to ensure patients with “red-flag” 
symptoms can still be immediately referred, and the correct management of patients 
with negative test results but ongoing symptoms.  Therefore, there is large scope for 
future research into the best use of faecal Hb concentration in the primary care setting. 
 
8.6 Overall conclusions 
 
This work supports the hypothesis that faecal Hb concentration can act as a predictor 
of colorectal neoplasia.  The potential for utilisation of faecal Hb concentration 
measurements below the cut-off used to determine risk of future diagnosis of advanced 
neoplasia, either as an interval cancer or diagnosed at the subsequent screening 
round, demonstrates the huge potential that exists with FIT; this is in stark contrast to 
the far more restrictive nature of gFOBT.  Therefore, FIT is the test of choice in 
screening programmes worldwide as the principle initial screening test before the gold-
standard colonoscopy. 
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It is important to appreciate that the results reported in this thesis - all obtained using 
the OC-Sensor FIT (Eiken Chemical Co, Japan) - may have been different if using an 
analytical system from another manufacturer.  For example, the lower limit of 
quantitation varies between manufacturers, meaning that the number of individuals with 
undetectable faecal Hb concentration reported throughout this work may not be 
transferable across different systems.  Nevertheless, some important messages can be 
drawn with regard to the relationship between faecal Hb concentration and colorectal 
neoplasia both in screening and symptomatic populations. 
 
With full implementation of quantitative FIT for screening now approved in Scotland to 
replace the current gFOBT/FIT two-tier reflex algorithm, many further opportunities will 
exist for future research with the objective being to uncover strategies that may 
improve sensitivity for advanced neoplasia without having a negative impact on 
specificity and the number of false positive test results.  The fact that a proportion of 
interval cancer cases were associated with low faecal Hb concentrations, as were 
some colorectal cancer cases in the symptomatic population investigated, shows that 
the test will never operate perfectly and some cases of colorectal cancer will always be 
missed in screening.  However, it is clear that it would be desirable to lower the faecal 
Hb concentration cut-off to reduce the proportion of interval cancer arising in the 
screened-population.  Currently, the deliberate restriction of the test positivity rate to 
around 2% both in the Scottish evaluation of FIT screening and through the two-tier 
algorithm derived with gFOBT and qualitative FIT is driven by constraints on the 
available colonoscopy resource in Scotland.  However, it is hoped that as a result of 
the promise shown by data from pilot study of FIT utility in primary care, where it seems 
that urgent referrals could be reduced by up to 40%, some of the colonoscopy resource 
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could be redirected towards colorectal cancer screening or surveillance of known or 
previous colorectal disease.   
 
Further scope also exists for investigation into potential strategies to improve efficiency 
of the colorectal cancer screening programme, through making better use of the 
adjustable cut-off afforded by quantitative FIT.  One interesting area is the concept of 
reducing the cut-off faecal Hb concentration and extending the screening interval.  
Some preliminary analysis would be possible with the screen-detected colorectal 
cancer, interval cancer, and colorectal cancer cases detected at the subsequent 
screening round to allow a hypothetical calculation of the number of cases that would 
be detected at an initial screening round with a much lower cut-off faecal Hb 
concentration than that used in the evaluation, with the subsequent round after two 
years then missed.  However, a longer follow-up period is required than is currently 
available and a weakness would exist with the return of the Scottish programme to the 
use of gFOBT.  The forthcoming adoption of FIT into the Scottish Programme will allow 
a better study design to investigate the potential benefits of lowering the cut-off faecal 
Hb concentration and extending the screening interval. 
 
Further work is also warranted to examine, with greater statistical power, the trends 
that are emerging in some publications with regard to site differences between interval 
cancer and screen-detected colorectal cancer.  No significant differences were 
detected in the cohort examined in this work, but the sample size was small.  It is 
interesting that women had a far higher overall proportion of rectal colorectal cancer 
than men, and it would be intriguing to determine if some biological factor is 
responsible for this, or if it was more simply an anomaly that was unique to the cohort 
studied on this occasion.  With theories previously offered that colorectal cancer at this 
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site may associate with faster tumour growth rates, and also that blood arising in the 
rectum is more likely to contain non-haemolysed erythrocytes, further sub-site analysis 
is area deserving of future research.  Likewise, detailed pathological analysis of factors 
which may show a more common association with interval cancer compared to screen-
detected colorectal cancer can be performed to uncover reasons why some lesions 
associate with very low faecal Hb concentrations.  Anomalies will always occur, but a 
greater understanding of why some colorectal cancers are missed may drive novel 
detection strategies.  It is possible that further investigation of test sensitivity according 
to lesion sub-site using a large cohort can be conducted following full roll-out of FIT 
within the Scottish Bowel Screening Programme. 
 
More comprehensive analysis of any gender inequalities occurring with FIT screening 
is justified.  Much debate exists within the screening community around the use of 
individualised cut-off faecal Hb concentrations according to gender.  A 
recommendation made in a review from Australia strongly encourages researchers to 
publish results according to gender where possible; (Massat et al., 2013) this 
recommendation should be followed to build the evidence base around gender 
differences in colorectal cancer screening programmes using FIT. 
 
Finally, perhaps the strongest message arising from the work presented in this thesis is 
that faecal Hb concentration should be incorporated as the major risk factor in risk 
scoring models developed for use in colorectal cancer screening.  With some existing 
scoring models already showing promising results for prediction of risk when 
incorporating factors such as age, gender, family history, BMI and lifestyle data, it 
seems that faecal Hb concentration can greatly add to their power.  This is backed up 
by the sizeable odds ratio calculated in this work for advanced neoplasia in elevated 
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categories of faecal Hb concentration compared to those with low, or undetectable 
faecal Hb concentration.  On this basis, faecal Hb concentration can no longer be 
ignored as a strong predictor of risk of advanced neoplasia, and should now be better 
utilised both in screening and symptomatic populations. 
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Appendix: Contributions to the Work in this Thesis 
 
 
 
Chapter 2: The relationship between results with the guaiac faecal occult 
blood test/Faecal Immunochemical Test two-tier reflex screening algorithm 
and severity of colorectal neoplasia 
 
Results published as:  Fraser, C. G., Digby J., McDonald P. J., Strachan J. A., Carey F. 
A., Steele R. J. C. (2012) Experience with a two-tier reflex gFOBT/FIT strategy in a 
national bowel screening programme. J Med Screen;19(1):8–13. 
 
JD obtained the data from the Bowel Screening Scotland (BoSS) IT system, Central 
Vision laboratory information system and UniSoft endoscopy IT system, performed 
statistical tests and undertook the initial data analysis, prepared the draft and final 
tables and figures, and participated in the preparation of the manuscript. 
 
CGF (second supervisor) conceived the study and wrote the first draft of the paper, 
PJMcD supervised the analytical performance of the gFOBT and FIT, JAS was 
consultant in charge of the Scottish Bowel Screening Centre Laboratory, FAC was 
consultant pathologist responsible for the pathology and histology and RJCS (first 
supervisor) was Clinical Director of the Scottish Bowel Screening Programme.  All 
authors saw drafts of the paper and participated in preparation of these and approved 
the final version. 
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For the thesis chapter, JD recast the published work with more focus on the 
comparison of the clinical outcomes of those with an initial weak positive guaiac faecal 
occult blood test (gFOBT) result with those with a strong positive gFOBT result.  The 
Introduction was rewritten and expanded to explain how this focus could act as a 
surrogate marked for comparison of those with elevated faecal haemoglobin 
concentration.  The Results and Discussion sections were also expanded to show new 
analysis and interpretation including gender differences and odds ratios for advanced 
neoplasia detection and stage and site of colorectal cancer between the routes to 
positivity. 
 
Chapter 3: The relationship between faecal haemoglobin concentration and 
severity of colorectal neoplasia 
 
Results published as:  Digby, J., Fraser, C. G., Carey, F. A., McDonald, P. J., Strachan, 
J. A., Diament, R, H., Balsitis, M. & Steele, R. J. C. (2013) Faecal haemoglobin 
concentration is related to severity of colorectal neoplasia. J Clin Pathol, 66(5), 415-
419. 
 
JD conceived the study, obtained the data from Central Vision laboratory information 
system and UniSoft endoscopy IT system, performed statistical tests and undertook the 
initial data analysis, prepared the draft and final tables and figures, and wrote the first 
draft of the paper with CGF and participated in the preparation of the manuscript. 
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CGF (second supervisor) played a major role in the generation of the faecal 
haemoglobin concentration data and wrote the first draft of the paper with JD, FAC was 
consultant pathologist responsible for the pathology and histology in NHS Tayside, 
PJMcD was Scottish Bowel Screening laboratory Team Leader and supervised the 
analytical performance of the gFOBT and Faecal Immunochemical Test for 
haemoglobin (FIT), JAS was consultant in charge of the Scottish Bowel Screening 
Centre Laboratory, RHD was Director of NHS Ayrshire & Arran’s Bowel Screening 
Programme, MB was consultant pathologist responsible for the pathology and histology 
in NHS Ayrshire & Arran and RJCS (first supervisor) was Clinical Director of the 
Scottish Bowel Screening Programme.  All authors saw drafts of the paper and 
participated in preparation of these and approved the final version. 
 
For the thesis chapter, JD recast the paper to expand and update the review of the 
existing literature.  Results were displayed in greater detail and included multivariate 
analysis to show odds ratios for colorectal cancer and advanced neoplasia according to 
faecal haemoglobin categories, gender, and age categories.  An expanded Discussion 
section was also written. 
 
Chapter 4: The relationship between faecal haemoglobin concentration and 
interval cancers 
 
Results published as:  Digby, J., Fraser, C. G., Carey, F. A., Lang, J., Stanners, G. &  
Steele, R. J. C. (2015) Interval cancers using a quantitative faecal immunochemical 
test for haemoglobin (FIT) when colonoscopy capacity is limited. J Med Screen. pii: 
0969141315609634. [Epub ahead of print] 
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JD obtained the data on the screen-detected cancers UniSoft endoscopy IT system, 
performed statistical tests and undertook the initial data analysis, prepared the draft 
and final tables and figures, and wrote the first draft of the paper with CGF and 
participated in the preparation of the manuscript. 
 
CGF (second supervisor) played a major role in the generation of the faecal 
haemoglobin concentration data and wrote the first draft of the paper with JD, FAC was 
consultant pathologist responsible for the pathology and histology in NHS Tayside, JL 
and GS derived the data for the interval cancers and RJCS (first supervisor) was 
Clinical Director of the Scottish Bowel Screening Programme and initiated the project.  
All authors saw drafts of the paper and participated in preparation of these and 
approved the final version. 
 
For the thesis chapter, JD recast the paper to expand all sections.  This included the 
Results being displayed in greater detail including graphics to show distribution of the 
faecal haemoglobin concentrations associated with all colorectal cancer cases and 
proportions of interval cancers found within ranges of faecal haemoglobin 
concentrations.  A much expanded Discussion section was also written including in 
depth interpretation and speculation as to the reasons for gender differences in site 
and the implications for the Scottish Bowel Screening programme with full roll-out of 
the Faecal Immunochemical Test for haemoglobin. 
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Chapter 5: The relationship between faecal haemoglobin concentration and 
detection of advanced colorectal neoplasia in the subsequent screening 
round 
 
JD conceived the study, obtained the data from the Bowel Screening Scotland (BoSS) 
IT system, Clinical Portal information system and Endoscopy Management System 
(EMS) IT system, performed statistical tests and undertook the initial data analysis, 
prepared the draft and final tables and figures, and wrote the Chapter. 
 
CGF (second supervisor) played a major role in the generation of the faecal 
haemoglobin concentration data, FAC was consultant pathologist responsible for the 
pathology and histology in NHS Tayside, RHD was Director of NHS Ayrshire & Arran’s 
Bowel Screening Programme, MB was consultant pathologist responsible for the 
pathology and histology in NHS Ayrshire & Arran and RJCS (first supervisor) was 
Clinical Director of the Scottish Bowel Screening Programme. 
 
Chapter 6: The relationship between faecal haemoglobin concentration and 
degree of deprivation 
 
Results published as:  Digby, J., McDonald P.J., Strachan J. A., Libby G., Steele, R. J. 
C. & Fraser, C. G. (2014) Deprivation and faecal haemoglobin: implications for bowel 
cancer screening. J Med Screen. 21(2), 95-97. 
 
JD conceived the study, obtained the data from the Bowel Screening Scotland (BoSS) 
IT system, Clinical Portal information system and Endoscopy Management System 
(EMS) IT system, retrieved Scottish Index of Multiple Deprivation (SIMD) quintiles, 
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performed statistical tests and undertook the initial data analysis, prepared the draft 
and final tables and figures, and wrote the paper. 
 
PJMcD supervised the sample handling and analytical performance of the FIT.  GL was 
a Research Statistician at the Scottish Bowel Screening Research UnitGL obtained 
data, analysed data and contributed to manuscript.  JAS was consultant in charge of 
the Scottish Bowel Screening Centre Laboratory supervised the sample handling and 
analytical performance of the FIT.  RJCS and CGF led the gaining of funding and 
initiated the project.  All authors saw drafts of the paper and participated in preparation 
of these and approved the final version.   
 
For the thesis chapter, JD wrote a much expanded version than the published short 
paper version.  Results were displayed in greater detail and included multivariate 
analysis to show odds ratios for a positive screening test result and Positive Predictive 
Values (PPVs) for advanced neoplasia for each deprivation quintile.  An expanded 
Discussion section was written including the work in context of the aims of the thesis 
and other recently published work. 
 
Chapter 7: Faecal haemoglobin concentration as an indicator of significant 
colorectal disease in patients presenting to primary care with colorectal 
symptoms 
 
Results published as: Mowat, C., Digby, J., Strachan, J. A., Wilson, R., Carey, F. A., 
Fraser, C. G. & Steele, R. J. C. (2015) Faecal haemoglobin and faecal calprotectin as 
indicators of bowel disease in patients presenting to primary care with bowel 
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symptoms. Gut. Published Online First: doi:10.1136/gutjnl-2015-309579. [Epub ahead 
of print] 
 
JD collected the FIT result data, determined referral status from Clinical Portal 
information system and clinical outcomes from Endoscopy Management System (EMS) 
IT system, performed statistical tests and undertook the initial data analysis, prepared 
the draft and final tables and figures, and wrote the Results section of the manuscript.  
 
CM was Consultant Gastroenterologist in NHS Tayside and conceived, designed and 
planned the study and wrote the first draft of the manuscript.  JAS was consultant in 
charge of the Scottish Bowel Screening Centre Laboratory and conceived, designed 
and planned the study and supervised the sample handling and analytical performance 
of the FIT and faecal calprotectin test.  RW was Biomedical Scientist and analysed the 
faecal samples.  FAC was consultant pathologist responsible for the pathology and 
histology in NHS Tayside. CGF (second supervisor) wrote sections of the manuscript.  
RJCS (first supervisor) conceived, designed and planned the study.  All authors saw 
drafts of the paper and participated in preparation of these and approved the final 
version. 
 
For the thesis chapter, JD recast the paper with a focus only on the use of FIT in the 
symptomatic population.  The Introduction was expanded to update the review of the 
existing literature.  Results were displayed in greater detail and included comment on 
gender differences in test performance and colorectal cancer site.  An expanded 
Discussion section was also written including comment on up-to-date issues 
surrounding the latest update to NICE guidelines. 
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